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Chapter 1
Age is a major risk factor for many common diseases including cancer, cardiovascular disease, 
hypertension, osteoarthritis, and type 2 diabetes. The process of ageing is described as a decline in 
intrinsic physiological functioning over time, leading to an increased mortality rate [1]. All cells and 
tissues experience progressively decreased functioning over time, but it is not clear which of these 
changes are causal to age-related phenotypes and diseases. Although age is the most powerful risk 
factor for many common diseases, the underlying molecular mechanisms are still largely unknown. 
Biological theories of ageing are dived in two main groups: the programmed ageing theory and 
the theory of cellular ageing [2]. The programmed ageing theory suggests that ageing is regulated 
by biological clocks operating throughout lifespan. This regulation would depend on changes in 
gene expression that affect systems responsible for maintenance, repair, and defense responses. The 
second theory of cellular ageing is based on the concept that damage, either due to environmental 
impacts on living organisms, normal byproducts of metabolism, or inefficient repair systems 
accumulates throughout the lifespan, and causes ageing. Despite the recent advances in molecular 
biology and genetics, the mysteries that control human lifespan are yet to be unraveled [3].
AGEING RESEARCH IN ANIMAL MODELS
The first studies into the regulation of lifespan were performed in animal models, such as yeast 
(Saccharomyces cerevisiae), round worms (Caenorhabditis elegans), fruit flies (Drosophila melanogaster), 
and mice (Mus musculus). Genetically engineered animals allow for better understanding of the 
molecular mechanisms of ageing. An example is a mouse model that expresses a proofreading 
deficient form of the mitochondrial DNA (mtDNA) polymerase [4]. The mutation resulted in randomly 
accumulated mtDNA mutations during the course of mitochondrial biosynthesis. The mice displayed 
a normal phenotype at birth and early adolescence, but subsequently acquired many features of 
premature ageing (such as weight loss, reduced subcutaneous fat, osteoporosis, anemia, reduced 
fertility, and heart enlargement) and had a reduced lifespan. These results demonstrate that the 
accumulation of mtDNA mutations leads to premature ageing in mice. In addition, a significant 
decrease in the mitochondrial energetic capacity with ageing has been identified in yeast, round 
worms, and fruit flies [5]. Finally, a study in human volunteers showed that the mtDNA content in 
muscle declined with ageing [6]. They found reduced levels of mitochondrial gene transcripts and 
proteins, and a declined capacity for mitochondrial energy production, resulting in lower physical 
function and higher insulin resistance, both more common in the elderly. 
Animal models are still instrumental in studying the molecular mechanisms of disease processes: the 
short life span of some model species enable longitudinal studies and experimental manipulations 
[7]. While these studies have been crucial for the identification of some ageing regulating genes and 
pathways, a limitation is that the findings can be difficult to translate to human ageing. The Ageing 
Gene Database (GenAge) provides a publically available manually curated collection of all genes 
related to longevity and ageing in model organisms [8]. Today, about 300 human genes and about 
2,000 genes in animals have been related to longevity and/or ageing. 
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AGEING RESEARCH USING CELL LINES
Next to animal studies, cell culture studies have been used to study ageing. In 1961, Hayflick et 
al. [9] discovered that human fibroblasts derived from embryonic tissues could only divide a finite 
number of times in culture, a phenomena called “replicative senescence”. In 1990, Harley et al. found 
that telomeres (repetitive sequences at the end of your chromosomes) shorten at each passage. 
The telomere length contributes to the stabilization of the telomeres, and is the key in avoiding 
replicative senescence [10]. Recently, scientists in Japan were able to either accelerate the process 
of ageing within human fibroblast cell lines, or to reverse the process of ageing [11]. They targeted 
two genes (GCAT and SHMT2) that produce the amino acid glycine in the mitochondria, and by 
reprogramming the fibroblast cell lines the researchers restored age-associated respiration defects. 
Yet, the connection between the in vitro findings and the ageing organism remains a subject of 
controversy, in spite of decades of study [12]. 
USE Of POPULATION-bASED COHORTS 
The studies described in this thesis made use of human population-based cohort studies to 
examine ageing and age-related comorbidities: a sample of a population is selected for longitudinal 
assessment of exposure-outcome relations [13]. Compared to animal- and cell line models, the 
results of human population-based studies are easier to translate to the human situation. The type 
and amount of genetic and/or genomic diversity between the samples is exploited to understand 
the molecular mechanisms, rather than active genetic or genomic manipulations in model systems. 
Population studies can be used to evaluate multiple hypotheses, particularly when data are 
repeatedly collected. The subjects are followed in time to record the development of risk factors for 
diseases. 
Today, population-based epidemiological studies have identified many risk factors related to negative 
health outcomes. For example, the causal association between smoking and lung cancer [14] and 
the association between obesity and increased risk of developing post-menopausal breast cancer 
[15] have been identified in population-based studies. However, the results of an epidemiological 
study may be due to an alternative explanation, which is called confounding. Confounding occurs 
when both the exposure and the outcome are correlated with another risk factor. For example, 
one study found alcohol intake to be associated with the risk of coronary heart disease. However, 
smoking may have confounded the association between alcohol intake and coronary heart disease. 
The studies described in this thesis investigated the role of genetic and genomic factors and the 
interplay of such factors with environmental factors. When the biology underpinning the molecular 
epidemiology is used to study the effect on age-related diseases, residual confounding can be 
largely circumvented [16]. 
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We used genetic studies, transcriptomic studies, and epigenetic studies to better understand the 
molecular mechanisms of ageing and age-related phenotypes and diseases.
GENETIC STUDIES
The human genome consists of four nucleotides: Adenine (A), Thymine (T), Cytosine (C), and 
Guanine (G). They form basepairs (bp) (A with T, and C with G), and the total length of the human 
genome is approximately 3,300,000,000 bp. The central dogma of molecular biology involves the 
genetic code (which is hard-wired into the DNA) to be copied to mRNA (transcription) or DNA (DNA 
replication). Proteins can be synthesized using the information in the mRNA as a template (Figure 1) 
[17]. Approximately 70% of the human genome is transcribed, of which only 2% is protein coding 
[18]. 
Although the DNA sequences of all humans are similar, no two humans are genetically identical. 
Today, over 88 million genetic variants have been found [19], which means that there is roughly one 
variant every 40 bp. Individuals are different in approximately 5.0 million sites in their genomes, so 
on average, 1 in 660 bp varies between two independent individuals in a population [19]. The most 
common DNA variants observed in a single genome are called single nucleotide polymorphisms 
(SNPs). A SNP is a site in the genome where one base pair of the chromosome varies, and this variant 
occurs in >1% of the population. If the variant is less frequent it is called a rare variant, a mutation 
refers to (very) rare pathological variations. 
When a SNP is located in a protein-coding sequence it could result in an amino acid change, which 
may modify the peptide and/or the entire protein. This could alter the function, the activation, the 
localization, and the stability of the protein. If the SNP occurs in a region of the genome that regulates 
transcription of the gene, it could change the expression by affecting binding of transcription factors 
for example.
Hypothesis-free genome-wide association studies (GWAS) have been developed to identify SNPs 
associated with any trait of interest. In a GWAS, a dense set of SNPs (at least 300,000) across the 
genome is genotyped to survey the most common genetic variation for association with the trait 
of interest. The number of SNPs studied is much larger compared to a candidate gene approach, 
and the analysis is hypothesis free, so no prior knowledge about the biology of the trait is needed. 
Using haplotype information from HapMap [20,21] or the 1000 genomes project [22,23], many more 
SNPs that are correlated can be imputed. After such imputation, GWAS data of multiple different 
studies can be combined in a GWAS meta-analysis. A meta-analysis increases the chance of success 
to identify significantly associated SNPs, which is caused by increased power of the analysis. 
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figure 1. The central dogma of molecular biology. DNA contains the information needed to make all of 
our proteins, and RNA is the messenger carrying the information to the ribosomes. A SNP in the DNA could 
influence both the RNA and the protein structure (image adapted from Genome Research Limited, Wellcome 
Trust Sanger Institute). 
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Genetic approaches in ageing research have shown that ageing and longevity are difficult to dissect. 
Human lifespan variation is mainly determined by environmental factors, whereas the heritability is 
25-30% and expected to be polygenic [24]. Today, a number of attempts have been made to identify 
the genetic components of longevity by both candidate-gene studies and GWAS approaches. While 
thousands of SNPs have been associated with common diseases and traits [25,26], SNPs in/near 
APOE, FOXO3, and 5q33.3 are the only identified genetic loci consistently associated with longevity 
[27-35]. This may be explained by the interaction of ageing with a number of environmental factors 
(for example, advances in medical care, better lifestyle choices, healthier diets, etc.). Since 1985, the 
life expectancy at birth increased by 6 years for men and 3 years for women in the Netherlands (CBS 
levensverwachting 2015). Therefore, the current variation in lifespan in a population seemed to be 
mainly determined by non-genetic factors [36,37]. However, family studies in human centenarians 
and their offspring showed an important genetic component to survival to older ages beyond 100 
years. And this genetic influence appears to get stronger with older age [38]. The centenarians are 
expected to have inherited longevity assurance mechanisms that attenuate their ageing rate and 
protect them from age-related diseases [39].
TRANSCRIPTOMIC STUDIES
Since ageing is characterized by many alterations at the molecular, cellular, and tissue level [40], 
transcriptome analyses might capture these temporal effects more robustly than genetic studies. 
The  transcriptome  is the set of all RNA molecules in one cell or a population of  cells; it is highly 
dynamic and changes with time and in response to external environmental conditions. The 
transcriptome (also referred to as gene expression levels) is an important intermediate between the 
genetic code and the synthesized proteins (Figure 1) [17]. Next to the protein-coding genes (which 
are transcribed into messenger RNA (mRNA) and translated into proteins), there are many non-
coding regions in the DNA which are transcribed into functional (non-coding) RNA molecules, such 
as transfer RNAs (tRNA), small nuclear RNAs (snRNA), ribosomal RNAs (rRNAs), micro RNAs (miRNA), 
and long non-coding RNAs (lncRNA). In general, non-coding RNAs function as regulators of gene 
expression at the transcriptional and post-transcriptional level. 
The studies described in this thesis focused on mRNAs and lncRNAs. mRNAs form the largest 
family of RNA molecules. They are transcribed in the nucleus, transported to the cytoplasm, and 
translated (in the ribosomes) into polymers of amino acids, also called proteins. lncRNAs are non-
protein coding RNA molecules longer than 200 nucleotides. lncRNAs are poorly conserved across 
species, suggesting that they may be subject to different evolutionary constraints [41]. However, a 
proportion of lncRNAs have been demonstrated to be biologically relevant: they can modulate the 
function of transcription factors by several different mechanisms, including functioning themselves 
as co-regulators, modifying transcription factor activity, or regulating the association and activity of 
co-regulators [42,43]. 
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Gene expression levels can be measured with many different techniques, for example, with northern 
blotting or with reverse transcription-quantitative PCR (RT-qPCR). In this thesis, we only used 
genome-wide techniques (gene expression microarrays and RNA sequencing) which measure gene 
expression levels for a large number of RNAs within one sample. 
Microarray technology to measure gene expression levels
Hybridization- based microarray approaches can be run at high throughput. Microarray data is 
relatively easy to analyze and the arrays are relatively inexpensive. However, the arrays have several 
limitations, which include: reliance upon existing knowledge of protein-coding sequences; high 
background levels caused by cross-hybridization [44,45], and a limited dynamic range of detection. 
There are differences between different microarray platforms that are available on the market. For 
example, Illumina arrays include only one or two probes per gene (mostly positioned on the 3’ end 
of the gene), while Affymetrix arrays use multiple probes per exon. Therefore, combining results of 
different platforms can be challenging [46].
RNA sequencing (RNA-seq) 
RNA sequencing uses recently developed next generation-sequencing technologies. In short, a 
population of RNAs is converted to a library of cDNA fragments with adaptors attached to both 
ends. Each molecule is then sequenced in a high-throughput manner to obtain short sequences 
from both ends [47]. One advantage is that it is not limited to known protein-coding sequences; 
it allows investigating new alternative RNA transcripts and new non-coding RNAs, and the precise 
location of the new transcription boundaries could be identified. In addition, RNA-seq data gives 
information about how exons are connected (different isoforms), and could give insight into allele 
specific expression. RNA-seq does not have an upper limit for quantification. Consequently, it has a 
large dynamic range of expression levels over which transcripts can be detected. And last but not 
least, genetic variants (SNPs, insertions, deletions) can be measured in the transcripts. 
EPIGENETIC STUDIES
The epigenome is a series of chemical modifications that occur on the DNA or specific amino acids 
in histone proteins. They regulate the transcriptome by making the DNA more or less accessible 
for binding of proteins that regulate gene expression. There are two main types of epigenetic 
modifications: DNA methylation and histone modifications. 
DNA methylation is the most studied and best understood epigenetic modification: a methyl group 
is added on the 5-position (C5) of cytosine nucleotides that are found next to a guanine nucleotide 
in the DNA sequence. These sites are called CpG sites. There are about 28 million CpG sites in the 
genome, but these are not evenly distributed: the largest part of the genome is depleted of CpG 
sites with less than one quarter of the expected frequency. By contrast, clusters of CpG sites (also 
called CpG islands) occur in promoters of housekeeping genes [48] (Figure 2). DNA methylation 
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is well conserved across species (plants, animals, and fungi), but it can change during life; DNA 
methylation is tissue specific, and it is influenced by environmental factors like exercise, food intake, 
smoking, and stress. 
figure 2. DNA methylation and regulation of the genome (image adapted from Stirzaker et al. [48]). CpG 
islands are often associated with gene promoters and are resistant to DNA methylation. Gene expression 
can occur, and is highly correlated with high levels of gene body (genic) methylation. CpG-poor regions 
(intergenic), with the exception of enhancers, are typically methylated. Similarly, CpG-poor promoters are 
silenced by DNA methylation and exhibit a closed chromatin structure unless gene expression is required 
(tissue specific). White circles are unmethylated CpGs; black circles are methylated CpGs.
Histone modifications are catalyzed by a number of enzyme families; the best characterized 
modifications include acetylation and methylation of histones H3 and H4. The modifications directly 
alter DNA-protein interactions by changing the chromatin structure, which will alter the ability for 
a gene to be transcribed and expressed. Acetylation adds an acetyl group to lysine amino acids: 
this causes loosening of chromatin to promote gene activation [49]. Histone deacetylases (which 
remove the acetyl group) cause chromatin condensation or tightening and gene inactivation. 
Methylation can occur on lysine or arginine amino acids and can occur in mono-, di- or tri-methylation 
events. This mark can be associated with both gene activation and inactivation [50].
In large population-based studies, mainly DNA methylation (CpG methylation) is studied. This is 
mainly driven by the technological possibility to measure DNA methylation in a reasonably high 
throughput fashion. The most used technique to measure DNA methylation in population studies 
is with microarrays. Alternative techniques, such as targeted bisulfite sequencing and methylC-
capture sequencing, are under development, but remain too expensive up to now. 
Microarray technology to measure DNA methylation
The Infinium Human Methylation 450K BeadChips measure DNA methylation levels of 485,000 CpG 
sites genome wide (1.7% of all CpG sites) for 12 samples simultaneously. The primary focus of the 
Infinium BeadChips is on CpG islands and promoter regions: they cover 99% of the RefSeq genes 
(with an average of 17 CpG sites per gene) and 96% of the CpG islands. Like the gene expression 
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arrays, DNA methylation arrays are relatively inexpensive and easy to analyze. Therefore, they are 
very popular in large population based cohort studies. 
INTEGRATING GENOMIC APPROACHES
To better understand the role of genetic variation and its consequences at various genomic levels 
during ageing and in age-related comorbidities, we analyzed integrated levels of genetic and 
genomic data. With integrated data analysis, we hoped to identify key genetic factors that regulate 
DNA methylation and gene expression levels resulting in age-related traits and diseases (Figure 3).
figure 3. biological systems multi-omics from the genome, epigenome, transcriptome, proteome 
and metabolome in relation to the complex phenotypes that change and occur during ageing (image 
adapted from Ritchie et al. [51]). Arrows indicate the flow of genetic information from the genome level to the 
metabolome level and, ultimately, to the phenotype of interest: ageing. The red crosses indicate inactivation 
of transcription or translation. 
Me = methylation; TF = transcription factor; TFbs = transcription factor binding site.
The concept of “genetical genomics” was first introduced in 2001 [52]. Genetic variants were 
correlated with molecular quantitative traits, such as DNA methylation and gene expression levels. 
Instead of focusing on direct associations between SNP and disease, the molecular markers are used 
as endophenotypes [53]. Because the molecular markers intermediate between the genes and the 
disease outcome, their closer proximity to the genetic variation translates into larger effect sizes. 
Furthermore, given that the endophenotypes are measurable traits regardless of disease status, 
their use can enhance power by including both affected and unaffected study subjects.
502007-L-bw-Peters
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Detection of cis- and trans-eQTLs
By combining gene expression levels and SNP variant information, it is possible to identify expression 
quantitative trait loci (eQTLs). eQTLs indicate what portion of the variation in gene expression is 
explained by the SNPs in the regulatory regions near the gene (cis-eQTLs or direct effects), or to 
SNPs that reside further away on the chromosome or even on different chromosomes (trans-eQTLs 
or indirect effects) (Figure 4). 
figure 4. eQTLs can be either direct effects (cis-eQTLs) or distant, indirect effects (trans-eQTLs) (image 
adapted from Wolen et al. [54]). (A) The left-most gene (red) codes for a transcription factor (TF’) protein that 
activates the transcription of genes A (green) and B (blue) by binding to their respective promoters. In the 
normal scenario all genes are transcribed at their full potential, as indicated by the bar graph on the right. 
(b) A SNP in gene A’s promoter region hinders TF binding, causing a reduction in the rate at which gene A 
is transcribed, while gene B is unaffected. Thus, gene A is being regulated by a cis-eQTL because its level of 
expression is associated with a nearby SNP located on the same chromosome. (C) A SNP in the TF gene’s DNA 
binding region hinders binding with all downstream promoters, regardless of whether the regulated gene is 
located near the TF gene, like gene A, or located on an entirely different chromosome, like gene B. In fact, all 
genes regulated by this TF would be linked to a trans-eQTL at the site of this TF polymorphism.
Cis and trans-eQTLs are mapped by testing the correlation between SNP alleles and the variation 
in gene expression levels. Cis-eQTL SNPs are often located close to the transcription start site (TSS) 
of genes or within gene bodies: as the distance between the eQTL SNP and the TSS decreases, the 
eQTL effect size generally increases [55-57]. These SNPs may alter the transcription binding sites 
or other cis-regulatory elements that may affect transcription. In contrast to cis-eQTLs, the effect 
sizes of trans-eQTLs are generally small. Because of the small effect sizes, the number of reported 
trans-eQTL has remained low [58-60]. However, these trans-eQTL analyses are especially interesting, 
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because they allow us to identify downstream affected disease genes which are not implicated by 
GWAS studies before. Additionally, they have the ability to reveal previously unknown biological 
connections between two proteins, which is very important for a better understanding of the 
disease pathogenesis. 
Combining DNA methylation and gene expression data
Apart from genetic variation influencing gene expression levels, we also investigated the possible 
role of the epigenome on gene expression levels. Since lifestyle and environmental factors (such as 
smoking [61-68], diet [69-71], and infectious disease [72]) change the epigenome, this analysis could 
give more insight into what genes are strongly influenced by the environment. Because epigenetic 
modifications are potentially reversible [73], these genes might represent interesting targets for 
anti-ageing therapies. 
THE ROTTERDAM STUDy
All studies described in this thesis are performed within a large population based cohort study, 
the Rotterdam Study (RS). In the Netherlands, this study is also known as “Erasmus Rotterdam 
Gezondheid Onderzoek” (ERGO). The Rotterdam Study (www.epib.nl/rotterdamstudy) is a prospective 
population-based single center cohort study in the well-defined suburb of Ommoord in the city of 
Rotterdam, the Netherlands, studying determinants of chronic disabling diseases [74]. It consists of 
three sub-populations: Rotterdam Study I (RS-I) started in 1990 and consists of 7,983 persons (out of 
10,215 invitees), aged 55 years and over. This cohort was extended in 1999 with 3,011 participants 
(out of 4,472 invitees) who had become 55 years of age or moved into the study district since the 
start of the study, called Rotterdam Study II (or RS-II). In 2006, a further extension of the cohort was 
initiated in which 3,932 subjects (out of 6,057 invitees) were included, aged 45 years and over, called 
Rotterdam Study III (RS-III). In total, the Rotterdam Study comprises 14,926 subjects. 
All participants were examined in detail at baseline. In summary, a home interview was conducted 
(~2 hours) and the subjects had an extensive set of examinations (~5 hours) in a specially built 
research facility in the center of their district. The examinations were repeated every 3-4 years in 
characteristics that could change over time. An overview of baseline and follow-up visits is given in 
Figure 5. 
The main objective of the Rotterdam Study is to investigate the prevalence and incidence of and 
risk factors for chronic diseases in the elderly. The Rotterdam Study has been approved by the 
Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare and Sport of the 
Netherlands, implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam 
Study)”. All participants provided written informed consent to participate in the study and to obtain 
information from their treating physicians.
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Measurements in blood
Both the DNA methylation and the gene expression levels have been measured in peripheral blood 
taken by venipuncture. For DNA methylation, the DNA was extracted from the white blood cells 
(stored in EDTA tubes) by standardized salting out methods. For gene expression levels, total RNA 
was isolated from the peripheral blood (collected in PAXgene tubes, which immediately stabilize 
the RNA).
PHENOTyPES STUDIED
Next to ageing and the general age-related phenotypes (for example, blood pressure, cholesterol 
levels, and muscle strength) [75], we focused on musculoskeletal comorbidities like osteoarthritis 
and chronic pain in this thesis. With ageing, musculoskeletal comorbidities have become the most 
frequent cause of physical activity limitations and reduced self-management behavior. Physical 
inactivity is a major cause of reduced quality of life, as well as many common diseases and even 
premature death [76]. 
Osteoarthritis [25] is a common degenerative joint disease affecting the whole joint characterized 
by pain, stiffness, and disability. The structural characteristics of the disease are articular cartilage 
loss, formation of new bone, increased thickness of the bone, and cyst formation.
Chronic pain causally relates to an initial local pain stimulus, such as low back pain or local pain due 
to OA or rheumatoid arthritis (RA). However, only a selection of patients with OA or RA will develop 
chronic pain, which is accompanied by central sensitization. Nerve impulses keep alerting the brain 
about tissue damage that no longer exists, which results in enhancement of the response. 
THE CHARGE CONSORTIUM
When combining data of multiple studies in a meta-analysis approach, the power of the study can 
be increased, and the changes of success in discovering new loci is higher. The Cohorts for Heart and 
Ageing Research in Genomic Epidemiology (CHARGE) consortium was formed to facilitate genome-
wide association study meta-analyses and replication opportunities among multiple large and well 
phenotyped longitudinal cohort studies [77]. The scientific work in the CHARGE consortium takes 
place in phenotype- and method-specific working groups. 
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In 2002, we started a Gene Expression Working Group. In this working group, we standardized the 
pipelines for analyzing gene expression data. Cohorts that participated in the Gene Expression 
Working Group are presented in Figure 6: the Framingham  Heart  Study  (FHS, United States of 
America); the Grady Trauma Project (GTP, United States of America); the Heart and Vascular Health 
Study (HVH, United States of America); the Multi-Ethnic Study of Atherosclerosis (MESA, United 
States of America); the NIDDK-Phoenix Study (NIDDK/PHOENIX, United States of America); the San 
Antonio Family Heart Study (SAFHS, United States of America); the Genetic Epidemiology Network 
of Arteriopathy (GENOA, United States of America); the Atherosclerosis Risk in Communities 
Study  (ARIC, United States of America); the Age,  Gene,  Environment,  Susceptibility  Study (AGES, 
Iceland); the Rotterdam Study (RS, the Netherlands); the Fehrmann et al. dataset (FEHRMANN, 
the Netherlands); the Genetics, Osteoarthritis and Progression study (GARP, the Netherlands); the 
KOoperative gesundheitsforschung in der Region Augsburg (KORA, Germany); the Study of Health 
In Pomerania (SHIP, Germany); the Invecchiare in Chianti, ageing in the Chianti area (InCHIANTI, 
Italy); the Estonian Gene Expression Cohort (EGCUT, Estonia); the Dietary, Lifestyle, and Genetic 
determinants of Obesity and Metabolic syndrome study (DILGOM, Finland); and the Brisbane 
Systems Genetics Study (BSGS, Australia).
AIM Of THIS THESIS
The overall objective of this thesis is to integrate different genetic and genomic approaches to better 
understand ageing and age-related comorbidities. We assessed the effects of genetic variants, 
gene expression levels, and DNA methylation levels on age-related phenotypes, and additionally 
we combined the different levels of -omics data (genomics, epigenomics, and transcriptomics) to 
identify eQTLs and potentially functional CpG-methylation sites regulating gene expression levels. 
The research presented in this thesis examines genomic data from whole blood samples drawn 
from human population based studies. The work focuses on identifying new genetic and genomic 
biomarkers that are related to ageing and age-related comorbidities, rather than discovering 
“regenerative medicine” for anti-ageing therapies. 
In Chapter 2, ageing and three age-related phenotypes (blood pressure and hypertension, circulating 
lipid levels, and muscle strength) are studied in relation with the transcriptome. In Chapter 3, genetic 
and transcriptomic data are combined to identify cis- and trans-eQTLs. In Chapter 4, we integrated a 
number of genomic analyses for different age-related musculoskeletal comorbidities (osteoarthritis 
and chronic pain).
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AbSTRACT
Disease incidences increase with age, but the molecular characteristics of ageing that lead to 
increased disease susceptibility remain inadequately understood. Here we perform a whole-blood 
gene expression meta-analysis in 14,983 individuals of European ancestry (including replication) 
and identify 1,497 genes that are differentially expressed with chronological age. The age-associated 
genes do not harbor more age-associated CpG-methylation sites than other genes, but are instead 
enriched for the presence of potentially functional CpG-methylation sites in enhancer and insulator 
regions that associate with both chronological age and gene expression levels. We further used 
the gene expression profiles to calculate the ‘transcriptomic age’ of an individual, and show that 
differences between transcriptomic age and chronological age are associated with biological 
features linked to ageing, such as blood pressure, cholesterol levels, fasting glucose, and body mass 
index. The transcriptomic prediction model adds biological relevance and complements existing 
epigenetic prediction models, and can be used by others to calculate transcriptomic age in external 
cohorts.
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INTRODUCTION 
Chronological age is a major risk factor for many common diseases including heart disease, cancer, 
and stroke, three of the leading causes of death. Although chronological age is the most powerful 
risk factor for most chronic diseases, the underlying molecular mechanisms that lead to generalized 
disease susceptibility are largely unknown. Genome-wide association studies (GWAS) have identified 
thousands of single nucleotide polymorphisms (SNPs) associated with common human diseases 
and traits [1,2]. Despite this success, APOE, FOXO3, and 5q33.3 are the only identified loci consistently 
associated with longevity [3-11]. Ageing has proven difficult to dissect in part due to its interactions 
with environmental influences (e.g., lifestyle choices, diet, local exposures), other genetic factors, 
and a large number of age-related diseases [11], making the individual factors difficult to detect. 
Since studies in model organisms have shown that ageing is characterized by many alterations at 
the molecular, cellular, and tissue level [12], a transcriptome analysis might lend greater insight than 
a static genetic investigation. Therefore, the aim of this study was to exploit a large-scale population-
based strategy to systematically identify genes and pathways differentially expressed as a function 
of chronological age. In contrast to the relatively invariable genome sequence, the transcriptome is 
highly dynamic and changes in response to stimuli. Previous gene expression studies in the context 
of ageing have primarily focused on model organisms [13-15] or have been confined to specific 
ageing syndromes such as Hutchinson-Gilford progeria [16]. One report identified age-related 
expression-modules across four separate datasets [17], while other studies examined age-associated 
gene expression changes in relatively small cohorts [18-22]. 
To our knowledge, we perform here the first large-scale meta-analysis of human age-related gene 
expression profiles with well powered discovery and replication stages. In addition, this is the 
first large-scale study testing the hypothesis that changes in gene expression with chronological 
age are epigenetically mediated by changes of methylation levels at specific loci. Finally, we take 
advantage of our large set of samples to build a transcriptomic predictor of age, and we compare 
our transcriptomic prediction model with the epigenetic prediction models of Horvath [23] and 
Hannum et al. [24].
We identified 1,497 genes that are differentially expressed with chronological age. These genes are 
enriched for the presence of potentially functional CpG-methylation sites in enhancer and insulator 
regions. Our transcriptomic age predictor complements the existing epigenetic prediction models, 
and can be used by others to calculate transcriptomic age in external cohorts.
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RESULTS
1,497 genes differentially expressed with chronological age
The discovery stage included six European-ancestry studies (n=7,074 samples) with whole-blood 
gene expression levels for roughly half of the genes in the human genome (n=11,908 significantly 
expressed genes across different platforms). We identified 2,228 genes with age-associated 
expression in the discovery stage (P<4.2E-6) after adjusting for technical variables and confounding 
factors such as sex, cell counts and cigarette smoking (Supplementary Figure 1A). The replication 
stage included 7,909 additional whole-blood samples, in which we replicated association results 
for 1,497 genes (P<2.2E-5). Discovery and replication results were highly correlated (r=0.972, 
Supplementary Figure 1B) and complete results are shown in Supplementary Data 1. After meta-
analysis of discovery and replication stages, the expression levels of 897 genes were negatively 
associated and 600 genes were positively correlated with chronological age. The top 50 most 
significantly associated genes are presented in Table 1. 
Transferability of ageing-transcriptome signatures
To examine the generalizability of the results of our differential expression meta-analysis, we tested 
whether the 1,497 identified genes were also differentially expressed in relation to chronological age 
in other ancestry samples, in brain tissue, and in specific blood sub-cell-types (Supplementary Data 
1). In Native Americans (n=1,457), 95% of the 1,497 genes were significantly expressed, and 71% 
(1,005 genes) were associated with chronological age (p<0.05). In Hispanic Americans (n=1,244), 
40% of the 1,497 genes were significantly expressed, and 74% (440 genes) were associated with 
chronological age in the same direction (p<0.05). In African Americans (n=359), 99% of the genes 
were significantly expressed, and 27% (392 genes) were associated with chronological age in the 
same direction (p<0.05) (Supplementary Table 1). 
In both types of brain tissue studies (cerebellum and frontal cortex, n=394), approximately 58% of 
the 1,497 genes were significantly expressed. Of these, 19% (163 genes) and 26% (229 genes) were 
associated with chronological age in the same direction (p<0.05) in cerebellum and frontal cortex, 
respectively (Supplementary Table 2, Supplementary Figure 2, and Supplementary Table 3). Among 
the top 50 age-associated genes, three genes were associated with chronological age in all tissues: 
SERPINE2, LDHB, and BZW2 (p<0.05) (Supplementary Data 2). 
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Table 1. Top 50 age-associated genes. For the 50 most significant age-associated genes, the discovery 
P-value (and Z-score), the replication P-value (and Z-score), and the meta-analysis P-value (and sample size 
and Z-score) are shown. The last two columns display whether the genes were also significantly associated 
with age in the brain tissues cerebellum and frontal cortex.  
Discovery Replication Meta-analysis Generalization
Gene Rank Z-score P-value Z-score P-value N Z-score P-value Cerebellum frontal 
Cortex
CD248 1 -32.48 2.32E-231 -40.13 4.07E-352 15,266 -51.46 1.62E-577 NA NA
LRRN3 2 -29.12 2.03E-186 -33.55 7.81E-247 15,266 -44.38 3.53E-430 N Y (-)
NELL2 3 -23.65 1.18E-123 -23.48 6.93E-122 15,266 -33.31 2.67E-243 N Y (-)
LEF1 4 -22.18 5.57E-109 -22.46 9.38E-112 15,266 -31.56 1.22E-218 NA NA
CCR7 5 -21.14 3.59E-99 -22.44 1.48E-111 15,266 -30.83 1.04E-208 NA NA
ABLIM1 6 -22.32 2.34E-110 -20.73 1.71E-95 15,266 -30.41 4.41E-203 N Y (+)
GZMH 7 18.68 7.03E-78 20.97 1.26E-97 15,266 28.07 2.39E-173 NA NA
MYC 8 -18.96 3.36E-80 -19.51 9.94E-85 15,266 -27.20 5.96E-163 NA NA
CD27 9 -17.65 1.07E-69 -20.68 5.13E-95 15,266 -27.15 2.76E-162 NA NA
FAM102A 10 -19.46 2.24E-84 -18.68 7.11E-78 15,266 -26.95 5.68E-160 N Y (+)*
SERPINE2 11 -16.08 3.71E-58 -20.95 1.91E-97 14,385 -26.34 7.66E-153 Y (-) Y (-)**
SLC16A10 12 -20.39 2.29E-92 -16.51 3.15E-61 13,809 -26.15 1.00E-150 Y (+) Y (-)
FCGBP 13 -15.76 5.50E-56 -20.83 2.49E-96 15,266 -25.95 1.65E-148 NA Y (+)*
GPR56 14 17.52 9.47E-69 19.02 1.21E-80 15,266 25.86 2.03E-147 NA NA
BACH2 15 -17.82 4.64E-71 -17.75 1.85E-70 15,266 -25.14 1.71E-139 N NA
SYT11 16 17.23 1.72E-66 18.23 3.24E-74 15,266 25.08 8.82E-139 Y (-) Y (-)
PDE9A 17 -17.21 2.22E-66 -18.20 5.44E-74 15,266 -25.05 1.91E-138 N N
NG 18 -17.01 7.41E-65 -17.52 9.87E-69 15,266 -24.42 1.16E-131 NA NA
FLNB 19 -15.78 4.26E-56 -18.61 2.87E-77 15,266 -24.36 4.94E-131 N Y (+)**
NT5E 20 -17.45 3.29E-68 -16.59 8.23E-62 15,039 -24.06 6.98E-128 NA NA
FGFBP2 21 17.45 3.51E-68 15.79 3.51E-56 15,266 23.47 8.43E-122 NA NA
TGFBR3 22 15.00 7.73E-51 17.66 9.15E-70 15,266 23.13 2.41E-118 N Y (+)*
ITM2C 23 -14.41 4.24E-47 -17.73 2.45E-70 15,266 -22.78 7.22E-115 N N
ATF7IP2 24 -15.52 2.73E-54 -16.61 5.85E-62 15,266 -22.73 2.34E-114 NA Y (-)*
CR2 25 -16.29 1.10E-59 -15.85 1.51E-56 15,266 -22.71 3.49E-114 NA NA
FAIM3 26 -17.92 8.65E-72 -14.22 7.40E-46 15,266 -22.65 1.41E-113 NA NA
PHGDH 27 -13.25 4.56E-40 -18.30 8.10E-75 15,266 -22.39 4.85E-111 N Y (+)*
LDHB 28 -15.63 4.33E-55 -15.96 2.42E-57 15,266 -22.34 1.55E-110 Y (-)* Y (-)**
SIRPG 29 -15.64 4.16E-55 -15.45 7.71E-54 15,266 -21.97 5.58E-107 NA NA
FCRL6 30 13.29 2.83E-40 17.65 9.90E-70 15,266 21.95 9.70E-107 NA NA
PDE7A 31 -15.58 9.40E-55 -15.37 2.68E-53 15,266 -21.88 4.42E-106 NA NA
NSIP 32 -14.44 3.12E-47 -16.19 5.74E-59 15,266 -21.68 3.13E-104 N N
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Table 1. (Continued)
Discovery Replication Meta-analysis Generalization
Gene Rank Z-score P-value Z-score P-value N Z-score P-value Cerebellum frontal 
Cortex
PAICS 33 -16.00 1.26E-57 -14.34 1.29E-46 15,266 -21.42 9.39E-102 N Y (+)**
BZW2 34 -14.93 2.19E-50 -15.18 4.55E-52 15,266 -21.29 1.42E-100 Y (-)** Y (-)**
OXNAD1 35 -15.59 9.09E-55 -14.32 1.71E-46 15,266 -21.12 5.66E-99 NA NA
CX3CR1 36 14.09 4.14E-45 15.66 3.04E-55 14,385 21.07 1.67E-98 NA NA
SCML1 37 -14.00 1.58E-44 -15.69 1.92E-55 15,266 -21.01 5.02E-98 NA NA
RPL22 38 -14.91 3.03E-50 -14.79 1.79E-49 15,266 -20.99 8.61E-98 N Y (-)**
LDLRAP1 39 -14.57 4.19E-48 -14.82 1.15E-49 15,266 -20.78 6.69E-96 N NA
RHOC 40 12.89 4.89E-38 15.93 3.71E-57 15,266 20.43 8.94E-93 N Y (+)
LTB 41 -14.90 3.55E-50 -14.02 1.11E-44 15,266 -20.43 9.52E-93 NA NA
FAM134B 42 -15.17 5.88E-52 -13.43 3.96E-41 15,266 -20.19 1.31E-90 N N
LBH 43 -14.18 1.29E-45 -14.22 7.04E-46 15,266 -20.07 1.28E-89 NA Y (-)**
PRSS23 44 14.07 5.76E-45 14.07 6.25E-45 15,266 19.89 5.11E-88 NA NA
SUSD3 45 -14.26 4.01E-46 -13.91 5.30E-44 14,385 -19.87 6.90E-88 NA NA
PIK3IP1 46 -14.93 2.02E-50 -13.13 2.16E-39 15,266 -19.81 2.58E-87 Y (+)* Y (+)**
MFGE8 47 -12.46 1.23E-35 -15.34 4.09E-53 15,266 -19.70 2.06E-86 N N
AGMAT 48 -13.77 4.14E-43 -14.09 4.34E-45 15,266 -19.70 2.31E-86 NA NA
NKG7 49 14.43 3.17E-47 13.42 4.53E-41 15,266 19.67 3.67E-86 NA NA
PPP2R2B 50 13.49 1.81E-41 14.26 4.19E-46 15,266 19.63 9.40E-86 Y (-)* Y (-)
Y = p<0.05; Y* = p<0.01; Y** = p<0.0001; N = p>=0.05; NA= not expressed; N = sample size; (-) or (+) gives the 
direction of the effect with age. Y = p<0.05; Y* = p<0.01; Y** = p<0.0001; N = p>=0.05; NA= not expressed; N = 
sample size; (-) or (+) gives the direction of the effect with age.
Novel and known age-associated genes and pathways
To differentiate between changes caused by cell composition and other biological mechanisms, we 
clustered genes based on co-expression networks in GeneNetwork (see Methods) and performed 
pathway analysis on the clusters of co-expressed genes. Among the negatively age-correlated 
genes, three major clusters were identified (Figure 1, Supplementary Data 3A-M). The largest group 
(cluster #1, 109 genes) consisted of three sub-clusters enriched for: 1a) RNA metabolism functions, 
ribosome biogenesis, and purine metabolism, 1b) multiple mitochondrial and metabolic pathways 
including ten mitochondrial ribosomal protein (MRP) genes consistent with earlier ageing studies 
in mice, Caenorhabditis elegans [25] and Drosophila melanogaster [26-28], and 1c) DNA replication, 
elongation and repair, and mismatch repair [26]. The second cluster of negatively correlated genes 
(cluster #2, 57 genes) contained factors related to immunity; including T- and B- cell signaling genes, 
and genes involved in hematopoiesis. The third tight cluster (cluster #3) included 12 genes, of which 
11 encoded cytosolic ribosomal subunits: 7 RPL-genes (RPL8, RPL11, RPL18, RPL28, RPL30, RPL35, and 
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RPL36), 3 RPS-genes (RPS14, RPS16, and RPS29) and UBA52 (ribosomal protein L40). The other gene 
of the cluster (#12) was NACA, a nascent polypeptide-associated complex alpha subunit. The protein 
encoded by the NACA gene forms the nascent polypeptide-associated complex (NAC), which binds 
to nascent proteins as they emerge from the ribosome [29]. Strikingly, the mRNA abundance of 
many genes encoding ribosomal subunits and mitochondrial ribosomal proteins were significantly 
associated with chronological age: 34 ribosomal genes were significantly associated, of which 33 
were negatively correlated with chronological age (Supplementary Table 4), and 10 mitochondrial 
ribosomal protein (MRP) genes were significantly negatively correlated with chronological age 
(Supplementary Table 5). 
The positively age-correlated genes revealed four major clusters (Figure 1, Supplementary Data 
3N-V): cluster#1 (77 genes): innate and adaptive immunity, cluster#2 (9 genes): actin cytoskeleton, 
focal adhesion, and tight junctions, cluster#3 (8 genes): fatty acid metabolism and peroxisome activity, 
and cluster#4 (6 genes): lysosome metabolism and glycosaminoglycan degradation. 
For both brain tissue studies, we checked the number (and %) of overlapping age-associated genes 
for the different functional clusters: 24 genes (11.7% of the genes expressed in cerebellum) and 33 
genes (of the genes expressed in frontal cortex) of all pathway genes (278 genes) were associated 
with chronological age (Supplementary Tables 6 and 7). In cerebellum, the best replicating 
pathway was the positively age-correlated cluster #4: lysosome metabolism and glycosaminoglycan 
degradation. In frontal cortex, the best replicating pathway was the positively age-correlated cluster 
#2: actin cytoskeleton, focal adhesion, and tight junctions. 
Associations with prior ageing candidate genes
We investigated the intersection between genes significantly associated with chronological 
age in our study and candidate genes from previous human and animal studies (170 genes, see 
Supplementary Tables 8 and 9). Thirty-three of the 170 candidate genes were significantly associated 
with chronological age in our WB meta-analysis, including members of the mTOR/FOXO pathways 
(FOXO1, VEGFB, EIF4G3, SREBF1, STAT3, and RPS6KB1) [30], DNA repair (ATM) [31], and prior multi-
species candidates (LDHB, IGJ, IRF8,and FCGR1A). Twenty-eight of the 33 significant age-associated 
genes (~85%) have the same expression directionality in our CHARGE meta-analysis as previously 
reported in a variety of studies in humans and other model organisms. 
Premature ageing syndrome genes ATM (ataxia-telangiectasia), DKC (dyskeratosis congenita) and 
WRN (werner syndrome) all exhibited lower transcript abundance in older individuals, concordant 
with loss-of-function alterations in disease-related mutations. Based on the co-expression 
analyses, these genes clustered together with genes encoding proteins involved in DNA and RNA 
metabolism, DNA repair, and purine/pyrimidine metabolism. The Hutchinson-Gilford progeria gene 
LMNA showed higher mRNA levels in the elderly, consistent with earlier findings in muscle [32], and 
clustered with actin remodeling genes. 
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figure 1. Pathway analysis on the clusters of co-expressed genes. We ran a co-functionality network 
analysis on 897 down-regulated genes with age (negative effect direction) and 600 up-regulated genes 
with age (positive effect direction) using GeneNetwork. With a correlation threshold of 0.7, we selected all 
clusters bigger than 4 genes and ran per-cluster pathway analyses using KEGG, Reactome, and GO-terms in 
WEBGESTALT. Benjamini & Hochberg FDR was used for multiple testing corrections. The significant threshold 
0.05 after correction for multiple testing was applied. (A) Three clusters of down-regulated genes with 
age and (b) four clusters of genes up-regulated with age were enriched for functional pathways in KEGG, 
Reactome, and GO terms; the specific pathways are mentioned next to the (sub)cluster names.
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Methylation association patterns for top age-associated loci
Given the possible role of the methylome in ageing, we investigated whether age-associated 
methylation accompanied age-associated expression for the 1,497 age-associated genes. We 
analyzed methylation of 135,230 CpG sites (regions of DNA where a cytosine nucleotide occurs 
next to a guanine nucleotide) in or near (±250kb) the age-associated genes in WB or PBMCs from 
seven cohorts (N=3,073). We chose CpGs in a 250kb vicinity because earlier studies have shown 
that methylation can regulate gene expression levels at this distance [33], and that long range 
enhancer activities are present and actively regulate gene expression at a wide scale [34]. We 
observed significant associations between methylation and chronological age for 31,331 CpG sites, 
and between expression and methylation for 12,280 CpG sites, based on a conservative Bonferroni 
threshold (P<3.7E-7) (top results for each gene in Supplementary Data 4). 1,248 of the 1,497 age-
associated genes (83%) had ≥1 significant mediating CpGs and the number of significant mediating 
CpGs per gene ranged from 1 to 154 (Supplementary Data 4). 
To test whether the age-associated genes were enriched for nearby CpG methylation sites 
associated with chronological age or expression, we performed a similar analysis for a set of 1,497 
randomly selected genes matched for similar gene length and mean WB expression (see Methods 
and Supplementary Figures 3A-D). Compared to the set of random genes, age-associated genes 
had only mild enrichment for CpG methylation sites associated with chronological age (Figure 2A; 
Odds Ratio (OR) =1.04; 95% Confidence Interval (CI) =1.02-1.06; P=7.9E-5), but strong enrichment for 
CpG methylation sites associated with expression (Figure 2B; OR=2.68; 95%CI=2.58-2.78; P<1E-300). 
This pattern was consistent across all cohorts (Supplementary Figure 4) and within subsets of CpG 
methylation sites annotated to specific biological features (i.e., enhancer regions, promoter regions, 
CpG islands, etc.) (Supplementary Figure 5), and was robust to the entire range of significance 
thresholds (see Methods). This is consistent with a scenario where many methylation sites associate 
with chronological age, but only those with regulatory potential lead to altered transcript expression 
with chronological age. 
We used Sobel tests (see Methods) for all CpG methylation sites to investigate whether the observed 
patterns could potentially reflect a methylation-mediated relationship between chronological age 
and transcript levels. In total, 1,248 of the 1,497 age-associated genes (83%) had ≥1 CpG site with 
a significant Sobel test after Bonferroni adjustment for the number of CpGs tested (Supplementary 
Data 4). These potentially mediating CpG sites were less likely to reside in CpG islands (OR=0.28; 
95%CI=0.26-0.30; P<1E-300) or in promoters (OR=0.38; 95%CI=0.36-0.40; P<1E-300) and more 
likely to be located in enhancers (OR=2.29; 95%CI=2.17-2.41; P=2.7E-188) and insulators (OR=1.44; 
95%CI=1.23-1.67; P=6.6E-6), compared to non-mediating CpGs within 250kb of age-associated 
genes (Supplementary Figure 6). This pattern is again consistent with the mediation of age-
associated transcripts by age-associated methylation of CpG sites with specific regulatory roles. 
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figure 2. Age-associated genes are enriched for the presence of potentially functional methylation sites.
(A) Quantile-Quantile (QQ) plot of the observed p-values (-log10P) for the methylation~age associations. 
The plot in black shows p-values from the 1,497 significant age-associated genes, whereas the plot in red 
shows p-values for 1,497 random genes. We do not see enrichment for the 1,497 age-associated genes. (b) 
QQ plot of the observed p-values (-log10P) for the expression~methylation associations. The plot in black 
shows p-values from the 1,497 significant age-associated genes, whereas the plot in blue shows p-values for 
1,497 random genes. The age-associated genes are enriched for CpG methylation sites that associate with 
gene expression levels. 
Transcriptomic age prediction as a surrogate biomarker
All 11,908 discovery genes were used to build a predictor for age using a leave-one-out-prediction 
meta-analysis (see Methods). For each cohort in turn, we left out that cohort as the validation 
sample and re-ran the discovery meta-analysis on the other cohorts to avoid overlap between the 
discovery and validation sample (Supplementary Data 5A). The difference between the predicted 
transcriptomic age and chronological age (delta age) may be a reflection of altered biological age 
(see Methods). The correlation between chronological age and transcriptomic age was significant 
in all cohorts (P<2E-29) (Figure 3A-H). The average absolute difference between predicted age and 
chronological age was 7.8 years (n=8,847 samples, Supplementary Table 10). A positive delta age, 
interpreted as reflecting more rapid biological ageing, was consistently associated with higher 
systolic and diastolic blood pressure, total cholesterol, HDL cholesterol, fasting glucose levels, 
and body mass index (BMI) (Table 2, Supplementary Table 11). All analyses were adjusted for 
chronological age, and after adjustment for BMI all phenotypes remained associated in the same 
direction (Table 2, Supplementary Table 12). For systolic blood pressure, the added predictive value 
of the transcriptomic predictor over chronological age is shown for the Rotterdam Study (Figure 
4A-C). Other phenotypes showed the same pattern.
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figure 4. The added value of the transcriptomic predictor. To show the added value of the transcriptomic 
predictor, we choose one biological ageing phenotype systolic blood pressure (SBP), and plotted its 
correlation with chronological age (A), delta age (b), and the transcriptomic age (C) in the Rotterdam Study 
(n=597 samples with SBP data available). Delta age represents the difference between chronological age and 
transcriptomic age. SBP was plotted on the y-axis, and the age-related values were plotted on the x-axes. 
SBP was significantly associated with chronological age (P=4.0E-04), but SBP was even stronger associated 
with transcriptomic age (calculated with a cohort specific prediction formula based on gene expression 
levels) (P=8.7E-09), Therefore, the transcriptomic predictor adds value over chronological age alone. Other 
biological ageing phenotypes showed the same pattern.
502007-L-bw-Peters
42
Chapter 2
We compared our transcriptomic predictor with two already published epigenetic predictors of age 
of Horvath [23] and Hannum et al. [24] in 1,396 individuals from the KORA study and the Rotterdam 
Study, all having gene expression levels and methylation data available. The transcriptomic 
predictor was less strongly correlated with chronological age than the two epigenetic predictors 
(Supplementary Figure 7), which can be explained by the different data types used: we used gene 
expression data instead of DNA methylation data. 
Transcriptomic age and epigenetic age (both Hannum and Horvath) were positively correlated, 
with r2 values varying between 0.10 and 0.33 (Supplementary Figure 7). Interestingly, all three age 
predictors were associated with different ageing phenotypes (Supplementary Tables 13 and 14), 
i.e., the transcriptomic predictor was significantly associated with systolic blood pressure, waist-hip-
ratio, and smoking; the epigenetic Horvath predictor was associated with waist-hip-ratio only; and 
the epigenetic Hannum predictor was associated with fasting glucose, waist-hip-ratio, and smoking 
(all analyses were adjusted for chronological age, sex, and BMI). By adding two predictors into 
one formula (one transcriptomic predictor and one epigenetic predictor), both predictors added 
value (significant effect) to the phenotype associations, i.e. for waist-hip-ratio in KORA (explained 
variance transcriptomic predictor=0.015%, Horvath predictor=0.005%, Hannum predictor=0.006%; 
transcriptomic+Horvath=0.017%, and transcriptomic+Hannum=0.016%) (Supplementary Tables 15 
and 16).
DISCUSSION
Age-associated changes in gene expression levels point towards altered activity in defined age-
related molecular pathways that may play vital roles in the mechanisms of increased susceptibility 
to ageing diseases. In contrast to earlier, smaller studies [17-21] of human age-related molecular 
differences, we detected and replicated 1,497 age-associated genes in 14,983 individuals of European 
ancestry. Additionally, many of our associations were generalized across different ancestries and 
multiple cell and tissue types. Because we had much smaller sample sizes for both brain tissue 
(n=394) and the other ancestry groups (1,244 Hispanic Americans, 1,457 Native Americans, and 359 
African Americans), we used a nominal p-value threshold (P<0.05) in these specific sub-analyses. 
Larger sample sizes will ultimately be needed to fully understand the transferability of the ageing-
transcriptome signatures. 
A potential limitation of our study is that we relied on a linear regression model to identify age-
associated genes. A linear model assumes constant change over age, which may not be always 
correct in biological processes that stretch over several decades (adulthood). A recent study 
demonstrated that a quadratic regression model has a higher statistical fit to cross-sectional gene 
expression datasets over linear models [35]. Although we chose to apply a linear regression model in 
our study, we recognize that more complex models could be investigated in future studies. 
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Our human age-expression and pathway enrichment analysis results were consistent with known 
ageing mechanisms including dysregulation of transcription and translation, metabolic function, 
DNA damage accumulation, immune senescence, ribosome biogenesis, and mitochondrial decline. 
Houtkooper et al. [25] and others [26,27] highlighted the key role of mitochondria in ageing and 
longevity in model organisms. Mitochondria regulate a multitude of different metabolic and 
signaling pathways and also play an important role in programmed cell death [36]. The number of 
mitochondria decreases and their capacity to produce energy is reduced with chronological age 
[37-39]. Consistent with these reports, a large number of mitochondrial ribosomal proteins (MRPL24, 
MRPL3, MRPL35, MRPL45, MRPS18B, MRPS26, MRPS27, MRPS31, MRPS33, and MRPS9) showed lower 
expression at higher chronological age in our study, supporting the hypothesis that age-dependent 
mitochondrial dysfunction plays a causal role in human ageing. 
The large immune function associated clusters (cluster #2 and cluster #1 of the negatively and 
positively correlated genes, respectively) reflect immune senescence. The relative abundance 
of immune cells in WB shifts with ageing, with naïve T-cells decreasing and highly differentiated 
effector and memory T-cells increasing with chronological age [28,40-44]. Consistent with immune 
senescence, the mRNA abundance of the chemokine receptor CCR7 and cell differentiation antigens 
CD27 and CD28 was lower in older individuals (P=1.0E-208, P=2.8E-162, and P=5.8E-59). Notably, 
these results were consistent in many of the blood sub-cell-types. For example, CCR7 was lower in 
older individuals across multiple cell types including CD4+ cells (P=1.0E-08), CD8+ cells (P=3.0E-15), 
CD14+ cells /monocytes (P=8.5E-3), and PBMCs (P=3.0E-3). This suggests that genes in the immune 
associated clusters reflect a biological function related to a more general ageing phenotype , at least 
in multiple immune cell types, and are not solely accountable to cell count differences. We also note 
that cell subset classification is to a greater or lesser extent artificial, reflecting our current ability 
to distinguish cells based on specific small sets of available markers. Accepted subpopulation of 
cells can often be further broken down into additional subgroups as the tools for such classification 
become more sophisticated. The analysis of unfractionated cell populations (such as our study) adds 
a layer of complexity to the interpretation, but is not necessarily less informative than the analysis of 
marker defined subpopulations.
Aside from the immune clusters, we identified and newly emphasized pathways associated with 
human ageing, for example, glycosaminoglycan degradation and actin remodeling. These pathways 
have previously been implicated in life span regulation of the model organisms Caenorhabditis 
elegans and Drosophila melanogaster [45-47]. Glycosaminoglycans (GAGs) influence cell migration, 
proliferation and differentiation, and play a role in wound healing [48,49]. Impaired degradation 
of GAGs in extreme lysosomal storage disorders lead to chronic, progressive effects on a variety 
of organs and physiologic systems [50]. Tissue repair and regeneration are known to be impaired 
in the elderly and inhibition of GAG degradation may be therapeutic in these contexts [51]. Our 
findings suggest GAG degradation as a candidate mechanism for the age-associated changes. The 
actin cytoskeleton is a critical structural element in eukaryotic cells that is crucial in mediating cell 
responses to both internal and external signals in yeast [52]. Actin dynamics have clearly been linked 
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to yeast replicative ageing through both reactive oxygen species mediated apoptosis and through 
selective sequestration of healthy mitochondria to new daughter cells during cell division [52,53]. 
Our pathway analysis indicates that the actin cytoskeleton may be similarly important in human 
ageing. While much prior effort in targeting actomyosin dynamics has been aimed at cancers, recent 
studies indicate that targeted modulation of these systems could also have benefits in immune-
mediated pathologies [48].
In addition to these novel candidate pathways, our 1,497 age-associated genes contain genes in 
many pathways known to be associated with ageing. Beyond the immune-related pathways, we 
confirm an age-associated role for mitochondrial function [54], metabolic function [12], ribosome 
biogenesis [55], DNA replication, elongation and repair [56,57], focal adhesion [58], and lysosome 
metabolism [59], and suggest a number of new potential age-related targets within these pathways, 
including TTC27 (ribosome biogenesis); CCDC34 (ribosomal cluster); ARHGAP15, DOCK10, FAM129C, 
FCRLA, GIMAP7, and VPREB3 (T- and B- cell signaling genes and genes involved in hematopoiesis); 
GZMH, SAMD9L, and TAGAP (innate and adaptive immunity). Of note, overexpression of the full-
length ARHGAP15 protein in COS-7 and HeLa cells resulted in an increase in actin stress fibers and 
cell contraction, relating the newly ageing emphasized actin remodeling pathway and the focal 
adhesion pathway in ageing to immune cell changes [60]. Thus, by using co-expression networks, 
we identified new genes and pathways that are likely important in human ageing, opening new 
avenues of inquiry for future studies. 
Age-related epigenetic changes have recently been examined including a large study combining 
data across 7,844 non-cancer samples from 82 individual datasets to define a set of age-methylation 
clock genes. Only 35 of our 1,497 age-related genes were found among the genes harboring the 353 
age-methylation clock CpG sites reported by Horvath [23], suggesting that our age-associated genes 
may not be particularly enriched for age-associated CpG methylation sites. To test this formally, we 
analyzed the DNA methylation sites (CpG sites only) within 250kb (upstream and downstream) of 
all 1,497 age-associated genes, as well as a comparison set of 1,497 randomly chosen unassociated 
genes. We observed that the genes exhibiting age-associated transcript levels in blood are much 
more likely than other genes to harbor CpG methylation sites that associate with expression levels, 
but are not substantially more likely to harbor methylation differences in close CpG sites associated 
with chronological age. These results suggest that genes showing age-related expression differences 
are characterized primarily by the presence of nearby CpG sites with regulatory potential, rather 
than by the presence of age-associated CpG methylation sites, which are abundant everywhere in 
the genome. A limitation of our study is that we used the Illumina Infinium HumanMethylation450K 
BeadChip Array for measuring methylation levels: this array queries only 1.6% of all CpGs in the 
genome and the CpG selection is biased towards CpG islands. In addition, we did not examine 
non-CpG methylated sites, which have recently been suggested to play a role in regulating gene 
expression as well [61]. Other techniques – whole genome bisulfite sequencing [62] and methylC-
capture (MCC) sequencing [63] for example – have definite technical advantages (higher resolution 
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and no CpG island selection bias), but these have currently not been applied to a large number of 
samples. 
Although the CpG selection on the methylation array is biased towards CpG islands, the CpG 
sites for which methylation was associated with both expression and chronological age were 
strongly enriched for enhancer activity. This is consistent with the concept that methylation at 
enhancers is more variable and may regulate gene expression in development [64] and/or in 
environmental responses, while promoter methylation is comparatively stable. Interestingly, the 
age- and expression-associated CpGs were also enriched at insulators, which function to block the 
communication between an enhancer and a promoter, thereby preventing inappropriate gene 
activation. Taken together, these results suggest that the age-associated genes reported here may 
be regulated by methylation of CpG sites in specific functional regions, and that studying both 
methylation and expression as potential joint effectors of the ageing process may significantly 
improve the prediction of age and identification of novel age-related genes and pathways.
Using gene expression levels as a predictive biomarker indicated that individuals having higher 
predicted than chronological age also have clinical features consistent with an older age, such as 
higher blood pressure and total cholesterol levels. Developing a strongly predictive gene expression 
set as a biomarker panel has clinical potential to identify subjects at risk for early biological ageing, 
and provide a tool for targeting susceptible individuals for early intervention. It remains to be seen 
whether the transcriptomic age can serve as a surrogate marker to predict age-associated decline 
in other tissues. Therefore, the development of a robust transcriptomic predictor for age will require 
independent and prospective validation across different tissues. 
We observed that both the transcriptomic predictor and the epigenetic predictors were significantly 
associated with a number of phenotypes, but that the pattern of association differed among the 
predictors. Therefore, the transcriptomic age and the epigenetic age should be combined to 
obtain the optimal biological age prediction. A general transcriptomic prediction formula has 
been calculated that is freely available (Supplementary Data 5B). These results suggest that the 
biological mechanisms behind the transcriptomic and the epigenetic predictors are different. The 
exact mechanism of these differences need further examination in larger sample sizes and subgroup 
analysis were different diseases are studied. In addition, the predictors need to be evaluated for their 
prognostic value. In conclusion, gene expression levels are likely to become a valuable addition to 
evolving indicators of age based on epigenetic and telomeric age predictors. Ideally, a combination 
of transcriptomic, epigenetic, and telomeric elements could further improve and refine age 
prediction. 
In conclusion, we have identified a compendium of genes and pathways associated with human 
chronological age. By leveraging transcriptional information across large, multi-ethnic cohorts, 
different tissue types, and genomic repositories, we captured an unprecedented overview of the 
complex and temporally dynamic biological pathways orchestrating the ageing process. Our list of 
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genes should provide a rich trove of data for future ageing studies. While the pursuit of an anti-ageing 
panacea in humans remains a distant goal, our work has generated new biological hypotheses and 
will serve as a roadmap for future studies aimed at translating findings into treatment strategies for 
age-related diseases.
METHODS
Study design
We performed a differential expression meta-analysis in 7,074 human peripheral blood samples 
from six independent cohort studies, including EGCUT (n=1,086), FHS – 2nd generation (n=2,446), 
INCHIANTI (n=698), KORA (n=993), ROTTERDAM STUDY (n=881), and SHIP-TREND (n=970) 
(Supplementary Table 17). Gene expression data for each dataset was obtained using either 
PAXGene (Becton Dickinson) or Tempus Tubes (Life Technologies), followed by hybridization to 
Illumina Whole-Genome Expression BeadChips (HT12v3 or HT12v4) or Affymetrix Human Exon 1.0 
ST GeneChips. 
We replicated the significantly associated transcripts in 7,909 peripheral blood samples from seven 
independent cohort studies, including BSGS (n=862), DILGOM (n=512), FEHRMANN (n=1,191), FHS 
– 3rd generation (n=3,180), GTP (n=359), HVH (n=121 on the Illumina HT12v3 platform and n=227 
on the Illumina HT12v4 platform), and NIDDK/PHOENIX (n=1,457) (Supplementary Table 18). Gene 
expression data for these datasets was also obtained using either PAXGene (Becton Dickinson) or 
Tempus Tubes (Life Technologies), followed by hybridization to Illumina Whole-Genome Expression 
BeadChips (HT8v2, HT12v3, or HT12v4 arrays) or Affymetrix Human Exon 1.0 ST GeneChips. 
We generalized the significantly replicated transcripts in 4,644 samples with other tissue types, 
including: CD4+ cells of EGCUT (n=302) and a Boston sample (n=213), CD8+ cells of EGCUT (n=299), 
CD14+ cells (or monocytes) of a Boston sample (n=213) and MESA (n=354), LCLs of GENOA (n=869), 
lymphocytes of SAFHS (n=1,244), PBMCs of GARP (n=134) and PMBC-MS (n=228), and brain tissue 
(cerebellum and frontal cortex) of NABEC-UKBEC (n=394) (Supplementary Table 19). Gene expression 
data of these datasets was obtained by tissue specific RNA isolation and hybridization to Illumina 
Whole-Genome Expression BeadChips (WG6v1, HT12v3 or HT12v4), Affymetrix Human Exon Arrays, 
or Affymetrix Human Gene Arrays. 
The study outline is summarized in Supplementary Figure 8. The study populations, the RNA 
isolation methods, the amplification and labeling methods, and the array types used for each study 
are described in the supplementary methods. The covariates used in each study are presented in 
Supplementary Tables 17-19. 
Phenotype
Chronological age was defined as the length of time in years between birth and blood draw, using 
two decimals. Detailed descriptions of the chronological age distributions, fasting status, and the 
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available covariates from the participating cohorts are presented in Supplementary Tables 17-19 
and Supplementary Figures 9A-V. 
Illumina pipeline: gene expression probes and normalization procedure
The different Illumina platforms used by the different cohorts share a large number of probes with 
identical 50-mer probe sequences. Therefore, we harmonized the probes across the HT12-v3 and 
the HT12-v4 platforms by determining the probe sequences from the different annotation files 
for each platform; renumbering the probes on the basis of unique probe sequences. In total, we 
identified 56,330 unique Illumina probes (11,453 probes measured only on the HT12-v3 platform, 
7,529 probes measured only on the HT12-v4 platform, 37,348 probes measured on both platforms). 
Genes were declared significantly expressed in the discovery data when 1) the detection p-values 
calculated by GenomeStudio were <0.05 in more than 10% of all discovery samples, and 2) the 
probes were measured in at least two cohorts. This resulted in 23,170 transcripts considered as being 
significantly expressed in our Illumina discovery; these transcripts code for 15,639 well characterized 
unique genes. 3,484 genes have more than one Illumina probe on the HT12 platform. Illumina 
gene expression data was quantile-normalized to the median distribution and subsequently log2-
transformed. The probe and sample means were centered to zero.
Affymetrix pipeline: gene expression probes and normalization procedure
The Affymetrix platform generated CEL files, containing both gene-based and exon-based 
expression levels. We used the gene-based expression levels and normalized the data using 
Affymetrix Power Tools: probes with RLE mean values >3.0 (range 1.34-12.71) were considered to 
be significantly expressed. This resulted in 16,798 well characterized unique genes in the Affymetrix 
discovery. Samples with all probeset RLE means >0.7 were defined as outliers and excluded from 
further analysis. A genetic expression SNP analysis was undertaken to locate mislabeled samples 
and re-identify them where possible with high confidence. After exclusions and re-identification, 
the RMA normalization was repeated. 
Differential expression with chronological age
All Illumina studies ran a least squares linear regression model (lm) using the normalized and 
standardized gene expression values as dependent variables, chronological age as an explanatory 
variable, and with adjustments for the potential confounders: sex (factor), fasting and smoking 
status (both factors), plate origin (factor), RNA quality (RIN/RQS), and cell counts (# of granulocytes, 
lymphocytes, monocytes, erythrocytes, and platelets), so: 
lm(gene expression ~ chronological age + confounders + batch effects) 
The Affymetrix cohort ran a multivariate stepwise PC regression, using the normalized and 
standardized gene expression values as dependent variables, chronological age as an explanatory 
variable, and the significant technical covariates: all_probeset_mean, all_probeset_stdev, neg_
control_mean, neg_control_stdev, pos_control_mean, pos_control_stdev, all_probeset_rle_mean, 
all_probeset_mad_residual_mean, RNA quality (RIN), and RNA processing batch. Batch was included 
in modeling as a random factor while all others were fixed factors.
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Meta-analysis of significantly expressed genes
We ran four separate meta-analyses: one for the studies using the Illumina platforms in the discovery 
phase, one for the Illumina discovery studies plus the FHS Affymetrix discovery results, one for 
the replication sample combined, and one for the discovery samples plus replication samples for 
validated results in order to re-rank the final results list. For these meta-analyses, we used a sample 
size weighted meta-analysis based on p-values and the direction of the effects; using p-values, a 
Z-statistic characterizing the evidence for association was calculated. The Z-statistic summarized the 
magnitude and the direction of the effect. An overall Z-statistic and p-value was calculated from 
the weighted sum of the individual statistics. Weights were proportional to the square-root of the 
number of individuals examined in each sample and standardized such that the squared weights 
sum to 1. 
We calculated the Z-scores and p-values using the Meta-Analysis Tool for genome-wide association 
scans (METAL) [65]. METAL is a flexible and computationally efficient command line tool that was 
developed for meta-analyzing GWAS studies, but can easily be adapted to gene expression studies. 
Because we are dealing with gene expression levels and not SNPs, we changed the SNPID column 
to probe IDs and gave all probes a minor allele A and a major allele G, a minor allele frequency=0.10, 
and a + strand. For the positions, the probe chromosomes and the midpoint position of the probes 
were used. Sample sizes, effect directions, and p-values were extracted from the linear model results 
files. We extensively tested what input parameters to use for meta-analyzing gene expression data. 
By using similar allele names, allele frequencies, and allele strands for all cohorts, we forced METAL 
to use the default meta-analysis approach. We tested an inverse variance weighted meta-analysis 
(using the effect size estimates and the standard errors), and found that our METAL meta-analysis 
results were identical to the meta-analysis results using the R package Meta.
Meta-analysis of discovery samples 
To calculate which genes are significantly associated with chronological age, we ran a sample 
size weighted meta-analysis based on p-values and the direction of the effects of the results of 
the Affymetrix and the Illumina meta-analyses. Combining the 16,798 Affymetrix probes and the 
15,639 Illumina probes, these platforms have 11,908 genes significantly expressed in WB samples 
in common.
Replication phase. Genes with a p-value <4.20E-6 (0.05 / 11,908 genes tested) were considered 
transcriptome-wide significantly associated with chronological age. We replicated these findings in 
an additional 8,009 samples (Supplementary Table 18). Replication cohorts used the same analysis 
plan and R-scripts as the discovery phase, however, some covariates were not available in these 
cohorts and ethnicities could be different than European-ancestry. 
Meta-analysis of the replication cohorts. We meta-analyzed the summary statistics of the replication 
cohorts using METAL. Genes were considered significantly replicating if P<2.23E-5 (0.05/2,238 genes 
tested) and the overall Z-score was in the same direction as the overall Z-score of the discovery 
meta-analysis. 
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Meta-analysis of discovery and replication cohorts. We additionally performed a meta-analysis based 
on the summary statistics of all discovery and all replication cohorts and obtained two-sided 
P-values. 
Generalization phase
To see whether our findings are specific for WB, we tried to generalize our significantly replicating 
transcripts in samples of other tissue types, including CD4+ cells, CD8+ cells, CD14+ cells (monocytes), 
LCLs, lymphocytes, PBMCs, and brain tissue (both cerebellum and frontal cortex) (Supplementary 
Table 19). If we had data of one tissue type of more than one cohort, we ran a meta-analysis based 
on the summary statistics of both cohorts. Because sample sizes of these tissue types were very 
small, we considered p-values <0.05 (with an identical effect direction) sufficient to document 
generalization of the effect. 
Pathway analysis of significant genes
We used WEBGESTALT (http://bioinfo.vanderbilt.edu/webgestalt/analysis.php) and GeneNetwork 
(http://genenetwork.nl:8080/GeneNetwork/pathway_network.html) for pathway analysis of age-
associated transcripts. First, we ran the co-functionality network analysis separately on 897 
down-regulated genes and 600 up-regulated genes, using a correlation threshold of 0.7. Of 897 
down-regulated genes, 192 formed cluster groups at this threshold, and of 600 up-regulated genes, 
114 formed cluster groups. We next re-ran the co-expression cluster analysis on these 192 and 114 
genes, using a correlation threshold of 0.65 to see if small clusters could be merged together if a 
lower co-expression threshold was applied. We selected clusters with 5 and more genes for pathway 
analysis; in total 178 and 100 down- and up-regulated genes respectively. Based on the clustering 
analysis, we performed per-cluster pathway analysis. Pathways were selected using KEGG, Reactome 
and GO-terms. In WEBGESTALT Benjamini & Hochberg FDR was used for multiple testing corrections. 
The significant threshold 0.05 after correction for multiple testing was applied. 
Analysis of chronological age, methylation, and expression 
For 3,073 blood samples with methylation data available from the Illumina 450K array, we analyzed 
methylation for CpG sites within 250kb of the 1,497 genes identified in the differential expression 
meta-analysis. For this analysis we performed a new meta-analysis of samples from seven cohorts 
including EGCUT (n=82), InChianti (n=485), KORA (n=735), Rotterdam Study (n=726), BSGS (n=610), 
GTP (n=315), and GARP (n=120); all samples were derived from whole-blood except for GARP 
(PBMCs). After filtering (to remove non-specific probes and probes with SNPs in the probe target as 
documented by Price et al.), 135,230 CpG sites within 250kb of the 1,497 age-associated genes were 
eligible for analysis [66]. 
Within each cohort, we fit two linear regression models where we considered as our dependent 
variable either standardized gene expression values for a particular gene or methylation β-values, 
which are measures of the proportion of DNA methylated within a sample, for a particular CpG 
site. In Model 1, we regressed methylation β-values on chronological age. In Model 2, we regressed 
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gene expression on both methylation and chronological age. In both models we adjusted for 
the following potential confounders as available in each cohort: sex, fasting- and smoking status 
(both modeled as categorical variables or factors), and cell counts (# of granulocytes, lymphocytes, 
monocytes, erythrocytes, and platelets). In Model 1, where methylation was the dependent variable 
we adjusted for chip and row on chip (both as factors). In Model 2, where the dependent variable 
was gene expression we adjusted for plate origin (factor) and RNA quality (RIN/RQS). For each of the 
age-associated genes, we fit these models separately for each CpG site within 250kb (upstream or 
downstream) of the gene. 
To combine results from these models across cohorts, we performed a sample size weighted meta-
analysis based on the t-statistics from these models. For each model, we calculated a Z-score as 
the weighted sum of t-statistics across the seven cohorts. As above, weights were proportional to 
the square-root of the number of individuals analyzed in each cohort and selected such that the 
squared weights sum to 1. To test for mediation of the age-expression relationship by methylation 
of a particular CpG site, we used the Z-scores from Model 1 and Model 2 to perform a Sobel test [67], 
such that our Sobel Z-score was equal to: 
SobelZ = Z1 Z2 /   Z1
2 + Z2
2  (1)
where Z1 is the meta-analysis Z-score from the association between methylation and chronological 
age in Model 1, and Z2 is the meta-analysis Z-score from the association between expression 
and methylation, adjusted for chronological age, in Model 2. To assess overall significance for 
each model (Model 1, Model 2, and the Sobel test), we used a Bonferroni-adjusted α-level of 
.05/135,230=3.70 × 10-7 for all CpG sites tested. To assess whether sites in each gene were significant, 
we assessed Bonferroni significance for each gene according to the number of CpG sites tested in 
that gene.
To test whether the genes were enriched for CpG sites associated with chronological age in Model 
1, or CpG sites associated with expression in Model 2, we performed similar analyses on a set of 
1,497 random genes. We chose these genes by first selecting the 5000 least-associated genes from 
the original age-expression analysis. We then used the optmatch R package [68] to select a subset 
of 1,497 random genes that were well-matched to the 1,497 age-associated genes in terms of gene 
length (bp) and the log of mean expression in WB. By doing this, we obtained a set of 1,497 random 
genes that were similar to the 1,497 age-associated genes in distributions of gene length, mean 
expression, and number of CpG sites within 250kb (Supplementary Figure 3A-D). We then performed 
the meta-analysis for Models 1 and 2 for all eligible CpG sites (after filtering to remove sites with 
probes that were non-specific or harbored genetic variants) within 250kb of these genes. We used 
Fisher’s exact test to test whether there was an increased proportion of significant (p<α) CpG sites in 
each model in the age-associated genes compared to the random genes. For our main enrichment 
test we set α=2.37×10-7 as in the original analysis but to ensure robustness we re-performed the 
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enrichment test for a wide range of α-levels, ranging from 10-20 to .05, and observed that results were 
consistent for all α-levels considered.
To identify whether the mediating CpG sites were located in functionally relevant regions, we took 
two main approaches. First, we intersected the CpG positions with the hg19 CpG island annotation 
track from UCSC Genome Browser (http://genome.ucsc.edu), to determine whether each site was 
located in a CpG island, CpG shore (+/- 1.5 kb from island) or CpG shelf (+/- 1.5 kb from shore). 
Second, we intersected the CpG positions with ENCODE’s ChromHMM annotation for lymphoblastoid 
cell line GM12878, which uses a hidden Markov model to assign genomic features based on the 
combinatorial pattern of various chromatin marks [69]. The ChromHMM annotation allowed us to 
identify CpGs located in promoters, enhancers, and insulators. We then used Fisher’s exact test to 
assess whether there was significant enrichment of each feature in mediating CpG sites compared 
to other CpG sites within the 1,497 genes. 
Query of candidate age-expression associated genes and pathways
A total of 204 candidate genes were identified from a variety of sources including Mendelian ageing 
disorders, longevity genetics candidates [11,12,70-72], and members of key ageing pathways, 
mainly FOXO/mTOR, key DNA repair genes, regulators of telomere maintenance, and mitochondrial 
ribosomal proteins [12,25,71,73]. Additional candidates included those from past human or multi-
species expression studies [74-76], and markers of naïve or differentiated immune cells [77]. Animal 
model gene names were translated to human homolog names. All genes and their known human 
alias names were searched against the discovery and replication results. Thirty-three genes were not 
tested due to lack of measurement or blood expression below filtered levels. Most candidate genes 
(n=126) were analyzed but did not meet the strict discovery thresholds to be carried forward to 
the replication phase (Supplementary Table 9). Of 45 genes carried into replication, 33 convincingly 
replicated in WB (Supplementary Table 8). 
Transcriptomic age prediction as surrogate biomarker
To investigate how accurate biological age can be predicted from gene expression levels, we 
performed a leave-one-out prediction analysis, i.e., re-running the meta-analysis excluding each of 
the validation cohorts. For all models, we used the standardized residuals of the gene expression 
levels, which were obtained by adjusting the gene expression levels for the technical covariates 
(RNA quality, batch effects) and some biological covariates (sex, fasting status, smoking status, and 
cell counts). 
To predict age, we needed to have the estimated effect sizes of the gene expression levels on 
chronological age (model 1: chronological age ~ gene expression). However, effect sizes from the 
meta-analysis were for chronological age on gene expression levels (model 2: gene expression ~ 
chronological age). We used an equivalent transformation to convert the effect size in model 2 to 
that in model 1 by the following equation:
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n + z2
b = z  (2)
where b  is the effect size of the gene expression level on chronological age (model 1), based on 
standardized chronological age and standardized gene expression levels, so that it needs to be 
interpreted in standard deviation (SD) unit for both chronological age and gene expression level; z 
is the z-statistic for association from the meta-analysis; and n is the sample size. We then conducted 
an approximate ridge regression analysis based on a random effect model, which is analogue to 
the best linear unbiased prediction (BLUP) approach in mixed linear model analysis, to estimate the 
effect sizes of all 11,908 genes jointly taking correlations between probes into account. The random 
effect model can be written as:
y = X ∗ bR + e (3)
where y is the vector of age phenotype and X is the matrix of gene expression level, bR is a vector of 
effects of gene expression on age with:
bR ~ N(0,1σ
2
b) (4)
and e is a vector of residual with:
e ~ N(0,1σ2e) (5)
In a ridge regression analysis, bR can be estimated as 
b R = (X'X + Iλ)-1 X'y (6)
where
λ = σe
2 / σb
2 (7)
In a single probe based meta-analysis, the analysis is equivalent to:
b = D-1X'y (8)
where b is a vector of effect sizes estimated from the meta-analysis and D is the diagonal matrix 
of X'X. If the gene expression level of each probe is standardized, the i-th diagonal element of D is: 
Dii = n  (9)
with n being the sample size. We therefore have 
X'y = Db  (10)
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so that 
b R = (X'X + 1λ)-1 Db = (R + 1λ/n)-1b  (11)
where R is the correlation matrix between probes. This method largely follows the method that was 
proposed to estimate the joint effect sizes of SNPs using summary data from GWAS and linkage 
disequilibrium between SNPs from a reference sample [78]. We estimated bR using b  from the meta-
analysis (excluding the validation cohort) and probe correlation matrix R from reference samples 
(also independent from the validation cohort). 
We calibrated the parameter λ using BSGS as the validation cohort (finding a λ value that maximized 
prediction accuracy in BSGS) (Supplementary Figure 10) and applied it to the prediction analysis in 
the other validation cohorts (Supplementary Data 5A). We call this an approximate method because 
the correlation matrix R consisted of weighted averages (weighted by sample size) from up to 6 
of the discovery cohorts rather than all the samples pooled together. We applied the estimates of 
the individual genes from the ridge regression analysis to the left-out sample (validation sample) 
to predict age, and calculated the correlation coefficient of chronological age and the predicted 
transcriptomic age (Figure 3A-H).
Since the effect sizes of the probes were estimated from the meta-analyses excluding the validation 
sample, the validation set is completely independent from the discovery (training) set, so that the 
prediction accuracy is unbiased. We created the predictor of an individual in the validation cohort as
 
Z = Σi χv(i) b R(i) (12)
with χv(i) being the gene expression level of i-th probe in the validation cohort. We scaled Z using the 
mean and standard deviation (SD) of chronological age from the validation cohort:
SZ = μage + (Z - μz) ∗
σage
σz
 (13)
where µage and σage are the mean and SD of chronological age from the validation cohort, and µz 
and σz are the mean and SD of the predictor Z. Delta age was defined as the difference between the 
scaled transcriptomic predicted age (SZ) and chronological age for each individual. 
We explored whether delta age was associated with any multi-systemic biological parameter (or 
biomarker) of ageing, such as sex, blood pressure, cholesterol levels, glucose levels, etc. For all 
biomarkers used, outliers were excluded from the analysis. Associations were tested using a linear 
model, including the phenotype of interest as the outcome (the dependent variable) and the delta 
age as the independent variable; all associations were adjusted for chronological age. To overcome 
the effects of obesity on cardiovascular disease and other traits, we additionally adjusted for BMI in 
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a second model. Additionally, we tested whether the biological parameters were directly associated 
with chronological age (Supplementary Table 20), so:
lm(phenotype~chronological-age)  (14)
Transcriptomic age prediction for external cohorts
A general transcriptomic predictor (Z) was generated which can be used by external researchers 
for future purposes. This predictor was calculated using the prediction meta-analysis of all cohorts 
(except BSGS on which we calibrated the λ parameter) (Supplementary Figure 10). Cohorts that have 
chronological age available should scale the predictor as we did for the validation cohorts (equation 
13), using the mean and SD of chronological age and the mean and SD of the predictor (Z).
To make our predictor useful to cohorts that do not have chronological age available, we further 
transformed the predictor to a scaled transcriptomic predictor (in years). This scaled predictor was 
calculated using the mean and SD of chronological age from all discovery cohorts in the meta-
analysis (equation 13). Since the individual level age data was not available, the SD of chronological 
age was calculated using the pooled variance method (Supplementary Table 21).
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AbSTRACT
Genome-wide association studies (GWAS) have uncovered numerous genetic variants (SNPs) that 
are associated with blood pressure (BP). Genetic variants may lead to BP changes by acting on 
intermediate molecular phenotypes such as coded protein sequence or gene expression, which 
in turn affect BP variability. Therefore, characterizing genes whose expression is associated with 
BP may reveal cellular processes involved in BP regulation and uncover how transcripts mediate 
genetic and environmental effects on BP variability. A meta-analysis of results from six studies of 
global gene expression profiles of BP and hypertension in whole blood was performed in 7,017 
individuals who were not receiving antihypertensive drug treatment. We identified 34 genes that 
were differentially expressed in relation to BP (Bonferroni-corrected p<0.05). Among these genes, 
FOS and PTGS2 have been previously reported to be involved in BP-related processes; the others 
are novel. The top BP signature genes in aggregate explain 5%-9% of inter-individual variance in BP. 
Of note, rs3184504 in SH2B3, which was also reported in GWAS to be associated with BP, was found 
to be a trans regulator of the expression of 6 of the transcripts we found to be associated with BP 
(FOS, MYADM, PP1R15A, TAGAP, S100A10, and FGBP2). Gene set enrichment analysis suggested that 
the BP-related global gene expression changes include genes involved in inflammatory response 
and apoptosis pathways. Our study provides new insights into molecular mechanisms underlying 
BP regulation, and suggests novel transcriptomic markers for the treatment and prevention of 
hypertension. 
AUTHOR SUMMARy
The focus of blood pressure (BP) GWAS has been the identification of common DNA sequence 
variants associated with the phenotype; this approach provides only one dimension of molecular 
information about BP. While it is a critical dimension, analyzing DNA variation alone is not sufficient 
for achieving an understanding of the multidimensional complexity of BP physiology. The top loci 
identified by GWAS explain only about 1 percent of inter-individual BP variability. In this study, we 
performed a meta-analysis of gene expression profiles in relation to BP and hypertension in 7,017 
individuals from six studies. We identified 34 differentially expressed genes for BP, and discovered 
that the top BP signature genes explain 5%-9% of BP variability. We further linked BP gene 
expression signature genes with BP GWAS results by integrating expression associated SNPs (eSNPs) 
and discovered that one of the top BP loci from GWAS, rs3184504 in SH2B3, is a trans regulator of 
expression of 6 of the top 34 BP signature genes. Our study, in conjunction with prior GWAS, provides 
a deeper understanding of the molecular and genetic basis of BP regulation, and identifies several 
potential targets and pathways for the treatment and prevention of hypertension and its sequelae.
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INTRODUCTION 
Systolic and diastolic blood pressure (SBP and DBP) are complex physiological traits that are 
affected by the interplay of multiple genetic and environmental factors. Hypertension (HTN) is a 
critical risk factor for stroke, renal failure, heart failure, and coronary heart disease [1]. Genome- wide 
association studies (GWAS) have identified numerous loci associated with BP traits [2,3]. These loci, 
however, only explain a small proportion of inter-individual BP variability. In aggregate the 29 loci 
reported by the International Consortium of Blood Pressure (ICBP) consortium GWAS account for 
about one percent of BP variation in the general population [3]. Most genes near BP GWAS loci are 
not known to be mechanistically associated with BP regulation [3]. Therefore, further studies are 
needed to determine whether the genes implicated in GWAS demonstrate functional relations to 
BP physiology and to uncover the molecular actions and interactions of genetic and environmental 
factors involved in BP regulation.
Alterations in gene expression may mediate the effects of genetic variants on phenotype variability. 
We hypothesized that characterizing gene expression signatures of BP would reveal cellular 
processes involved in BP regulation and uncover how transcripts mediate genetic and environmental 
effects on BP variability. We additionally hypothesized that by integrating gene expression profiling 
with genetic variants associated with altered gene expression (eSNPs or eQTLs) and with BP GWAS 
results, we would be able to characterize the genetic architecture of gene expression effects on BP 
regulation.
Several previous studies have examined the association of global gene expression with BP [4,5] or 
HTN [6,7]. Most of these studies, however, were based on small sample sizes and lacked replication 
[4,5,6,7]. To address this challenge, we conducted an association study of global gene expression 
levels in whole blood with BP traits (SBP, DBP, and HTN) in six independent studies. In order to avoid 
the possibility that the differentially expressed genes we identified reflect drug treatment effects, 
we excluded individuals receiving anti-hypertensive treatment. The eligible study sample included 
7,017 individuals: 3,679 from the Framingham Heart Study (FHS), 972 from the Estonian Biobank 
(EGCUT), 604 from the Rotterdam Study (RS) [8], 597 from the InCHIANTI Study, 565 from the 
Cooperative Health Research in the Region of Augsburg [KORA F4] Study [9], and 600 from the Study 
of Health in Pomerania [SHIP-TREND] [10]. We first identified differentially expressed BP genes in the 
FHS (n=3,679) followed by external replication in the other five studies (n=3,338). Subsequently, 
we performed a meta-analysis of all 7,017 individuals from the six studies, and identified 34 
differentially expressed genes associated with BP traits using a stringent statistical threshold based 
on Bonferroni correction for multiple testing of 7,717 unique genes. The differentially expressed 
genes for BP (BP signature genes) were further integrated with eQTLs and with BP GWAS results 
in an effort to differentiate downstream transcriptomic changes due to BP from putatively causal 
pathways involved in BP regulation.
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RESULTS
Clinical characteristics
After excluding individuals receiving anti-hypertensive treatment, the eligible sample size was 
7,017 (FHS, n=3,679; EGCUT, n=972; RS, n=604; InCHIANTI, n=597; KORA F4, n=565 and SHIP-TREND, 
n=600). Clinical characteristics of participants from the four studies are presented in Table 1. The 
mean age varied across the cohorts (FHS=51, EGCUT=36, RS=58, InCHIANTI=71, KORA F4=72 and 
SHIP-TREND=46 years) as did the proportion of individuals with hypertension (11% in FHS, 19% in 
EGCUT, 35% in RS, 45% in InCHIANTI, 26% in KORA, and 12% in SHIP).
Table 1. Clinical characteristics of the study cohorts
fHS 
N=3,679
EGCUT 
N=972
RS 
N=604
InCHIANTI 
N=597
KORA f4 
N=565
SHIP-TREND 
N=600
Age (years) 51 ± 12 36 ± 14 58 ± 8 71 ± 16 72 ± 5 46 ± 13
Sex, male (%) 42 49 46 46 51 43
Hypertension (%) 11 19 35 45 26 12
BMI (kg/m2) 27.2 ± 5.3 24.8 ± 4.4 26.8 ± 4.1 27.0 ± 4.2 29.8 ± 4.6 26 ± 4.2
Systolic BP (mm Hg) 118 ± 15 122 ± 16 132 ± 20 132 ± 20 129 ± 21 120 ± 15
Diastolic BP (mm Hg) 74 ± 9 76 ± 10 82 ± 11 78 ± 10 73 ± 11 75 ± 9
Identification and replication of differentially expressed bP signature genes
At a Bonferroni corrected p<0.05, we identified 73, 31, and 8 genes that were differentially expressed 
in relation to SBP, DBP, and HTN, respectively in the FHS, which used an Affymetrix array for expression 
profiling, and 6, 1, and 1 genes in the meta-analysis of the 5 cohorts that used an Illumina array 
(Illumina cohorts): EGCUT, RS, InCHIANTI, KORA F4 and SHIP-TREND (Supplementary Table 1). For each 
differentially expressed BP gene in the FHS or in the Illumina cohorts, we attempted replication in 
the other group. At a replication p<0.05 (Bonferroni corrected), 13 unique genes that were identified 
in the FHS were replicated in the Illumina cohorts, including 10 for SBP (CD97, TAGAP, DUSP1, FOS, 
MCL1, MYADM, PPP1R15A, SLC31A2, TAGLN2, and TIPARP), 5 for DBP (CD97, BHLHE40, PRF1, CLC, and 
MYADM), and 2 for HTN (GZMB and MYADM) (Table 2). Each of the unique BP signature genes in 
the Illumina cohorts, 6 for SBP (TAGLN2, BHLHE40, MYADM, SLC31A2, DUSP1, and MCL1), 1 for DBP 
(BHLHE40) and 1 for HTN (SLC31A2), replicated in the FHS. All 6 Illumina cohorts BP signature genes 
that replicated in the FHS were among the 13 FHS BP signature genes that replicated in the Illumina 
cohorts. The BP signature genes identified in the FHS showed enrichment in the Illumina cohorts 
at pi1=0.88, 0.75, and 0.99 for SBP, DBP, and HTN respectively (pi1 value indicates the proportion of 
significant signals among the tested associations [11]; see details in the Methods section). Figure 1 
shows that the mean gene expression levels of the top BP signature genes were consistent with the 
BP phenotypic changes observed in the FHS and the Illumina cohorts. 
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The 73 SBP signature genes in the FHS (55 of these 73 genes were measured in the Illumina cohorts) 
at a Bonferroni corrected p<0.05 in aggregate explained 9.4% of SBP phenotypic variance in the 
Illumina cohorts, and the 31 DBP signature genes from the FHS (22 of these 31 genes were measured 
in the Illumina cohorts) in aggregate explained 5.3% of DBP phenotypic variance in the Illumina 
cohorts. These results suggest that in contrast to common genetic variants identified by BP GWAS, 
which explain in aggregate only about 1% of inter-individual BP variation [3], changes in gene 
expression levels explains a considerably larger proportion of phenotypic variance in BP. 
Meta-analysis of the six cohorts identifies differentially expressed bP signature genes
A meta-analysis of differential expression across all six cohorts revealed 34 differentially expressed 
BP genes at p<0.05 (Bonferroni corrected for 7,717 genes that were measured and passed quality 
control in the FHS and Illumina cohorts), including 21 for SBP, 20 for DBP, and 5 for HTN (Table 2 and 
Supplementary Figure 2). All of the 34 differentially expressed BP signature genes showed directional 
consistency in the FHS and the Illumina cohorts (Table 2). The 34 BP signature genes included all 13 
genes that were cross-validated between the FHS and the Illumina cohorts. Of the 34 BP signature 
genes, 27 were positively correlated with BP and only 7 genes were negatively correlated. MYADM 
and SLC31A2 were top signature genes for SBP, DBP, and HTN. At FDR<0.2, 224 unique genes were 
differentially expressed in relation with BP phenotypes, including 142 genes for SBP, 137 for DBP, and 
45 for HTN (details are reported in the Supplementary Text 1 and 2, and Supplementary Tables 3-5).
functional analysis of differentially expressed bP signature genes
We used gene set enrichment analysis (GSEA) to identify the biological process and pathways 
associated with gene expression changes in relation to SBP, DBP, and HTN in order to better 
understand the biological themes within the data. As shown in Table 3, the GSEA of genes whose 
expression was positively associated with BP showed enrichment for antigen processing and 
presentation (p<0.0001), apoptotic program (p<0.0001), inflammatory response (p<0.0001), 
and oxidative phosphorylation (p=0.0018). The negatively associated genes showed enrichment 
for nucleotide metabolic process (p<0.0001), positive regulation of cellular metabolic process 
(p<0.0001), and positive regulation of DNA dependent transcription (p=0.0021).
Genetic effects on expression of bP signature genes 
Among the 34 BP signatures genes from the meta-analysis of all 6 studies, 33 were found to have cis-
eQTLs and 26 had trans-eQTLs (Figure 2A and Supplementary Table 2) based on whole blood profiling 
[12,13]. Of these, six master trans-eQTLs mapped to either five or six BP signature genes (no master 
cis-eQTL was identified). Five master trans-eQTLs (rs653178, rs3184504, rs10774625, rs11065987, 
and rs17696736) were located on chromosome 12q24 within the same linkage disequilibrium (LD) 
block (r2 >0.8, Figure 2B). We retrieved a peak cis- and trans-eQTL for each BP signature gene. The 
peak cis-eQTL explained 0.2-20% of the variance in the corresponding transcript levels, in contrast, 
the peak trans-eQTL accounted for very little (0.02-2%) of the corresponding transcript variance. 
Westra et al. also reported a similar small proportion of variance in transcript levels explained by 
trans-eQTLs [12]. 
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We then linked the cis- and trans-eQTLs of the 34 BP signature genes with BP GWAS results from 
the ICBP Consortium [3] and the NHGRI GWAS Catalog [14] (Figure 2 and Supplementary Table 2). 
We did not find any cis-eQTLs for the top BP signature genes that also were associated with BP in 
the ICBP GWAS [3]. However, the 6 master trans-eQTLs were all associated with BP at p<5E-8 in the 
ICBP GWAS [3] and were associated with multiple complex diseases or traits (Table 4). For example, 
rs3184504, a nonsynonymous SNP in SH2B3 that was associated in GWAS with BP, coronary heart 
disease, hypothyroidism, rheumatoid arthritis, and type 1 diabetes [12], is a trans-eQTL for 6 of our 
34 BP signature genes from the meta-analysis (FOS, MYADM, PP1R15A, TAGAP, S100A10, and FGBP2; 
Figure 2A-B and Table 4). These 6 genes are all highly expressed in neutrophils, and their expression 
levels are correlated significantly (average r2=0.04, p<1E-16). rs653178, intronic to ATXN2 and in 
perfect LD with rs3184504 (r2=1), also is associated with BP and multiple other diseases in the NHGRI 
GWAS Catalog [14]. It also is a trans-eQTL for the same 6 BP signature genes (Table 4). These two 
SNPs are cis-eQTLs for expression SH2B3 in whole blood (FDR<0.05), but not for ATXN2 (FDR=0.4). We 
found that the expression of SH2B3 is associated with expression of MYADM, PP1R15A, and TAGAP 
(at Bonferroni corrected p<0.05), but not with FOS, S100A10, or FGBP2. The expression of ATXN2 was 
associated with expression of 5 of the 6 genes (PP1R15A was not associated). Supplementary Figure 
3 shows the co-expression levels of the eight genes that were cis- or trans-associated with rs3184504 
and rs653178 genotypes. These results suggest that there may be a pathway or gene co-regulatory 
mechanism underling BP regulation involving these genes that is driven by this common genetic 
variant (rs3184504; minor allele frequency 0.47) or its proxy SNPs. 
We further checked whether the cis- or trans-eQTLs for the top 34 BP signature genes are associated 
with other diseases or traits in the NHGRI GWAS catalog [14]. We identified 12 cis-eQTLs (for 8 genes) 
and 6 trans-eQTLs (for 6 genes) that are associated with other diseases or traits in the NHGRI GWAS 
catalog [14] (Table 4). 
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DISCUSSION 
Our meta-analysis of gene expression data from 7,017 individuals from six studies identified and 
characterized whole blood gene expression signatures associated with BP traits. Thirtyfour BP 
signature genes were identified at Bonferroni corrected p<0.05 (224 genes were identified at 
FDR<0.2, reported in the S1 Text). Thirteen BP signature genes replicated between the FHS and 
Illumina cohorts. The top BP signature genes identified in the FHS (55 genes for SBP and 22 genes for 
DBP) explained 5-9% of inter-individual variation in BP in the Illumina cohorts on average. Among 
the 34 BP signature genes (at Bonferroni corrected p<0.05), only FOS [15] and PTGS2 [16] have been 
previously implicated in hypertension. We did not find literature support for a direct role of the 
remaining signature genes in BP regulation. However, we found several genes involved in biological 
functions or processes that are highly related to BP, such as cardiovascular disease (GZMB, ANXA1, 
TMEM43, FOS, KCNJ2, PTGS2, and MCL1), angiogenesis (VIM and TIPARP), and ion channels (CD97, 
ANXA1, S100A10, PRF1, ANTXR2, SLC31A2, TIPARP, and KCNJ2). We speculate that these genes may be 
important for BP regulation, but further experimental validation is needed. 
Seven of the 34 signature genes, including KCNJ2, showed negative correlation of expression with 
BP. KCNJ2 is a member of the potassium inwardly-rectifying channel subfamily; it encodes the 
inward rectifier K+ channel Kir2.1, and is found in cardiac, skeletal muscle, and nervous tissue [17]. 
Most outward potassium channels are positively correlated with BP. Loss-of function mutations in 
ROMK (KCNJ1, the outward potassium channel) are associated with Bartter’s syndrome, and ROMK 
inhibitors are used in the treatment of hypertension [18,19]. Previous studies reported that greater 
potassium intake is associated with lower blood pressure [20-23]. These data suggest that KCNJ2 
up-regulation may be a means of lowering BP. 
By linking the BP signature genes with eQTLs and with BP GWAS results, we found several SNPs 
that are associated with BP in GWAS and that also are trans associated with several of our top BP 
signature genes. For example, rs3184504, a non-synonymous SNP located in exon 3 of SH2B3, is 
associated in GWAS with BP, coronary heart disease, hypothyroidism, rheumatoid arthritis, and 
type I diabetes [12]. rs3184504 is a common genetic variant with a minor allele frequency of 
approximately 0.47; the rs3184504-T allele is associated with an increment of 0.58 mm Hg in SBP 
and of 0.48 mm Hg in DBP [2]. rs3184504 is a cis-eQTL for SH2B3, expression of this gene was not 
associated with BP or hypertension in our data. However, rs3184504 also is a trans-eQTL for 6 of our 
34 BP signature genes: FOS, MYADM, PP1R15A, TAGAP, S100A10, and FGBP2. These 6 genes are highly 
expressed in neutrophils [12], and are co-expressed. Prior studies have suggested an important role 
of neutrophils in BP regulation [24]. We speculate that these 6 BP signature genes, all driven by the 
same BP-associated eQTL, point to a critical and previously unrecognized mechanism involved in BP 
regulation. Further experimental validation is needed. 
One limitation of our study is the use of whole blood derived RNA for transcriptomic profiling. 
GSEA showed that the top enriched biological processes for the differentially expressed BP genes 
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include inflammatory response. Numerous studies have shown links between inflammation and 
hypertension [25-27]. The top ranked genes in inflammatory response categories provide a guide 
for further experimental work to recognize the contributions of inflammation to alterations in BP 
regulation. We speculate that using similar approaches in other tissues might identify additional 
differentially expressed BP signature genes. In conclusion, we conducted a meta-analysis of global 
gene expression profiles in relation to BP and identified a number of credible gene signatures of 
BP and hypertension. Our integrative analysis of GWAS and gene expression in relation to BP can 
help to uncover the genetic and genomic architecture of BP regulation; the BP signature genes we 
identified may represent an early step toward improvements in the detection of susceptibility, and 
in the prevention and treatment of hypertension. 
MATERIALS AND METHODS 
Study population and ethics statement 
This investigation included six studies (the Framingham Heart Study (FHS), the Estonian Biobank 
(EGCUT), the Rotterdam Study (RS) [8], the InCHIANTI Study, the Cooperative Health Research in the 
Region of Augsburg (KORA F4) Study [9], and the Study of Health in Pomerania (SHIP-TREND) [10], 
each of which conducted genome-wide genotyping, mRNA expression profiling, and had extensive 
BP phenotype data. Each of the six studies followed the recommendations of the Declaration of 
Helsinki. The FHS: Systems Approach to Biomarker Research (SABRe) in cardiovascular disease is 
approved under the Boston University Medical Center’s protocol H-27984. Ethical approval of EGCUT 
was granted by the Research Ethics Committee of the University of Tartu (UT REC). Ethical approval of 
the InCHIANTI study was granted by the Instituto Nazionale Riposo e Cura Anziani institutional review 
board in Italy. Ethical approval of RS was granted by the medical ethics committee of the Erasmus 
Medical Center. The study protocol of SHIP-TREND was approved by the medical ethics committee 
of the University of Greifswald. KORA F4 is a population-based survey in the region of Augsburg in 
Southern Germany which was performed between 2006 and 2008. KORA F4 was approved by the 
local ethical committees. Informed consent was obtained from each study participant. 
Definition of the phenotype
Hypertension (HTN) was defined as SBP ≥140 mm Hg or DBP ≥90 mm Hg. We excluded individuals 
receiving anti-hypertensive treatment because of the possibility that some of the differentially 
expressed genes we identified would reflect treatment effects. The eligible study sample included 
7,017 individuals: 3,679 from FHS, 972 from EGCUT, 604 from RS, 597 from InCHIANTI, 565 from KORA 
F4, and 600 from SHIP-TREND. 
Gene expression profiling 
RNA was isolated from whole blood samples that were collected in PaxGene tubes (PreAnalytiX, 
Hombrechtikon, Switzerland) in FHS, RS, InCHIANTI, KORA F4 and SHIP-TREND, and in Blood 
RNA Tubes (Life Technologies, NY, USA) in EGCUT. Gene expression in the FHS samples used the 
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Affymetrix Exon Array ST 1.0. EGCUT, RS, InCHANTI, KORA F4, and SHIP-TREND used the Illumina 
HT12v3 (EGCUT, InCHANTI, KORA F4, and SHIPTREND) or HT12v4 (RS) array. Raw data from gene 
expression profiling are available online (FHS [http://www.ncbi.nlm.nih.gov/gap; accession number 
phs000007], EGCUT [GSE48348], RS [GSE33828], InCHIANTI [GSE48152], KORA F4 [E-MTAB-1708] and 
SHIP-TREND [GSE36382]). The details of sample collection, microarrays, and data processing and 
normalization in each cohort are provided in the S2 Text. 
Identification and replication of differentially expressed genes associated with bP 
The association of gene expression with BP was analyzed separately in each of the six studies 
(Equation 1). A linear mixed model was used in the FHS in order to account for family structure. 
Linear regression models were used in the other five studies. In each study, gene expression level, 
denoted by geneExp, was included as the dependent variable, and explanatory variables included 
blood pressure phenotypes (SBP, DBP, and HTN), and covariates included age, sex, body mass index 
(BMI), cell counts, and technical covariates. A separate regression model was fitted for each gene. 
The general formula is shown below, and the details of analyses for each study are provided in the 
S2 Text and S6 Table. 
geneExp = BP +            covariates∑mj=1  (1)
The overall analysis framework is provided in Supplementary Figure 1. We first identified differentially 
expressed genes associated with BP (BP signature genes) in the FHS samples (Set 1) and attempted 
replication in the meta-analysis results from the Illumina cohorts (Set 2, see Methods, Meta-analysis). 
We next identified BP signature genes in the Illumina cohorts (Set 2), and then attempted replication 
in the FHS samples (Set 1). The significance threshold for pre-selecting BP signature genes in 
discovery was at Bonferroni corrected p=0.05 (in FHS, corrected for 17,318 measured genes [17,873 
transcripts], and in illumina cohorts, corrected for 12,010 measured genes [14,222 transcripts] that 
passed quality control). Replication was established at Bonferroni corrected p=0.05, correcting for 
the number of pre-selected BP signatures genes in the discovery set. We computed the pi1 value 
to estimate the enrichment of significant p values in the replication set (the Illumina cohorts) for 
BP signatures identified in the discovery set (the FHS) by utilizing the R package Qvalue [11]. Pi1 is 
defined as 1-pi0. Pi0 value provided by the Qvalue package, represents overall probability that the 
null hypothesis is true. Therefore, pi1 value represents the proportion of significant results. For genes 
passing Bonferroni corrected p<0.05 in the discovery set for SBP, DBP and HTN, we calculated pi1 
values for each gene set in the replication set. 
Meta-analysis 
We performed meta-analysis of the five Illumina cohorts (for discovery and replication purposes), 
and then performed meta-analysis of all six cohorts. An inverse variance weighted meta-analysis was 
conducted using fixed-effects or random-effects models by the metagen function in the R package 
Meta (http://cran.r-project.org/web/packages/meta/index.html). At first, we tested heterogeneity for 
each gene using Cochran’s Q statistic. If the heterogeneity p value is significant (p<0.05), we will use 
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a random-effects model for the meta-analysis, otherwise use a fixed-effects model. The Benjamini-
Hochberg (BH) method [28] was used to calculate FDR for differentially expressed genes in relation 
to BP following the meta-analysis of all six cohorts. We also used a more stringent threshold to 
define BP signature genes by utilizing p<6.5E-6 (Bonferroni correction for 7,717 unique genes [7,810 
transcript] based on the overlap of FHS and illumina cohort interrogated gene sets).
Estimating the proportion of variance in bP attributable to bP signature genes 
To estimate the proportion of variances in SBP or DBP explained by a group of differentially expressed 
BP signature genes (gene 1, gene 2, . . ., gene n), we used the following two models: 
Full model: 
BP =            gene i +           covariates ∑ni=1 ∑
m
j=1
 (2)
Null model: 
BP =            covariates ∑mj=1  (3)
The proportion of variance in BP attributable to the group of differentially expressed BP signature 
genes (h2BP_sig) was calculated as: 
h         = max(0,                                                     ) 2
BP_sig
σ         + σ          – σ        + σ 
G. null
2
err. null
2
G. full
2
err. full
2
σ
BP
2
 (4)
where σ2BP is the total phenotypic variance of SBP or DBP, σ
2
G.full and σ
2
err.full are the variance and error 
variance when modeling with the tested group of gene expression traits (gene 1, gene 2, . . ., gene 
n), and σ2G.null and σ
2
err.null are the variance and error variance when modeling without the tested 
group of gene expression traits. The proportion of the variance in BP phenotypes attributable to 
the FHS BP signature genes was estimated in the five Illumina cohorts, respectively, and then the 
average proportion values were reported. In turn, the proportion of the variance in BP phenotypes 
attributable to the Illumina BP signature genes was estimated in the FHS. 
Identifying eQTLs and estimating the proportion of variance in gene expression 
attributable to single cis- or trans-eQTLs 
SNPs associated with altered gene expression (i.e. eQTLs) were identified using genome-wide 
genotype and gene expression data in all available FHS samples (n=5,257) at FDR<0.1 (Joehanes R, 
submitted, 2014, and a brief summary of methods and results are provided in the S2 Text). A cis-eQTL 
was defined as an eQTL within 1 megabase (MB) flanking the gene. Other eQTLs were defined as 
trans-eQTLs. We combined the eQTL list generated in the FHS with the eQTLs generated by meta-
analysis of seven other studies (n=5,300) that were also based on whole blood expression [12]. 
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For every BP signature gene, we estimated the proportion of variance in the transcript attributable 
to the corresponding cis- or trans-eQTLs (h2eQTL) using the formula: 
h       = max(0,                                                              )2
eQTL
σ             + σ          – σ            + σ 
eQTL. null
2
err. null
2
eQTL. full
2
err. full
2
σ
gene
2  (5)
where σ2gene was the total phenotypic variance of a gene expression trait; σ
2
eQTL.full and σ
2
err.full were 
the variance and the residual error, respectively, when modeling with the tested eQTL; σ2eQTL.null and 
σ2err.null were the variance and the residual error when modeling without the tested eQTL. 
functional category enrichment analysis 
In order to understand the biological themes within the global gene expression changes in relation 
to BP, we performed gene set enrichment analysis [29] to test for enrichment of any gene ontology 
(GO) biology process [30] or KEGG pathways [31]. “Metric for ranking gene” parameters were 
configured to the beta value of the meta-analysis, in order to look at the top enriched functions 
for BP associated up-regulated and down-regulated gene expression changes respectively. One 
thousand random permutations were conducted and the significance level was set at FDR≤0.25 to 
allow for exploratory discovery [29]. 
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AbSTRACT
Genome-wide association studies (GWAS) have identified genetic loci associated with circulating lipid 
levels. To complement these findings, we conducted a meta-analysis of gene expression associations 
with triglycerides (TG), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), and total cholesterol (TC) 
from whole blood-derived mRNA levels using either the Affymetrix GeneChip Human Exon 1.0 ST or 
the Illumina HumanHT-12 Expression BeadChip arrays in 4,841 fasting individuals. Individuals taking 
lipid-lowering medications were excluded from analysis. Using a significance level of p<1 × 10-6 
(corresponding to Bonferroni correction for 12,492 unique genes across four traits), expression 
levels for 906 genes were significantly associated with levels of at least one lipid trait (793 for TG, 489 
for HDL-C, 20 for TC, and five for LDL-C). We identified a set of basophil and mast cell-related genes 
whose expression levels were highly associated with all four lipid traits. The two genes with the 
smallest p-values were HDC (pTG=5.3 × 10
-268, pHDL-C=5.2 × 10
-61, pTC=2.1 × 10
-11, pLDL-C=1.3 × 10
-21) and 
CPA3 (pTG=3.8 × 10
-191, pHDL-C=3.6 × 10
-36, pTC=2.7 × 10
-21, pLDL-C=2.5 × 10
-10). Expression levels of these two 
genes explained 23.1% and 18.1% of the total variation in log-transformed TG levels, respectively. Our 
findings add further support for the role of basophil and mast cells in the link between dyslipidemia 
and atherosclerosis. Furthermore, we observed significant associations between lipid levels and 
the expression levels of 95 known lipid-related genes in the LIPID MAPS proteomic database and 
47 genes identified by lipid. Thus, we provide evidence that gene expression data in whole blood 
may be helpful in identifying novel genes and pathways involved in the regulation and downstream 
effects of circulating lipid levels. 
AUTHOR SUMMARy
Large-scale genetic studies have identified DNA sequence variants that are associated with blood 
lipid levels. Identifying genes that are differentially expressed in relation to lipid levels may provide 
additional insights into the lipid regulatory landscape and help prioritize genes for therapeutic 
targeting. We examined the associations between whole blood expression levels of 12,492 genes 
and circulating lipid levels. Using gene expression data from 4,841 individuals, we identified 906 
genes whose expression was significantly associated with blood lipid levels. While our strongest 
associations were likely due to changes in gene expression caused by lipid levels, other associations 
may be involved in the regulation of lipid levels. To help identify the latter, we cross-referenced our 
findings with those from a large genome-wide association study (GWAS) meta-analysis of circulating 
lipid levels. Genes identified through the convergence of GWAS and the current gene expression 
study should be prioritized for further research on their potential roles in lipid regulation.
502007-L-bw-Peters
2
81
Transcriptomic Studies
INTRODUCTION
Dyslipidemia is a highly predictive and readily modifiable risk factor for atherosclerotic cardiovascular 
disease (CVD) [1]. Several pharmacologic therapies have been proven to effectively reduce the risk of 
CVD by altering lipid levels [2-4]. The discovery of new and targeted therapeutics through genomic 
approaches has recently been shown to be effective for lipid lowering and CVD event prevention 
[5,6]. 
Genome-wide association studies (GWAS) have identified 157 genetic loci associated with 
circulating levels of total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density 
lipoprotein-cholesterol (HDL-C), and triglycerides (TG) [7,8]. Yet the aggregate effect of single genetic 
variants only explain 10-12% of the total variation in circulating lipid levels [7,8]. Additional sources 
of inter-individual variability in lipid levels remain to be identified [9]. Gene expression reflects the 
integration of multiple levels of genomic regulation; thus, studies of gene expression studies may 
complement GWAS by offering an alternate high throughput and unbiased approach to identifying 
strong genetic associations. 
Identifying genes whose blood expression levels correlate with circulating lipid levels is important 
for two major reasons. First, these genes may be involved in upstream steps related to lipid synthesis 
or metabolism, or they may play a role in the downstream steps related to the pathobiology linking 
circulating lipids to the development of atherosclerosis [10].
The current meta-analysis of circulating lipid levels used gene expression data from whole blood-
derived mRNA in five population-based cohorts totaling 4,841 individuals who were not receiving 
lipid lowering medication. Using an analytic strategy that integrated multiple data sources (e.g., 
GWAS) shown in Figure 1, we were able to recapitulate known lipid pathway genes in addition to 
providing potential insights into whole blood gene expression correlates of circulating lipid levels.
figure 1. Overview of study design. 
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RESULTS
Study population characteristics
Study participants were generally middle-aged and elderly individuals from 5 observational studies 
with mean ages ranging from 49 to 72 years (Table 1). Individuals taking lipid-lowering medications 
were excluded from analysis. Lipid levels were comparable across cohorts with the exception of 
lower LDL-C levels in the Framingham Heart Study (FHS). Between 42 to 49% of participants in each 
cohort were men. 
Table 1. Characteristics of study populations.
Affymetrix cohort Illumina cohorts
Variables framingham SHIP-TREND KORA f4 RS-III InCHIANTI
n 3,978 917 750 736 604
n (with cell counts) 1,838 914 750 735 604
Age (years), mean±SD 52 ± 13 49 ± 13 70 ± 5 59 ± 8 72 ± 16
Sex (men), n (%) 1,658 (42%) 399 (44%) 367 (49%) 325 (44%) 268 (45%)
BMI (kg/m2), mean±SD 27.6 ± 5.6 27.2 ± 4.6 28.9 ± 4.6 27.4 ± 4.6 27.0 ± 4.3
Fasting (yes), n (%) 3,978 (100%) 917 (100%) 743 (99%) 724 (98%) 604 (100%)
Lipid levels, median (IQR)*
Triglycerides (mmol/L) 1.0 (0.8-1.5) 1.2 (0.9-1.7) 1.3 (0.9-1.8) 1.2 (0.9-1.7) 1.2 (0.9-1.6)
Total cholesterol (mmol/L) 5.0 (4.4-5.5) 5.5 (4.8-6.3) 5.9 (5.2-6.5) 5.7 (5.0-6.3) 5.3 (4.6-6.0)
HDL cholesterol (mmol/L) 1.5 (1.2-1.9) 1.4 (1.2-1.7) 1.4 (1.2-1.7) 1.4 (1.1-1.7) 1.4 (1.2-1.7)
LDL cholesterol (mmol/L)† 2.8 (2.3-3.4) 3.4 (2.8-4.1) 3.8 (3.2-4.4) 3.6 (3.0-4.2) 3.2 (2.6-3.8)
Microarray platform Affymetrix GeneChip 
Human Exon 1.0 ST
Illumina 
HumanHT-12 
v3 BeadChip
Illumina 
HumanHT-12 
v3 BeadChip
Illumina 
HumanHT-12 
v4 BeadChip
Illumina 
HumanHT-12 
v3 BeadChip
* Triglyceride conversion from mmol/L to mg/dl, multiply by 88.5. Cholesterol conversion from mmol/L to mg/dl, multiply by 38.6. † LDL 
cholesterol was computed using the Friedewald formula in Framingham, RS-III, and InChianti. 
blood count and lipid correlations
Among lipid traits, LDL-C and TC were highly correlated (Spearman r=0.85). To a lesser extent HDL-C 
and TG also were correlated (Spearman r=-0.51). Because tissue heterogeneity may be a potential 
confounding factor, we assessed its potential impact by examining associations between blood 
cell counts and lipid levels. The strongest Spearman correlations were observed for red blood cell 
counts and TG (r=0.26), HDL-C (r=-0.43), and LDL-C (r=0.24) in FHS (S1 Table). Weaker correlations 
were observed for TG and HDL-C levels in relation to white blood cell counts (r=0.25 for TG; r=-0.18 
for HDL-C), neutrophils (r=0.22 for TG; r=-0.17 for HDL-C), and monocytes (r=0.18 for TG; r=-0.20 
for HDL-C). All aforementioned correlations had p<1 × 10-14. Further adjustment for age did not 
substantially affect these correlations (S2 Table), suggesting that the association between lipids 
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and blood counts were not entirely due to age-related changes in both parameters. All subsequent 
analyses were adjusted for age, sex, technical covariates, and blood cell counts to address potential 
confounding.
Gene expression associations with circulating lipid levels
Due to differences in microarray platforms used across cohorts, we conducted a two stage meta-
analysis (Figure 1). In Stage 1, results from the cohorts using Illumina arrays were meta-analyzed. In 
Stage 2, results from the meta-analysis of Illumina arrays were meta-analyzed with results from the 
single Affymetrix cohort (FHS) using an inverse variance weighted random effects model. The Stage 
2 meta-analysis of 12,492 genes common to both platforms yielded 792 genes for TG, 488 for HDL-C, 
20 for TC, and five for LDL-C whose expression levels were significantly associated with lipid levels at 
a Bonferroni-corrected p<1.0 × 10-6. The ten most statistically significant expression associations for 
each lipid trait are presented in Table 2, and the complete results can be found in S1-S5 Files.
At a Bonferroni-corrected significance level of p<1.0 × 10-6, 906 genes were significantly associated 
with at least one lipid trait. Many of these 906 genes had similar patterns of gene expression 
associations with lipid traits, suggesting gene co-expression clusters (Figure 2). 
In particular, one cluster of genes, with inter-correlations ranging from 0.42 to 0.71, was highly 
associated with TG and HDL-C. Within this cluster were two sub-clusters based on co-expression 
patterns. One sub-cluster included ABCA1 and MYLIP, known lipid-regulating genes. The other 
sub-cluster included HDC, CPA3, MS4A2, GATA2, ENPP3, GCSAML, and AKAP12. Because several 
genes in the latter sub-cluster were known basophil and mast cell-specific genes, we examined the 
correlation between their expression levels and percent basophils in blood using data from FHS 
(Figure 3). As expected, moderate correlations were observed between percent basophils in blood 
and the expression levels of genes within this sub-cluster. The strongest of these correlations were 
for CPA3 (r=0.45, p=5.8 × 10-93), HDC (r=0.43, p=3.5 × 10-84), and MS4A2 (r=0.41, p=5.8 × 10-76). ABCA1 
and MYLIP were not correlated with percent basophils (r=0.08 and r=0.05, respectively).
In general, gene expression associations (i.e., t-statistics) for TC were highly correlated with those for 
LDL-C (r=0.81, p<1 × 10-16), and TG associations were inversely correlated with HDL-C associations 
(r=-0.74, p<1 × 10-16) (S1 Figure). Furthermore, results adjusting for body mass index (BMI) were 
highly similar to results without BMI adjustment (r>0.94 for all lipid traits) (S2 Figure). 
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figure 2. Heatmap of meta-analysis Z-scores for 906 genes whose expression levels were significantly 
associated (after bonferroni correction) with a circulating lipid in the meta-analysis (left inset figure). 
Upper inset table provides p-values for the associations between lipid levels and expression levels for each 
gene in the cluster. Lower inset table is a correlation matrix of the Pearson’s correlation coefficients for the 
co-expression of these genes. All models adjusted for age, age2, sex, batch effects, and blood cell counts.
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figure 3. Scatterplots of percent basophil versus gene expression levels in whole blood. Regression 
line and Pearson’s correlation coefficients are shown. Removal of 3 outliers for percent basophil slightly 
strengthened correlations for all genes except for GCSAML, SLC45A3, and ABCA1, whose correlations were 
slightly attenuated.
Cross-validation
To evaluate the reproducibility of our findings, we compared the strength and direction of gene 
expression associations across platforms (i.e., Stage I Affymetrix results compared to Stage I Illumina 
results) (Figure 4). Overall, TG and HDL-C had the strongest and most reproducible associations, 
whereas LDL-C and TC associations tended to be less reproducible. More importantly, gene 
expression levels of our top signals showed significant association with lipid levels (p<1.0 × 10-6) in 
both sets of cohorts (94 genes for TG, 40 for HDL-C, 0 for LDL-C, and 3 for TC).
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figure 4. Plots of gene expression associations (t-statistics) with circulating lipid levels in the Affymetrix 
cohort versus the meta-analysis of Illumina cohorts. Genes with Bonferroni-significant associations 
(p<1.0 × 10-6) in both sets of results are highlighted in red. All models adjusted for age, age2, sex, batch effects, 
and blood cell counts.
Percent of total variation explained
In aggregate, expression levels of the significant genes from our Stage 2 meta-analysis explained 
39.2% of the total variation in circulating TG levels, 18.1% for HDL-C, 6.4% for TC, and 1.9% for LDL-C. 
Expression levels in a few individual genes explained a large percentage of total variation in log-
transformed TG levels (Table 2). For example, substantial proportions of variation in TG levels were 
explained by HDC (23.1%), SLC45A3 (15.2%), GATA2 (17.3%), CPA3 (18.1%), MS4A2 (12.8%), ABCA1
(8.1%), and MYLIP (6.6%). But these estimates may be inflated because the same population was 
used to select significant genes and to compute the estimates for percent variation explained. As a 
sensitivity analysis, we computed the percent of total variation explained for the Illumina cohorts 
using the Bonferroni-significant genes in the Affymetrix cohort (and vice versa). The mean percent of 
total variation for lipid levels in the Illumina cohorts explained by the significant genes (in aggregate 
for a given lipid trait) in the Affymetrix set was 40.7% for TG, 16.8% for HDL-C, and 3.3% for TC. No 
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genes were significant for LDL-C in the meta-analysis of Illumina cohorts. Conversely, the significant 
expression levels in the Illumina cohorts explained 43.8% for TG, 16.4% for HDL-C, 3.2% for TC, and 
2.1% for LDL-C in the Affymetrix cohort. Thus, a large percentage of the total variation in blood 
lipid levels was explained by whole blood gene expression levels, and these findings were highly 
consistent across cohorts.
Gene ontology enrichment analysis 
At FDR q<0.05, LDL-C was significantly enriched for apolipoprotein receptor activity, driven by ABCA1 
and ABCA7 associations (S3 Table). TC gene expression results were highly enriched for functions 
related to DNA and RNA binding (S4 Table). HDL-C and TG gene expression results were enriched 
for protein binding (including IgE and kinase), poly(A) RNA binding, and structural constituents of 
ribosomes (S5 and S6 Tables).
Intersection of genetic variant and gene expression findings
Under the assumption that genes identified through both GWAS and gene expression are likely to 
represent expression levels that influence lipid levels (i.e., upstream effects), we cross-referenced our 
gene expression results with genetic loci identified by the Global Lipids Genetics Consortium (GLGC) 
[7,8]. We used three sources of eQTL (genetic variants associated with gene expression traits) in our 
analysis. The first source of eQTL was from an updated version of a previously described catalog of 
published eQTL in various tissues [11]. The second source was from gene expression in FHS samples 
(n=5,257) with 1000 Genomes-imputed genotype data. And the third source was from the Blood 
eQTL Browser (http://genenetwork.nl/bloodeqtlbrowser/) [12]. In total, we identified 5,105 cis-eQTL at 
p<5.0 × 10-8 or Bayes’ Factor >30 that included 210 unique genes available in our meta-analysis (S7 
Table). Among the cis-eQTL, 47 unique genes had p<0.05/210, DPEP2 expression had the association 
with the lowest p-value for TG and HDL-C levels (Table 3). 
Known lipid pathway proteins
Using the LIPID MAPS proteomic database (accessed on March 26, 2015), we conducted a look-up 
of known lipid pathway proteins in our meta-analysis results. Among the 1,205 human genes in 
the LIPID MAPS database, data on 699 genes were available for look-up in our results, of which 95 
(13.6%) reached statistical significance at a Bonferroni corrected p<0.05/699 with a lipid trait in our 
meta-analysis (Table 4). 
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Table 2. Top 10 genes whose expression levels were associated with circulating lipid levels, based on 
meta-analysis P-values of Affymetrix and Illumina cohorts. 
Affymetrix cohort  
(n=1,838) 
Illumina cohorts 
(n=3,003) 
Meta-analysis
Gene R2† t-statistic P-value R2† t-statistic P-value P-value
Total cholesterol
HDC 0.02 -6.76 1.9E-11 0.02 -6.90 5.3E-12 1.3E-21
CPA3 0.03 -7.79 1.2E-14 0.01 -6.04 1.5E-09 2.7E-21
ABCA1 0.02 -7.04 2.6E-12 0.01 -4.31 1.6E-05 2.0E-14
GATA2 0.01 -5.49 4.6E-08 0.01 -5.41 6.2E-08 2.7E-14
MS4A2 0.02 -6.84 1.1E-11 0.01 -3.53 4.1E-04 5.0E-12
IFIT3 0.01 -3.98 7.1E-05 0.01 -4.41 1.0E-05 3.4E-09
CPT1A 0.02 6.01 2.2E-09 0.00 2.50 1.2E-02 2.2E-08
EPSTI1 0.01 -4.02 6.0E-05 0.00 -3.91 9.4E-05 2.4E-08
ETS1 0.00 2.45 1.5E-02 0.01 5.14 2.7E-07 2.4E-08
AKAP12 0.02 -5.81 7.5E-09 0.01 -2.30 2.1E-02 1.1E-07
LDL cholesterol
HDC 0.01 -4.96 7.7E-07 0.01 -4.67 3.0E-06 2.1E-11
CPA3 0.01 -4.87 1.2E-06 0.01 -4.27 2.0E-05 2.5E-10
ABCA1 0.01 -4.76 2.1E-06 0.00 -3.45 5.6E-04 2.1E-08
GATA2 0.00 -3.26 1.2E-03 0.01 -3.97 7.1E-05 2.9E-07
E2F2 0.00 3.54 4.2E-04 0.00 3.61 3.1E-04 5.7E-07
GNA12 0.01 3.94 8.4E-05 0.00 3.00 2.7E-03 2.0E-06
PIM1 0.00 2.91 3.7E-03 0.00 3.59 3.3E-04 3.9E-06
STK24 0.00 -1.76 7.8E-02 0.00 -4.43 9.6E-06 4.3E-06
FTL 0.00 -2.33 2.0E-02 0.01 -3.82 1.3E-04 8.4E-06
SLC6A16 0.00 1.08 2.8E-01 0.01 4.73 2.3E-06 9.6E-06
HDL cholesterol
HDC 0.05 11.81 4.3E-31 0.06 11.90 1.2E-32 5.2E-61
CPA3 0.05 11.16 5.1E-28 0.04 7.46 8.8E-14 3.6E-36
AHSP 0.02 -6.46 1.4E-10 0.03 -10.75 6.2E-27 1.5E-35
MYLIP 0.01 5.96 3.1E-09 0.04 10.58 3.5E-26 2.8E-33
GATA2 0.03 8.74 5.4E-18 0.05 8.28 1.2E-16 3.2E-32
TSC22D3 0.02 6.50 1.0E-10 0.03 9.54 1.4E-21 1.2E-30
MS4A2 0.04 10.49 4.9E-25 0.03 6.54 6.3E-11 2.7E-30
HBD 0.01 -5.14 3.1E-07 0.03 -10.01 1.4E-23 1.7E-28
ALAS2 0.02 -7.86 6.8E-15 0.02 -7.89 3.1E-15 4.4E-28
CEBPD 0.00 3.18 1.5E-03 0.03 11.10 1.3E-28 4.5E-27
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Table 2. (Continued)
Affymetrix cohort  
(n=1,838) 
Illumina cohorts 
(n=3,003) 
Meta-analysis
Gene R2† t-statistic P-value R2† t-statistic P-value P-value
Triglycerides
HDC 0.20 -22.90 3.1E-102 0.24 -27.62 7.1E-168 5.3E-268
CPA3 0.24 -25.82 1.4E-125 0.17 -18.97 3.1E-80 3.8E-191
GATA2 0.15 -18.99 1.5E-73 0.18 -19.38 1.1E-83 1.6E-153
MS4A2 0.20 -22.75 4.4E-101 0.11 -14.42 3.6E-47 4.4E-131
ABCA1 0.08 -13.22 3.6E-38 0.08 -14.83 9.4E-50 1.1E-85
ENPP3 0.13 -17.41 6.5E-63 0.06 -10.91 1.0E-27 9.7E-79
MYLIP 0.07 -12.78 7.1E-36 0.06 -14.06 6.4E-45 1.7E-78
SLC45A3 0.01 -5.44 5.9E-08 0.19 -18.05 7.9E-73 5.8E-70
AKAP12 0.16 -19.97 2.2E-80 0.01 -4.37 1.2E-05 2.8E-50
AHSP 0.02 7.54 7.4E-14 0.05 12.51 6.7E-36 1.3E-47
* Regression models adjusted for age, age2, sex, technical covariates, and blood cell counts. † Gene expression-specific explained 
variance in the levels of the lipid trait (R2)
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Table 4. Meta-analysis associations between circulating lipid levels and expression levels of known lipid 
genes from LIPID MAPS proteome database.* 
Total Cholesterol LDL cholesterol HDL cholesterol Triglycerides
Gene Z P-value Z P-value Z P-value Z P-value
ABCA1 -7.7 2.0E-14 -5.6 2.1E-08 8.3 7.3E-17 -19.6 1.1E-85
ZDHHC18 -2.0 4.7E-02 0.5 6.4E-01 5.2 1.8E-07 -10.9 7.9E-28
ALOX5AP -2.4 1.7E-02 -2.8 5.6E-03 8.6 8.7E-18 -9.7 3.9E-22
PISD -2.8 5.4E-03 -1.0 3.1E-01 3.9 9.4E-05 -9.3 2.0E-20
RXRA -1.2 2.4E-01 -1.0 3.3E-01 6.7 1.5E-11 -8.9 6.1E-19
PIK3CD -1.2 2.4E-01 -1.5 1.4E-01 7.7 1.0E-14 -8.8 9.8E-19
GMEB2 -1.0 3.2E-01 -2.1 3.9E-02 8.0 1.7E-15 -8.4 5.0E-17
OSBP2 1.8 7.1E-02 2.4 1.6E-02 -5.3 1.3E-07 8.4 5.8E-17
SMPDL3A -2.1 3.9E-02 -2.3 2.0E-02 4.8 1.3E-06 -8.2 2.8E-16
DPM2 -0.1 9.0E-01 2.4 1.5E-02 -9.0 2.2E-19 8.2 3.0E-16
CXCL16 -1.4 1.5E-01 -1.5 1.4E-01 7.0 2.9E-12 -8.2 3.1E-16
SORL1 -0.7 4.6E-01 -0.4 7.0E-01 7.2 8.5E-13 -8.2 3.6E-16
PTGS2 -1.3 2.0E-01 1.2 2.4E-01 2.1 3.5E-02 -7.9 2.0E-15
CARM1 0.5 6.5E-01 2.3 2.1E-02 -7.1 1.0E-12 7.8 5.4E-15
EGLN2 -2.7 6.1E-03 -2.7 6.2E-03 4.9 9.3E-07 -7.6 4.0E-14
CPT1A 5.6 2.2E-08 3.5 3.9E-04 -1.9 5.5E-02 7.1 1.5E-12
CHPT1 -1.0 3.2E-01 0.6 5.3E-01 -6.7 1.6E-11 7.0 3.3E-12
SCAP -0.3 7.9E-01 -0.2 8.1E-01 6.3 2.4E-10 -6.9 6.7E-12
TLR4 -0.2 8.3E-01 -0.1 9.4E-01 5.8 8.2E-09 -6.8 1.2E-11
PIK3R2 1.8 6.5E-02 1.9 6.0E-02 -3.0 2.8E-03 6.6 4.3E-11
AGPAT3 0.9 3.9E-01 1.0 3.3E-01 -3.7 2.1E-04 6.5 5.9E-11
MMD -0.7 5.0E-01 0.8 4.4E-01 1.9 6.2E-02 -6.5 6.5E-11
SERINC1 -1.0 3.1E-01 -0.3 7.4E-01 2.5 1.3E-02 -6.5 9.7E-11
BCKDK 0.7 4.9E-01 1.2 2.2E-01 5.4 5.3E-08 -6.4 1.4E-10
HPGDS -2.7 6.6E-03 -2.3 2.0E-02 2.9 3.7E-03 -6.4 1.7E-10
ACSL5 2.3 2.4E-02 1.3 1.8E-01 -2.6 9.3E-03 6.3 3.4E-10
DBI -1.1 2.7E-01 -0.8 4.5E-01 -4.9 1.1E-06 6.0 2.0E-09
ADIPOR1 0.5 6.4E-01 2.5 1.1E-02 -5.8 7.5E-09 5.9 2.9E-09
PRKCQ 3.6 3.3E-04 1.1 2.8E-01 0.1 8.9E-01 5.8 7.1E-09
PIGB -0.2 8.2E-01 0.4 6.9E-01 3.5 4.9E-04 -5.7 1.2E-08
ALOX5 0.4 6.9E-01 0.9 3.6E-01 5.0 4.5E-07 -5.7 1.6E-08
PTGER2 2.5 1.2E-02 0.7 4.8E-01 -0.5 5.9E-01 5.6 1.9E-08
PREX1 0.6 5.4E-01 0.2 8.0E-01 5.2 1.6E-07 -5.6 2.2E-08
PGRMC1 -2.5 1.2E-02 -0.9 3.5E-01 0.5 6.1E-01 -5.5 3.8E-08
SDPR -0.7 4.9E-01 0.6 5.4E-01 1.1 2.5E-01 -5.4 7.9E-08
ABHD4 -1.5 1.4E-01 -1.2 2.4E-01 3.7 2.5E-04 -5.4 8.1E-08
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Table 4. (Continued)
Total Cholesterol LDL cholesterol HDL cholesterol Triglycerides
Gene Z P-value Z P-value Z P-value Z P-value
ZDHHC2 0.5 6.3E-01 1.7 8.3E-02 -5.4 8.3E-08 5.3 1.3E-07
HSD17B11 -2.6 1.0E-02 -1.7 8.5E-02 2.5 1.4E-02 -5.3 1.3E-07
ST6GALNAC4 -1.1 2.5E-01 0.9 3.8E-01 -6.2 4.6E-10 5.2 1.7E-07
DAD1 -3.3 9.9E-04 -3.0 2.3E-03 2.3 1.9E-02 -5.2 2.1E-07
SLC27A2 -2.0 4.5E-02 -2.1 3.2E-02 3.4 5.9E-04 -5.2 2.3E-07
SQLE -0.5 6.4E-01 -0.5 6.2E-01 -4.3 2.0E-05 5.2 2.4E-07
ANXA1 4.0 6.5E-05 1.0 2.9E-01 0.7 5.0E-01 5.1 3.5E-07
INPP5A -0.5 5.9E-01 -1.0 3.3E-01 5.6 2.6E-08 -5.1 4.3E-07
PLCG2 0.5 6.0E-01 0.2 8.3E-01 5.1 2.7E-07 -5.0 6.3E-07
ACSL3 -1.9 5.9E-02 -1.9 5.7E-02 4.1 5.0E-05 -5.0 6.5E-07
DAPP1 -3.5 5.1E-04 -1.9 5.2E-02 -2.6 1.0E-02 -4.9 8.8E-07
PNPLA6 -1.6 1.2E-01 -1.6 1.2E-01 2.9 4.2E-03 -4.9 1.1E-06
PITPNM1 -1.0 3.3E-01 0.0 9.9E-01 1.1 2.9E-01 -4.8 1.5E-06
SUCLG1 1.8 7.4E-02 0.8 4.5E-01 -1.8 7.3E-02 4.8 1.9E-06
ACOX1 -0.5 6.2E-01 0.8 4.4E-01 3.9 1.1E-04 -4.8 1.9E-06
PTGDS 0.0 9.7E-01 -1.0 3.3E-01 5.2 1.8E-07 -4.7 3.2E-06
ANXA11 -1.1 2.8E-01 -1.2 2.1E-01 4.4 1.0E-05 -4.6 4.3E-06
GDE1 0.5 6.3E-01 1.7 8.1E-02 -4.4 1.0E-05 4.6 4.5E-06
ALDH9A1 2.2 3.0E-02 1.6 1.1E-01 4.7 2.8E-06 -4.6 4.8E-06
CDS2 -1.5 1.3E-01 -0.6 5.4E-01 1.9 6.3E-02 -4.5 5.7E-06
LMF2 -2.2 3.1E-02 -2.3 2.4E-02 2.6 9.4E-03 -4.5 6.2E-06
PIGX 0.0 9.9E-01 0.3 7.7E-01 3.3 9.4E-04 -4.5 6.6E-06
ACAT1 0.4 6.8E-01 -0.8 4.4E-01 -2.3 2.0E-02 4.5 7.1E-06
PIP5K1C -0.4 6.7E-01 -0.6 5.3E-01 3.5 4.5E-04 -4.5 7.2E-06
PGS1 -0.9 3.7E-01 0.6 5.5E-01 0.3 7.5E-01 -4.5 7.3E-06
IMPA2 -0.6 5.4E-01 -0.4 7.0E-01 4.8 1.8E-06 -4.5 8.5E-06
RCHY1 -1.3 1.8E-01 -0.6 5.2E-01 2.4 1.6E-02 -4.4 8.8E-06
FDFT1 -1.2 2.4E-01 0.7 5.0E-01 -5.2 2.4E-07 4.4 1.1E-05
PICALM -0.7 5.0E-01 0.9 3.9E-01 2.7 7.3E-03 -4.4 1.1E-05
SEC14L4 2.1 3.5E-02 2.7 6.5E-03 -3.2 1.5E-03 4.4 1.3E-05
NUDT4 4.5 7.1E-06 3.5 5.4E-04 1.5 1.4E-01 4.4 1.3E-05
GPX1 -1.9 6.2E-02 0.3 8.0E-01 -5.5 3.8E-08 4.3 2.0E-05
GK -2.1 3.7E-02 1.9 5.7E-02 -0.8 4.1E-01 -4.3 2.0E-05
EBPL -0.2 8.2E-01 0.4 7.1E-01 -4.1 4.6E-05 4.2 2.4E-05
TMEM55A 0.2 8.4E-01 0.0 9.7E-01 3.9 8.1E-05 -4.2 3.3E-05
SLC25A29 0.9 3.9E-01 1.1 2.6E-01 2.0 4.2E-02 -4.1 3.9E-05
PAQR6 -1.8 7.6E-02 -1.4 1.6E-01 2.1 3.7E-02 -4.1 4.4E-05
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Table 4. (Continued)
Total Cholesterol LDL cholesterol HDL cholesterol Triglycerides
Gene Z P-value Z P-value Z P-value Z P-value
LRP10 -0.5 6.1E-01 1.3 2.0E-01 1.3 2.1E-01 -4.1 4.5E-05
ACAA1 -3.6 3.7E-04 -2.3 2.1E-02 0.5 6.1E-01 -4.0 5.4E-05
FAAH -0.1 9.0E-01 -0.6 5.2E-01 3.8 1.2E-04 -4.0 5.8E-05
CYB5R3 1.8 7.3E-02 2.9 3.9E-03 -4.5 6.7E-06 3.8 1.5E-04
OSBPL9 0.6 5.7E-01 -0.6 5.6E-01 4.0 5.8E-05 -3.8 1.7E-04
PLCB2 0.5 6.0E-01 -0.4 6.8E-01 5.0 4.9E-07 -3.7 2.6E-04
PTGES 0.1 9.2E-01 -0.6 5.8E-01 4.0 6.0E-05 -3.6 2.8E-04
RBM14 1.3 2.0E-01 -1.1 2.7E-01 4.5 8.2E-06 -3.6 2.9E-04
PIGN 2.4 1.6E-02 1.4 1.6E-01 4.3 2.1E-05 -3.6 3.1E-04
SREBF2 -0.2 8.7E-01 0.6 5.3E-01 -4.3 2.1E-05 3.6 3.3E-04
DNAJA1 -1.3 2.0E-01 0.0 9.8E-01 -5.5 4.3E-08 3.5 5.0E-04
PNPLA1 -0.6 5.8E-01 -1.1 2.5E-01 4.6 4.2E-06 -3.5 5.2E-04
STT3A 1.4 1.6E-01 0.2 8.6E-01 4.7 2.9E-06 -3.0 2.4E-03
AGPAT9 -0.2 8.8E-01 -1.0 3.3E-01 4.7 2.5E-06 -2.8 6.0E-03
PIP5K1B -1.7 9.7E-02 1.8 7.1E-02 -4.4 9.2E-06 2.6 9.4E-03
HSD17B12 3.2 1.6E-03 1.0 3.2E-01 4.9 8.5E-07 -2.4 1.5E-02
PSAP 1.4 1.5E-01 -1.3 1.9E-01 6.5 7.4E-11 -2.3 2.2E-02
CYP27A1 -0.2 8.5E-01 -1.2 2.5E-01 4.2 3.1E-05 -2.3 2.3E-02
ECHDC3 0.6 5.7E-01 -0.6 5.4E-01 4.6 3.9E-06 -2.1 3.5E-02
LDLR -4.4 1.1E-05 -3.7 2.3E-04 -3.6 3.0E-04 2.1 3.8E-02
ADIPOR2 1.3 2.1E-01 0.3 7.9E-01 4.1 3.8E-05 -2.0 4.8E-02
ALDH1A1 0.9 3.6E-01 -3.0 2.5E-03 6.5 7.8E-11 -1.1 2.7E-01
* Genes significantly associated with at least 1 lipid trait are shown (P<0.05/699 in bold).
DISCUSSION
Meta-analyzing data on 4,841 participants from five well-characterized population-based studies, 
we identified 906 genes whose expression levels were associated with circulating levels of at least 
one lipid trait, including 793 genes for TG, 489 for HDL-C, 20 for TC, and five for LDL-C. When the 
Affymetrix and Illumina cohorts were analyzed separately, we identified 105 genes whose expression 
levels were associated with circulating lipid levels in both data sets, suggesting highly reproducible 
results. Furthermore, we identified 13 additional genes reported in GWAS of lipids whose expression 
levels were also significantly associated with lipid levels, reflecting a convergence of signals from 
genetic variation and gene expression.
Our strongest associations included a set of co-expressed genes related to basophils and mast 
cells. The strongest associations within this gene set were for HDC and CPA3, which were previously 
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observed in a smaller study using co-expression network analysis [13]. HDC codes for histidine 
decarboxylase, a rate-limiting enzyme catalyzing the conversion of L-histidine to histamine, a pro-
inflammatory molecule secreted by mast cells, basophils, and macrophages. HDC expression was 
associated with levels of all four lipid traits. Gonen et al. demonstrated that incubating basophils 
or mast cells with low density lipoproteins (LDL) or very low density lipoproteins (VLDL) altered 
histamine release [14,15]. In addition, LDL and VLDL binding sites have been identified on human 
basophils and mast cells, providing further evidence of a biological interaction [16]. Of note, when we 
conducted analysis in FHS participants who were taking lipid-lowering medications (n=1,550), the 
association between HDC expression levels and LDL-C levels were not significant (p=0.97). HDC gene 
expression, however, remained strongly associated with TG, HDL-C, and TC levels. HDC knockout 
mice lose body weight in the face of a high fat diet, and develop hepatic steatosis [17]. ApoE and Hdc 
double knockout mice have reduced atherosclerotic areas and reduced expression of inflammatory 
genes despite having elevated serum cholesterol levels compared to ApoE single knockout mice 
[18]. These findings suggest that some of our observed associations may reflect downstream effects 
of lipid levels on gene expression, possibly through alternate or unrecognized pathways. A causal 
role, however, as demonstrated by knockout experiments, may also be invoked as part of a complex 
regulatory network. These complex relationships may partially explain the large proportion of total 
variation in lipid levels explained by our top associations. 
CPA3 codes for carboxypeptidase A3, a metalloexopeptidase found in the secretory granules of 
basophils and mast cells. These granules contain enzymes that digest LDL-C particles. Specifically, 
carboxypeptidase A degrades apolipoprotein B and A1, the primary apolipoproteins of LDL-C and 
HDL-C, respectively [19-23]. In turn, this carboxypeptidase-mediated process appears to increase 
LDL-C uptake by macrophages and, in turn, contributing to foam cell formation [24,25]. The negative 
correlation between CPA3 expression and LDL-C levels the we observed was consistent with the 
known biology. It remains unclear, however, whether, or how, carboxypeptidase A is involved in the 
regulation of other lipids.
Our findings are further supported by a large body of literature on the role of mast cells in the 
development of atherosclerosis. Mast cells accumulate in atherosclerotic lesions [26] and at the 
sites of intra-plaque hemorrhages [20,27], where they are thought to release histamine and matrix-
degrading proteases that lead to fragility of microvessels that eventually leads to hemorrhage [28]. 
Further, mast cells may recruit leukocytes to the plaque sites, increase lipid uptake by macrophages 
through heparin-bound LDL particles, and proteolyse high density lipoproteins, thereby leading to 
foam cell formation [22,29,30]. Our study may be limited to the extent that our findings were driven 
by tissue-specific gene expression. Still, our findings highlight the role of basophils and mast cells as 
potential mediators between circulating lipid levels and atherosclerosis. We minimized confounding 
due to differences in blood cell abundances by adjusting for complete blood counts. 
Several other limitations should be considered when interpreting our results. First, our results 
may not necessarily reflect gene expression in liver, the primary organ involved in the regulation 
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of circulating lipid levels. This may explain the lack of associations for several known lipid genes, 
whose expression may be tissue-specific [31-33]. Moreover, our study interrogated gene expression 
levels, but genetic control of lipid levels may be due, at least in part, to functional changes in genes 
or their protein products, as was shown to be the case with APOE [34]. These functional changes 
notwithstanding, we attempted to separate genes that may be involved in the regulation of lipid 
levels from those that are influenced by changes in lipids levels by examining the intersection of 
gene expression with GWAS results. Second, excluding participants on lipid-lowering medications 
may have limited our range of lipid levels, which in turn may limit the generalizability of our findings. 
We excluded treated individuals because of the likelihood that lipid medications alter the expression 
of many genes. Third, the overall weak associations with LDL-C may have been due to imprecision 
in the estimation of LDL-C levels through the use of the Friedewald equation in three of our cohorts. 
Lastly, due to the cross-sectional nature of our study, the large percentage of variation in TG and 
HDL-C levels explained by individual gene expression levels may be partly due to genes whose 
expression levels are influenced by circulating lipids rather than the other way around. One must 
keep in mind that this statistical measure also does not imply causality. Nonetheless, genes whose 
expression levels are altered by lipids are still important because they may represent mediators that 
link lipid levels to their associated complex diseases, as we believe to be the case for HDC and CPA3 
genes. 
Our study identified 906 genes whose expression levels in whole blood were associated with 
circulating lipid levels. The expression levels of these genes, in aggregate, explained a large 
proportion of the total variation in the lipid phenotypes – far greater than what has been reported 
in GWAS. By combining genetic and gene expression associations, we identified several known lipid 
regulatory genes, such as ABCA1 and MYLIP (i.e., upstream regulators), as well as genes that not only 
responded to changes in lipid levels (i.e., downstream effects) but may play a role in the development 
of atherosclerosis. Our study serves as a proof-of-principle that gene expression association in whole 
blood may be useful in identifying important genes involved in both the regulation and downstream 
effects of circulating lipid levels.
MATERIALS AND METHODS
Study populations
The Framingham Heart Study (FHS), a community-based, prospective study of CVD and its risk 
factors, began enrollment of the Offspring cohort in 1971 (n=5,124) [35,36]. The Third Generation 
cohort of 4,095 men and women enrolled individuals from 2002-2005 [37]. Participants underwent 
in-person evaluations every four to eight years. The current investigation was limited to the 2,446 
FHS Offspring cohort attendees at the 8th examination cycle (2005-2008) and 3,180 Third Generation 
attendees at the 2nd examination cycle (2008-2011) who provided fasting plasma samples for 
assessment of lipid levels and whole blood for RNA isolation and who consented to have their data 
used for genomic research. Participants receiving lipid-lowering drug therapy at the time of RNA 
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collection were excluded because their expression levels may have been altered by medication 
use. This exclusion resulted in 3,978 FHS participants available for further analysis. Of these 3,978 
participants, complete blood counts were available in 1,838 participants.
The Study of Health in Pomerania (SHIP-TREND) is a longitudinal population-based cohort study in 
West Pomerania, a region in the northeast of Germany, assessing the prevalence and incidence of 
common population-relevant diseases and their risk factors. Baseline examinations for SHIP-TREND 
were carried out between 2008 and 2012, comprising 4,420 participants aged 20 to 81 years. Study 
design and sampling methods were previously described [38]. Analyses for the present project were 
based on a subset of 917 fasting individuals from the SHIP-TREND study population who were not 
taking lipid lowering medications and had gene expression data available. 
KORA F4 (Cooperative Health Research in the Region of Augsburg) is a population-based survey of 
the KORA project in the region of Augsburg in Southern Germany [39]. The F4 cohort consists of 
3,080 individuals of German nationality. For the expression analysis we included a random subset 
of participants aged 61 to 82 years in F4 (2006-2008) [40,41]. After quality control and exclusion of 
individuals taking lipid lowering medications 750 remained for analysis.
The Rotterdam Study (RS) is a large prospective, population-based cohort study in the Ommoord 
district of Rotterdam, the Netherlands, investigating the prevalence, incidence, and risk factors of 
various chronic disabling diseases among Caucasians aged 45 years and over, as described elsewhere 
. The initial cohort, named Rotterdam Study I (RS‐I), started in 1989, and consisted of 7,983 persons 
aged 55 years or over, living in the well‐defined Ommoord district. In 1999, a second cohort, named 
Rotterdam Study II (RS‐II), was started and consisted of 3,011 participants who had reached 55 years 
of age or moved into the study district [42]. In 2006, a further extension of the cohort was initiated 
in which 3,932 subjects were included, aged 45 years or over, called Rotterdam Study III (RS‐III) [42]. 
The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All participants provided 
written informed consent to participate in the study and to obtain information from their treating 
physicians. Gene expression levels in whole blood were assessed in 881 subjects of RS-III, for whom 
serum lipid levels were also measured. Detailed methods describing the gene expression assay were 
described elsewhere [43].
The Invecchiare in Chianti (InCHIANTI) Study is a population-based, epidemiological study of risk 
factors contributing to the decline in physical functioning in late life [44]. Individuals were selected 
from the population registries of two small towns in Tuscany, Italy. Whole blood gene expression 
and fasting plasma lipid levels were available in 698 participants (two participants had missing 
LDL-C measures). We further excluded 90 (13%) participants who reported taking lipid-altering 
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medications at the time of blood draw. Thus, 606 participants remained for further analysis. Detailed 
methods describing the gene expression assay were described elsewhere [45].
Lipid quantification
Fasting levels of TC, HDL-C, and TG were assayed in plasma or serum samples using automated 
chemistry analyzers (see details in Supporting Information). Twelve individuals in Rotterdam (1.6%) 
and 7 individuals in KORA (1.0%) were not fasting at the time of blood draw; thus, all statistical 
models for those cohorts were additionally adjusted for fasting status. LDL-C was directly measured 
in the KORA and SHIP-TREND samples and calculated using the Friedewald equation for all other 
cohorts [46]. 
Gene expression assays
Whole blood samples were collected in PAXgene tubes (details in Supporting Materials) at the same 
clinic visit as the blood samples for lipid assays. RNA was extracted using the PAXgene Blood mRNA 
kit (Qiagen). RNA amplification was conducted using either the Ambion TotalPrep RNA Amp kit 
(InChianti, SHIP-TREND, KORA, and RS-III), or the NuGEN WT-Ovation Pico RNA Amplification System 
(FHS). FHS samples were assayed using the Affymetrix GeneChip Human Exon 1.0 ST microarray 
(Affymetrix, Inc., Santa Clara, California, USA). RS-III samples were assayed using the Illumina 
HumanHT-12 v4 (Illumina, San Diego, California, USA). KORA, SHIP-TREND, and InChianti samples 
were assayed using Illumina HumanHT-12 v3. Probes from the Affymetrix and Illumina arrays were 
mapped to RefSeq genes by matching mRNA sequences. Additional details of the mRNA processing 
and probe matching are described in the Supplemental Materials. The resulting Affymetrix and 
Illumina probe matches used for the current analysis are listed in S8 Table. For genes with multiple 
sets of Affymetrix and Illumina probes that matched, we selected the pair with the lowest p-value for 
association with each lipid in the meta-analysis.
Intersection of GWAS and gene expression findings
Three sources of cis-eQTL were used to link our gene expression findings to prior lipid GWAS findings. 
First, we used an updated version of a previously described cis-expression quantitative trait loci 
(eQTL) compilation across multiple tissues (see Supplemental Materials for details) [11]. Second, we 
queried cis-eQTL in the Blood eQTL Browser [12]. Lastly, we used the expanded FHS gene expression 
data (17,873 gene sets) linked to Affymetrix 500K mapping array and 50K supplemental array data. 
We focused on the 157 genetic loci identified to be associated with lipid levels in the Global Lipids 
Genetics Consortium [7,8]. After identifying cis-eQTL (±1 megabase upstream or downstream) with 
p<5.0 × 10-8 for these loci, we then conducted look-ups of the expression levels of those eQTL genes 
in relation to lipid levels in our gene expression meta-analysis.
Statistical analysis
Normalized, log-transformed gene expression levels were modeled as the dependent variable 
and lipid traits as the independent variable. TG levels were natural log-transformed. To account 
for familial relatedness among FHS participants, we used pedigree-based mixed-effect models in 
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the kinship package in R. The remaining cohorts used multivariable linear regression models. All 
models were adjusted for age, age2, sex, technical covariates, and blood cell counts (see details 
in Supplemental Materials). Additional models further adjusted for body mass index (BMI). To 
account for multiple comparisons in the primary meta-analysis, we used an experiment-wide 
Bonferroni correction for 12,492 genes across four traits, corresponding to a nominal p<1.0 × 10-6. 
Because the arrays from Illumina cohorts were processed similarly giving effect estimates on the 
same scale, an inverse variance weighted random effects meta-analysis of 37,348 common probes 
between the HumanHT-12 v3 and v4 arrays was performed first. Meta-analysis of Affymetrix and 
Illumina array gene expression estimates was conducted using the sample size weighted Z-score 
method by combining probes that mapped to the same mRNA on both array systems (see details 
in Supplemental Materials). To estimate the percent of total variation in lipid levels explained by 
our top gene expression signals, mean partial R2 was computed by taking the difference in model 
mean squared errors of the full and restricted models divided by the total variance in the lipid trait. 
The full model included the gene expression level(s) and other covariates (age, age2, sex, blood 
counts) as the independent variables. The restricted models were identical to the full models except 
the gene expression level(s) was omitted from the model. The gene ontology enrichment analysis 
was conducted by submitting a single ranked list of genes based on meta-analysis p-values of the 
gene expression results for each lipid trait to the GOrilla web-based software (http://cbl-gorilla.
cs.technion.ac.il/, accessed on March 18, 2015) [47].
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AbSTRACT
background: Lower muscle strength in midlife predicts disability and mortality in later life. Blood-
borne factors, including growth differentiation factor 11 (GDF11), have been linked to muscle 
regeneration in animal models. We aimed to identify gene transcripts associated with muscle 
strength in adults.
Methods: Meta-analysis of whole blood gene expression (overall 17,534 unique genes measured 
by microarray) and hand-grip strength in four independent cohorts (n=7,781, ages: 20-104 years, 
weighted mean=56), adjusted for age, sex, height, weight, and leukocyte subtypes. Separate 
analyses were performed in subsets (older/younger than 60, male/female). 
Results: Expression levels of 221 genes were associated with strength after adjustment for cofactors 
and for multiple statistical testing, including ALAS2 (rate limiting enzyme in heme synthesis), PRF1 
(perforin, a cytotoxic protein associated with inflammation), IGF1R and IGF2BP2 (both insulin like 
growth factor related). We identified statistical enrichment for hemoglobin biosynthesis, innate 
immune activation and the stress response. Ten genes were only associated in younger individuals, 
four in males only and one in females only. For example PIK3R2 (a negative regulator of PI3K/AKT 
growth pathway) was negatively associated with muscle strength in younger (<60 years) individuals 
but not older (>=60 years). We also show that 115 genes (52%) have not previously been linked to 
muscle in NCBI PubMed abstracts.
Conclusions: This first large-scale transcriptome study of muscle strength in human adults confirmed 
associations with known pathways and provides new evidence for over half of the genes identified. 
There may be age and sex specific gene expression signatures in blood for muscle strength.
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INTRODUCTION 
Muscle strength correlates with health and physical function, and poor muscle strength in midlife is 
a strong, independent predictor of health status decline and mortality over 25 years [1]. Sufficient 
muscle strength in the hands, arms and legs is needed for everyday functioning; persons with poor 
strength are at high risk of disability, injury from falls, and other age-related morbidities [2,3]. 
Hand-grip is a frequently used summary measure of strength because it correlates well with 
strength of other key muscles and is relatively easy to measure with high precision; Bohannon et al. 
reported strong correlations between grip and knee extension strength (Pearson R=0.77 to 0.8) in 
a sample aged 18 to 85 years [4], with Samson et al. reporting similar estimates [5]. Muscle strength 
(including grip strength) is a more important predictor of mortality risk than muscle mass [6,7], 
and grip strength (but not muscle mass) was associated with poor physical functioning in older 
adults [8]. The mechanisms underlying the association between lower strength and mortality are 
not entirely clear, but a recent large-scale multi-country follow-up study (n=142,861) reported that 
lower grip strength associated most strongly with cardiovascular mortality [9]. Current theories 
emphasize the role of denervation not compensated by adequate re-innervation, mitochondrial 
dysfunction, cellular senescence, inflammation, changes in microenvironment, and local skeletal 
changes, among other factors [10,11]. 
Studies of heterochronic parabiosis (connecting the blood circulations of young and old mice) found 
that circulating factors, in particular lower GDF11 (growth and differentiation factor 11) in older 
mice, explained the lower muscle regenerative capacity in older compared to younger muscle [12-
14]. It is well established that circulating factors, such as pro-inflammatory mediators and hormones 
(including testosterone), are strong correlates which predict the slope of decline of muscle mass 
and strength in ageing humans [15]. These blood borne factors may function as systemic regulators 
influencing muscle and may be different from gene expression patterns in muscle itself. 
Previous studies of transcriptome associations with muscle strength in humans were conducted 
predominantly in muscle tissue, and are mostly limited by small sample size [16] or focus on 
candidate genes [17]. These studies can be susceptible to false negatives statistical associations due 
to lack of power or coverage. A transcriptome-wide study of whole blood transcript associations 
with grip strength conducted by the InCHIANTI Ageing Study (mean age 72 years, 71% ≥72 years 
old) found only one gene, CEBPB (CCAAT/enhancer-binding protein beta, required for macrophage-
mediated muscle repair in a murine model [18]), to be associated with muscle strength in older 
humans after adjustment for confounders and multiple testing [19]. A follow-up study in humans 
found that CEBPB expression increased following exercise-induced muscle damage [20]. However, 
because of the limited sample size of both studies, important transcriptional signals may have been 
missed. 
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In the present study we sought to test associations between transcripts expressed in whole blood 
and hand grip strength in multiple adult human cohorts. The majority of RNA in whole blood 
samples is derived from immature erythrocytes and platelets (~70% from reticulocytes and ~18% 
from reticulated platelets); however, these are predominantly globin-related and are not actively 
transcribed by circulating cells [21]. The remaining approximately 12% of RNA is from circulating 
white blood cells of all types, driving non-globin related gene expression. We have also performed 
subgroup analyses by age-group and gender, to check for heterogeneity in the results. We used a 
robust meta-analysis framework within four independent cohorts (n=7,781 participants) from the 
CHARGE (Cohorts for Heart and Ageing Research in Genomic Epidemiology) consortium [22] to 
identify the genes whose levels of expression assessed by blood transcripts were associated with 
muscle strength. 
METHODS
Study sample
Characteristics of the cohorts are presented in Table 1. Complete data for the planned meta-analysis 
were available for 7,781 participants from four cohorts; the Framingham Heart Study [23] (FHS, 
n=5,576, ages=24-90), the InCHIANTI study [24] (n=667, ages=30-104), the Rotterdam Study [25] 
(RS, n=556, ages=46-89) and the Study of Health in Pomerania [26] (SHIP, n=982, ages=20-81) (total 
n=7,781). The FHS study included two related generations of participants (accounted for in the 
statistical methodology); the FHS Generation 2 (n=2,421, ages=40-90) and Generation 3 (n=3,155, 
ages=24-78) cohorts were included. The Netherlands Study of Depression and Anxiety [27] (NESDA, 
n=1,989, ages=18-65) is also reported, but was not included in the discovery meta-analysis due to 
unavailable data on white cell proportions necessary for the meta-analysis protocol. Overall the 
cohorts were quite similar with respect to sex-distribution and sampling methods, differing only 
by age distribution and lower mean hand-grip strength in the RS. Detailed study design and cohort 
information has been previously published [28].
Four additional subset analyses were performed. The sub-samples available were 1) older participants 
≥60 years (n=2,402), 2) younger participants <60 years (n=5,379), 3) male participants (n=3,557), 4) 
female participants (n=4,224).
Phenotype
The primary phenotype was hand-grip strength in kg (a normally distributed phenotype). In the FHS, 
hand grip strength was measured with a Jamar dynamometer with three trials performed in each 
hand, and the maximum of the six trials for each participant was used in the analysis. In InCHIANTI 
each participant recorded their maximum grip strength three times in each hand, and the maximum 
recorded value of the six trials was used. In the Rotterdam Study grip strength of the non-dominant 
hand was measured three times for each participant, and the maximum recorded value was used. In 
the SHIP cohort participants were asked to press the hand dynamometer firmly for several seconds, 
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once per hand (left and right), and the maximum value was used. Each participant in NESDA was 
measured twice with a Jamar dynamometer in their dominant hand, with the maximum recorded 
value used.
Table 1. Characteristics of the study cohorts.
Meta-analysis cohorts   Additional 
cohort ∞
Variables fHS Gen 2 * fHS Gen 3 * InCHIANTI ~ RS ~ SHIP ~ NESDA
N 2,421 3,155 667 556 982 1,989
N >= 60 years (%) 1,319 (54%) 48 (1%) 547 (81%) 264 (45%) 268 (27%) 158 (8%)
Sex (male), n (%) 1,095 (45%) 1,470 (47%) 311 (46%) 272 (46%) 435 (44%) 1,328 (67%)
Age (yrs), mean±SD 66 ± 8.9 46 ± 8.8 72 ± 15 60 ± 7.9 50 ± 14 42 ± 13
Age (yrs), min:max 40 : 90 24 : 78 30 : 104 46 : 89 20 : 81 18 : 65
WBC-counts yes ∴ yes yes yes yes no
Hand-grip strength
Mean±SD (Kg) 31 ± 12 38 ± 12 29 ± 12 25 ± 9.4 38 ± 12 38 ± 12
Min : max (Kg) 1 : 76 5 : 84 3 : 76 2 : 55 11 : 73 10 : 90
Microarray platform Affymetrix 
GeneChip 
Human Exon 
1.0 ST
Affymetrix 
GeneChip 
Human Exon 
1.0 ST
Illumina  
HumanHT-12 
v3 BeadChip
Illumina  
HumanHT-12 
v4 BeadChip
Illumina  
HumanHT-12 
v3 BeadChip
Affymetrix  
Human Ge-
nome U219 
Array
FHS = Framingham Heart Study; RS = Rotterdam Study 3; SHIP = Study of Health in Pomerania; NESDA = Netherlands Study of 
Depression and Anxiety; SD = standard deviation; WBC = white blood cell
* FHS cohorts analyzed together prior to overall meta-analysis; ~ Illumina-based cohorts analyzed together prior to overall meta-
analysis; ∞ cohort not included in meta-analysis due to data missing from analysis protocol; ∴ cell counts imputed in this dataset; 
see methods
Peripheral gene expression data
Blood samples were drawn from participants and RNA was isolated, reverse-transcribed to 
cDNA, which was then amplified and hybridized to a microarray individually for each cohort; 
methods described in detail [28]. Briefly, the FHS used Affymetrix Human Exon 1.0 ST GeneChips, 
characterizing the expression of 16,798 unique genes (after exclusion of probesets with relative 
log expression mean values <3). The InCHIANTI and SHIP studies used the Illumina HumanHT-12 
v3 Expression BeadChip Kit, and the RS used the Illumina HumanHT-12 v4 Expression BeadChip Kit, 
with 37,348 probes measured on both Illumina platforms (22,911 unique genes; after exclusions of 
probes expressed above background in <5% of participants this becomes 15,639 unique genes). 
These four studies in the primary analysis all used PAXgene tubes to isolate and stabilize the RNA, 
thereby limiting the technical variability between studies. Finally the NESDA cohort utilized the 
Affymetrix Human Genome U219 Array, with expression information available on 18,212 unique 
gene identifiers. Quantile normalization and log2 transformation was performed on the gene 
expression data in each cohort, and both probes and samples were z-transformed. Raw data from 
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gene expression profiling are available online (FHS [NCBI dbGAP: phs000363.v7.p8], InCHIANTI [GEO: 
GSE48152], NESDA [NCBI dbGAP: phs000486.v1.p1], RS [GEO: GSE33828] and SHIP-TREND [GEO: 
GSE36382]).
Systematically mapping pairs of probes to RefSeq transcripts (one Affymetrix Exon ST and one 
Illumina HumanHT-12 probe) found 26,746 probe-pairs corresponding to 17,534 unique RefSeq 
gene symbols. The assignment of a probe to one or more transcripts was performed as described 
previously [29]. For the Illumina arrays, the transcript sequences derived from the 48,803 probe 
sequences provided in the Illumina annotation file (HumanHT-12_V3_0_R3_11283641_A, version 
3.0, 7/1/2010) were mapped against all available mRNA sequences provided in the UCSC genome 
annotation database (version 06/30/2013) using string matching. Altogether 29,818 probes were 
successfully mapped to one or more validated mRNAs. Probes that could neither be mapped to 
a unique mRNA nor to a single annotated RefSeq gene using the UCSC database were flagged 
accordingly in the annotation file. In total, 27,171 probes (55.7%) were unambiguously associated 
with a single mRNA or gene. The same method and version of the UCSC database was used for 
mapping the probes of the Affymetrix GeneChip Human Exon 1.0 ST microarray. For this array, probe 
sequences were obtained from the annotation file version HuEx-1_0-st-v2.r2 restricting the probes 
to the main probe types of the core dataset with unique cross hybridization type, and combining 
them at the level of transcript cluster. For this array system, 196,515 probes (86.0%) of 17,876 
transcript clusters were unambiguously associated with a single mRNA or gene. Finally, the probes 
of both array systems were combined based on the same transcripts obtained from the mapping 
against the UCSC database. 
The Human Genome Nomenclature Committee [30] list 19,060 protein-coding genes (Sept 15, 2014), 
less than the total “unique identifiers” mapped by the two arrays used in the overall meta-analysis; 
this discrepancy is due to probes on the array mapping to non-protein-coding transcripts, which we 
have included under the term “unique genes” or “transcripts” in this manuscript.
Statistical analysis
Using the R statistical software [31] and package “lme4” [32] each cohort performed a linear mixed 
effects model for each probe in their microarray data, using the probe as the outcome, muscle 
strength as an independent variable, and with the following covariates included as fixed effects; 
age, sex, height (cm), weight (kg), cell count estimates (neutrophils, monocytes, basophils and 
eosinophils), and fasting state (where applicable). By including these factors as covariates in the 
models our results are independent of inter-individual variation in, for example, lymphocyte cell 
counts. The following covariates were included as random effects; batch (e.g. amplification and/
or hybridization), study site (in InCHIANTI), family structure (in FHS), and RNA quality (e.g. RNA 
Integrity Number – RIN – where available). Empirical cell counts were only available in half of the 
FHS cohort; the rest of the cohort was imputed using partial least square regression methods (see 
Online Methods for more details).
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Meta-analysis
A sample-size weighted meta-analysis method was used, where an overall p-value and Z-score for 
each probe are calculated which together describe the significance of the effect, and the direction 
and magnitude, respectively; this method was chosen over the effect size/standard error method 
because of the multiple array technologies and technical considerations that differed between the 
cohorts. The analysis was done using the Meta-Analysis Tool for Genome Wide-Association Scans 
(METAL) [33] which took the effect size, sample size, and p-values from the individual cohort results 
as input (we set the “minor allele”, “major allele”, “minor allele frequency”, and “strand” to the same 
fixed value for all cohorts and probes, as this package was developed for GWAS and these options 
are not relevant for gene expression data).
For each analysis (the primary analysis including all individuals, and the four subset analyses) the 
Illumina-based cohorts (InCHIANTI, RS, SHIP) were meta-analyzed together, as these technologies 
are very similar, then a secondary meta-analysis was performed which used the FHS results and 
the Illumina results as the input; these are the final meta-analysis results reported. This reduced the 
heterogeneity in the meta-analysis due to array differences between the cohorts.
Before interpretation of the results, probes were excluded if they were expressed in <5% of the 
sample or if the heterogeneity p-value calculated by METAL was <0.05. The Benjamini-Hochberg 
(BH) [34] false-discovery rate (FDR) correction was applied to determine the statistically significant 
probes for each analysis. Validation was defined as a gene with p<0.05 in the NESDA cohort.
Ontology enrichment and network analysis
The WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) online resource is a method for determining 
pathway enrichment [35]. We conducted a “Gene Ontology” analysis (database version: Nov 11, 
2012) and a “Human Phenotype Ontology” analysis (database version: May 20, 2014), which uses a 
systematic approach to phenotype abnormalities to link them into ontologies [36]. Default analysis 
options were selected, including BH multiple testing adjustment, and the list of 17,534 genes 
included in the meta-analysis we used as the “background”.
A co-expression analysis was performed in the FHS (as the study with the largest sample size) 
where Spearman correlations were determined between each gene significantly associated with 
muscle strength, and all other genes (after adjusting the data for the covariates mentioned in the 
Statistical Analysis methods section). Genes correlated with rho ≥0.5 were selected for visualization 
in Cytoscape (v3.2.1). Ontology enrichment of networks was performed in Cytoscape using the 
BiNGO plugin (v2.44).
A priori genes associated with muscle function
We selected sets of genes known to influence muscle function for a priori analysis to highlight 
whether the pathways in muscle tissue are also important in whole blood. Kelch proteins, including 
KLHL19, KLHL31, KLHL39m, and KLHDC1, are involved in skeletal muscle function and development; 
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canonical and non-canonical Wnt signaling play crucial roles in maintenance and development of 
skeletal muscle; insulin-like growth factors (IGF’s) are also known to play roles in muscle growth 
and homeostasis, and finally TGF-β family members, including myostatin (GDF8) [37] and GDF11. 
Supplementation of GDF11 in mice was reported to ameliorate the sarcopenia-like phenotype. In 
their 2007 study, Melov et al identified 586 unique genes expressed in muscle that were associated 
with endurance exercise training and differed between older and younger men [16], which we also 
checked for associations with muscle strength in this analysis.
Systematic literature search for genes
For each significant gene in the analysis a systematic search of literature was performed by 
accessing the “publications” list from GeneCards (www.genecards.org) [38], which has the advantage 
of including publications where the gene ID may have changed over time. From this list the title and 
abstract were downloaded from NCBI PubMed (www.ncbi.nlm.nih.gov/pubmed). Searches were then 
made within each publication for the text string “muscle”, and results counted.
RESULTS
Meta-analysis: genes associated with muscle strength
Overall, 26,746 probe-pairs (corresponding probes on the Affymetrix and Illumina platforms), 
mapping to 17,534 unique gene identifiers, were available for the meta-analysis. Including data from 
all 7,781 participants, 208 unique genes (246 probe-pairs) were associated with muscle strength 
(FDR<0.05; Figure 1; see Supplementary Table 1 for all significant results) after correction for multiple 
confounders, and excluding results with significant heterogeneity (het p<0.05) between cohorts; 
133 were negatively associated with grip strength, 75 were positively associated. 
Of the 208 unique genes associated with muscle strength in the meta-analysis all were significant 
in FHS alone (nominal p<0.05), and 79 (38%) were also “independently” associated with muscle 
strength in the Illumina meta-analysis (nominally significant; p<0.05). Details of the statistically most 
significant ‘top’ 20 transcripts are shown in Table 2. The proportion “independently replicated” was 
greater for the top 30 most significant genes identified in the meta-analysis (21 of 30=70%). 
Meta-analysis in subsets of the participants
The analyses in subsets of the participants identified 13 genes associated with muscle strength 
at transcriptome-wide significance in the meta-analysis that were not identified in the analysis of 
all participants together (Table 3; see Supplementary Table 2-4 for full results for each subset). We 
also investigated whether the 208 genes identified in the analysis of all individuals were nominally 
significant (p<0.05) in the subsets. 153 of the 208 genes were nominally significant in the older 
participants, 198 in the younger, 200 in the males and 121 in the females (Supplementary Table 1). 
Supplementary Table 5 includes additional information for all genes included in Tables 2 & 3.
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figure 1. Gene transcripts associated with muscle strength in all participants.
(A) Compares the individual meta-analyses performed in the Illumina-cohorts and the FHS separately. The 
dark grey points represent gene transcripts significantly associated with muscle strength (FDR<0.05). The 
light grey points were not significant in this analysis. The unfilled grey points were excluded due to significant 
heterogeneity (Cochran’s Q-test p<0.05 [33]). The solid grey line shows the trend across all the genes. (b) 
Shows the meta-analysis results by Manhattan plot. The dashed line indicates those probes significantly 
associated with grip strength after Benjamini-Hochberg correction, the solid line shows those significant 
after Bonferroni correction, for comparison.
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Table 2. Top 20 unique genes associated with muscle strength in the meta-analysis of all participants, 
with robust replication in Illumina.
Meta-analysis P-values
Z-score P-value bH 
P-value
fHS Illumina Gene Entrez- 
ID
Name
-5.67 1.5 x 10-8 2.0 x 10-4 3.9 x 10-7 9.9 x 10-3 ALAS2 212 aminolevulinate, delta-, synthase 2
5.37 7.8 x 10-8 3.1 x 10-4 4.3 x 10-7 4.0 x 10-2 HEATR5A 25938 HEAT repeat containing 5A
-5.28 1.3 x 10-7 3.9 x 10-4 2.7 x 10-5 1.2 x 10-3 PNP 4860 purine nucleoside phosphorylase
-5.17 2.4 x 10-7 4.7 x 10-4 1.1 x 10-6 5.0 x 10-2 STOM 2040 stomatin
5.14 2.8 x 10-7 4.7 x 10-4 7.9 x 10-6 1.1 x 10-2 RPS6KA5 9252 ribosomal protein S6 kinase, 90kDa, 
polypeptide 5
-5.09 3.7 x 10-7 5.8x10-4 5.4 x 10-5 1.8 x 10-3 MBNL3 55796 Muscleblind-Like Splicing Regulator 3
-5.07 3.9 x 10-7 5.8x10-4 2.3 x 10-6 4.4 x 10-2 RAD23A 5886 RAD23 homolog A (S. cerevisiae)
5.02 5.1 x 10-7 6.8x10-4 7.7 x 10-5 1.7 x 10-3 HNRNPA0 10949 heterogeneous nuclear 
ribonucleoprotein A0
-4.90 9.5 x 10-7 1.1x10-3 2.0 x 10-5 1.5 x 10-2 GID4 79018 GID Complex Subunit 4
-4.88 1.1 x 10-6 1.1x10-3 9.3 x 10-6 3.4 x 10-2 TFDP1 7027 transcription factor Dp-1
4.80 1.6 x 10-6 1.4x10-3 9.9 x 10-6 4.7 x 10-2 ARRDC3 57561 arrestin domain containing 3
-4.77 1.7 x 10-6 1.5x10-3 1.8 x 10-5 3.3 x 10-2 RIOK3 8780 RIO kinase 3
-4.71 2.5 x 10-6 1.8x10-3 1.9 x 10-5 4.1 x 10-2 NTAN1 123803 N-terminal asparagine amidase
4.66 3.1 x 10-6 2.2x10-3 8.1 x 10-4 6.0 x 10-4 PDE4D 5144 phosphodiesterase 4D, cAMP-specific
-4.62 3.8 x 10-6 2.4x10-3 1.1 x 10-4 1.2 x 10-2 RGCC 28984 Regulator Of Cell Cycle
4.61 4.1 x 10-6 2.5x10-3 9.6 x 10-5 1.4 x 10-2 POLR2B 5431 polymerase (RNA) II (DNA directed) 
polypeptide B
-4.59 4.4 x 10-6 2.5x10-3 6.1 x 10-5 2.4 x 10-2 EIF1B 10289 eukaryotic translation initiation factor 
1B
4.57 4.8 x 10-6 2.7x10-3 5.4 x 10-4 2.0 x 10-3 CIRBP 1153 cold inducible RNA binding protein
-4.57 4.8 x 10-6 2.7x10-3 6.2 x 10-5 2.7 x 10-2 ASGR2 433 asialoglycoprotein receptor 2
-4.55 5.3 x 10-6 2.9x10-3 3.8 x 10-5 4.5 x 10-2 CA1 759 carbonic anhydrase I
BH = Benjamini-Hochberg. Ordered by meta-analysis p-value. Showing top 20 results with nominal ‘replication’ (p<0.05) in Illumina.
Duplicate gene entries excluded. Full table in Supplementary Table 1. 
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Table 4. Top 20 probes in the fHS analysis that did not map to a corresponding Illumina probe, ordered 
by P-value. 
Estimate P-value bH P-value Chr Start Gene Name
-0.0037 1.76 x 10-6 1.49 x 10-3 1 144989319
-0.0028 4.89 x 10-6 2.88 x 10-3 9 37800563 DCAF10 DDB1 and CUL4 associated factor 10
0.0031 8.57 x 10-6 4.12 x 10-3 1 150522766 ADAMTSL4 ADAMTS(a disintegrin and metalloproteinase 
with thrombospondin motifs)-like 4
0.0038 9.29 x 10-6 4.15 x 10-3 16 89980135
0.0040 1.95 x 10-5 5.97 x 10-3 2 162412847 SLC4A10 solute carrier family 4, sodium bicarbonate 
transporter, member 10
0.0029 3.24 x 10-5 7.74 x 10-3 16 9186734
0.0031 3.93 x 10-5 8.51 x 10-3 1 44440179 ATP6V0B ATPase, H+ transporting, lysosomal 21kDa,  
V0 subunit b
-0.0027 4.10 x 10-5 8.64 x 10-3 3 63819562 THOC7 THO complex 7 homolog (Drosophila)
0.0032 5.38 x 10-5 9.81 x 10-3 20 3898284
0.0019 1.49 x 10-4 1.70 x 10-2 20 1316212
0.0018 1.89 x 10-4 1.91 x 10-2 3 128628719 ACAD9 | 
KIAA1257
acyl-CoA dehydrogenase family, member  
9 | KIAA1257
-0.0017 2.21 x 10-4 2.08 x 10-2 1 8021733 PARK7 parkinson protein 7
0.0036 3.18 x 10-4 2.69 x 10-2 12 57809458
0.0010 3.20 x 10-4 2.70 x 10-2 1 153901987 DENND4B DENN/MADD domain containing 4B
-0.0019 3.56 x 10-4 2.87 x 10-2 3 10157370 BRK1 BRICK1, SCAR/WAVE actin-nucleating 
complex subunit
-0.0028 3.84 x 10-4 2.97 x 10-2 2 95517671 TEKT4 tektin 4
-0.0014 3.95 x 10-4 3.03 x 10-2 1 247937996 OR9H1P olfactory receptor, family 9, subfamily H, 
member 1 pseudogene
0.0018 6.01 x 10-4 3.89 x 10-2 9 124042152 GSN-AS1 GSN(gelsolin) antisense RNA 1
0.0028 6.41 x 10-4 4.03 x 10-2 6 20451305
-0.0021 6.90 x 10-4 4.19 x 10-2 12 8024178 NANOGP1 | 
NANOG
Nanog homeobox pseudogene 1 | Nanog 
homeobox
BH = Benjamini-Hochberg. Blank gene symbols were not annotated to a specific gene. Table continued in Supplementary Table 9. 
Ordered by P-value. Not all probes map to gene ID’s.
Significant genes only available on one array
Due to differences between the array technologies and relative abundance of transcripts, not all the 
genes were eligible for the meta-analysis. In the analysis on all individuals, 1,123 probes (898 unique 
identifiers) were present on the Affymetrix Exon array that did not have a corresponding probe on 
the Illumina array; 21 of these probes were significantly associated with hand-grip strength after 
BH adjustment for multiple testing (see Table 4 for top 20 probes in the “all individuals” analysis and 
Supplementary Tables 6-8 for list of significant probes in each of the FHS analyses with significant 
results). In the Illumina array, 7,768 probes (6,119 unique gene identifiers) were available that did 
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not map to a gene/transcript in the Affymetrix Exon array (after excluding lowly expressed probes). 
None of the probes were significantly associated with muscle strength after BH multiple testing 
correction.
Ontology enrichment of strength-associated genes
Two analyses were performed to identify pathways using the WebGestalt web resource based on the 
208 genes associated with muscle strength in the meta-analysis of all participants;
1. Gene Ontology analysis found that 10 biological processes were significantly enriched (FDR<0.05) 
(Table 5) including “hemoglobin metabolic process” and related processes, “innate immune 
response” (18 genes) and the stress response (55 genes); 10 molecular functions were enriched 
(including “protein binding genes”), and 10 cellular component pathways were enriched 
(including “intracellular membrane-bound organelle”) (See Supplementary Table 9). 
2. Human Phenotype Ontology analysis found 10 phenotypes significantly enriched in the genes, 
including “Anemia due to reduced life span of red cells”, “Hemolytic Anemia”, and “Abnormality of 
erythrocytes” (See Supplementary Table 10).
Additionally, network analysis in the FHS of all genes correlated (rho≥0.5) with the strength-
associated genes (n=425) revealed four clusters with at least 10 genes, all of which had a number 
of significantly (FDR p<0.05) enriched pathways (Supplementary Table 11): 1) the largest cluster 
(n=333 of 425 genes) included “protein ubiquitination”, “erythrocyte homeostasis”, and “cellular 
metabolic process”. 2) The second cluster (n=32 genes) was enriched for genes in “regulation of cell 
communication”, “actin cytoskeleton” and “ATP metabolic process”. 3) The third cluster (n=18) had 
two enriched ontologies only: “cell surface receptor-linked signaling pathway” and “cytolysis”. 4) The 
final cluster (n=10) was enriched for terms including “negative regulator or immune system process” 
and “negative regulation of complement activation”.
A priori genes associated with muscle function
Of 20 IGF-related genes tested in this meta-analysis two were significantly associated with 
muscle strength: IGF1R (positively associated) and IGF2BP2 (negatively associated; meta-analysis 
FDR=3.2 x 10-2 and FDR=1.2 x 10-3, respectively). Expression of myostation (MSTN), follistatin (FST) 
and GDF11 were not associated with muscle strength (FDR>0.05). 40 unique Kelch genes were 
tested in the meta-analysis; none were associated with muscle strength in whole blood (FDR>0.05). 
18 unique Wnt genes (from WNT1 to WNT9B) were tested in the meta-analysis; none were associated 
with muscle strength in whole blood (FDR>0.05). All 10 Frizzled genes (FZD1-10, receptors for the Wnt 
pathway) were also available to test; none were associated with muscle strength. Similarly all three 
Dishevelled genes were available to test (DVL1-3, acts directly downstream of the Frizzled receptors) 
and none were associated with muscle strength. Of 586 genes identified by Melov et al that were 
differentially expressed in muscle tissue between old and young men following endurance training 
[16] four were associated with muscle strength in this analysis: ANP32B, CIRBP, MCM7 and MGST1.
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Most associated genes are not previously linked to muscle in the literature
For each of the 221 genes associated with muscle strength we searched in the published literature 
cataloged on GeneCards and NCBI Pubmed titles and abstracts, using the search term “muscle”: for 
115 of these 221 genes (52%) there were no mentions of muscle (as of Nov 12, 2014; Supplementary 
Table 12).
few genes replicate in the NESDA cohort
NESDA was not included in the meta-analysis due to data limitations: the lack of empirically 
determined or reliably imputed white cell count data, the use of a different microarray technology 
(a predecessor to the Exon array used by FHS, much more dissimilar than the v3/v4 Illumina arrays 
are to one another), and a younger population than the other cohorts included in the meta-analysis 
(max age=65, see Table 1). As noted above, in total 221 unique genes were associated with muscle 
strength across all the meta-analyses performed. Of 208 genes significantly associated with muscle 
strength in analysis 1 (all participants) it was possible to test 144 in the NESDA cohort; 7 genes were 
also associated with muscle strength (p<0.05) in the NESDA cohort (ACSL6, ALDH5A1, CARHSP1, 
FGL1, NRG1, PIGB, SIGLEC7). 
Associations with knee strength
Maximum knee and grip strength (both in Kg) were measured in 619 participants in the InCHIANTI 
study and were highly correlated (Pearson R=0.751), and were significantly associated after 
adjustment for age, sex, height and weight (coefficient=0.193, p=8.2 x 1015) in linear regression 
models with knee strength as the dependent variable.
DISCUSSION 
In this discovery study we set out to determine whether specific transcript levels in blood are 
associated with muscle strength in multiple human cohorts including mostly middle-aged 
volunteers. Previous cross-sectional (and longitudinal) studies have shown that the degree and rate 
of loss of strength (and muscle mass) is greater in older participants [39]. We therefore performed 
stratified analyses by age and gender to determine whether transcripts or pathways associated with 
muscle strength in whole blood differ between these groups. 208 unique genes were associated 
with muscle strength in the analysis of all participants (Table 2 for 20 most robust associations). 
Thirteen additional unique genes were identified that were only associated when participants were 
separated into older/younger or male/female groups (Table 3). In total 221 unique genes were 
associated with muscle strength in at least one analysis, 52% of which were not previously linked 
to the term “muscle” in the published literature cataloged on GeneCards and PubMed (as of Nov 12, 
2014).
We observe significant associations between muscle strength and expression of IGF1R and IGF2BP2 
(positive and negative directions of association with muscle, respectively), growth factors involved 
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in skeletal muscle growth [40,41]; the former is known to enhance cell survival by mediating IGF1 
signaling, and the latter modulates IGF2 translation and has genetic variants associated with type-2 
diabetes [42]. Of 586 genes that differ in expression in muscle between old and young men after 
endurance training [16], four were associated with grip strength in this study: MGST1 (negative 
direction), an immune mediator which may protect against oxidative stress [43]; MCM7 (positive 
direction), which regulates DNA replication during proliferation [44]; CIRBP (positive direction), 
which promotes inflammation in response to shock and sepsis [45]; and ANP32B (negative direction), 
a cell-cycle progression and anti-apoptosis factor [38]. These latter results suggest that most blood 
based gene expression associated with strength is different from that seen in muscle itself, which 
is not unexpected given the respective systemic regulatory versus myofibril maintenance functions 
involved. Further work should explore whether transcripts that alter in response to exercise show 
overlaps between circulating cells and muscle. Interestingly, no genes from the Wnt or Kelch 
pathways (both known to be important for muscle function [46,47]) were associated with strength in 
this analysis; nor was GDF11, a protein that can reverse age-related muscle dysfunction in mice [14], 
although as noted we observe associations between strength and expression of two IGF-related 
genes.
Other genes of note include CCR6 and PRF1 (both positively associated with muscle strength and 
age [48]): CCR6 is implicated in B-cell maturation and recruitment [49]; perforin (PRF1) is a protein 
secreted by cytotoxic T-cells which creates pores in membranes to permit apoptosis-inducing 
granzyme into the target cell [50]. These findings are consistent with the notion that inflammation 
may be associated with muscle repair, maintenance and turnover, at least in part by interfering with 
the production and biological activity of IGF-1 [51].
NANOG expression was measured in the FHS analysis only and is positively associated with 
strength in the FHS analysis (Table 4); NANOG can reverse ageing of some stem cells [52] and, in 
combination with three other genes (OCT4, SOX2, and LIN28, not significant in this analysis), can 
induce pluripotency of somatic cells [53]. This may suggest that differentiation (of whole blood cells) 
is inversely correlated with muscle strength, but the mechanisms are unclear.
Genes identified in subset analyses
Thirteen genes were associated with muscle strength at transcriptome-wide significance in the 
subset analysis only (Table 3). These were predominantly in the younger (<60 years) group and 
included PIK3R2, a negative regulator of the PI3K/AKT growth pathway; the negative expression 
association with strength suggests that there is increased PI3K activity (due to reduced expression of 
PIK3R2) with increasing muscle strength, in whole blood. This association is observed in the younger 
subset (p=6 x 10-5) but not in the older subset, even nominally (p=0.92), suggesting differences 
in growth pathway expression in blood with respect to muscle strength as individuals age. 
Similarly expression of PDK4 (inhibits pyruvate dehydrogenase in mitochondria, thereby reducing 
the conversion of pyruvate into acetyl-CoA) is negatively associated with strength, suggesting 
increased pyruvate dehydrogenase activity with increased strength in younger individuals only. 
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PKN2, (associated with height [42] and cell-cycle progression), is positively associated with strength 
in the younger individuals, underlining the difference in growth pathways in whole blood between 
younger and older individuals. See Supplementary Table 5 for more details on the other results.
Defensin, Alpha 4, Corticostatin (DEFA4, negative strength association in the analysis of females only) 
is a cytotoxic peptide that has antimicrobial activity against Gram-negative bacteria (predominantly) 
[49]. In males, expression of RAC1 (membrane-associated GTPase involved in signal transduction, 
including growth signals) and NDUFS1 (member of mitochondrial complex 1, may form part of the 
active site) were positively associated with muscle strength; these associations may suggest that on 
average males have specific energy and growth-related gene expression relating to strength.
No genes were associated (transcriptome-wide) in the older participants only; although the sample 
size was still reasonably high (2,402 participants), variability in the strength phenotype as individuals 
age and development of various co-morbidities plus chronic inflammation may reduce the power to 
detect associations. Subset-specific gene-expression associations with strength reported here need 
to be replicated and added to, as we may lack statistical power in this study to detect smaller-effect 
associations, and the microarrays do not quantify all transcripts or isoforms present.
Enrichment analysis
WebGestalt analyses identified statistically significant enrichment for genes in the biological process 
“Hemoglobin Metabolic Process” and the phenotypic abnormality “Hemolytic Anemia”, amongst 
others. Anemia is a cross-sectional correlate of muscle strength and predicts accelerated muscle 
strength decline with ageing [54], while hemoglobin levels are positively associated with muscle 
strength and density [54]. Circulating reticulocytes (erythrocyte precursors with some residual RNA 
present) were not adjusted for in this analysis and are likely the source of the associations with genes 
such as ALAS2 (strongest meta-analysis association, negative direction – a rate-limiting step in heme 
biosynthesis [55]). 
“Innate Immune Response” – which includes macrophages – genes were also enriched in the results. 
CEBPB, the gene implicated in the macrophage wound-healing response [18] and significantly 
associated with muscle strength in the 2012 study by InCHIANTI [19], did not replicate in the other 
cohorts. This could be due to methodological differences between the previous study and this meta-
analysis, as well as differences in age distribution (81% of the InCHIANTI cohort is aged >=60 years, 
compared to 31% in this analysis, which includes the InCHIANTI cohort; Table 1). The implications 
are unclear given the mouse model evidence of plausible biological mechanism [18] and evidence 
in humans that exercise-induced muscle damage is associated with CEBPB expression changes in 
whole blood [20]. Further work is required in older and frail groups.
Co-expression analysis of all genes correlated with those identified in the meta-analysis to be 
significantly associated with strength revealed four clusters. Ontology enrichment analysis of these 
revealed very similar results to those identified using WebGestalt only on the genes significantly 
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associated with strength, emphasizing the association of immune activation and cell signaling 
pathways to muscle strength in whole blood, in addition to hemoglobin pathways.
LIMITATIONS 
There are several potential limitations of this study including its cross-sectional design; it is not 
possible to determine a causal direction in this study for the associations reported, but the robustly 
identified markers emerging provide a sound foundation for follow-up studies to address causation. 
Grip strength is strongly correlated with strength in other key muscle systems (see introduction), 
but further work will be needed to confirm more specific gene expression associations with strength 
in other muscle groups. Grip strength can be influenced by non-muscle strength factors, including 
functional anomalies in the hands, for example caused by rheumatoid arthritis [56], and work is 
needed to clarify whether any of our findings reflect these alternative influences. 
Another potential limitation is the mixed cell subtype composition of “whole blood”: our analysis 
approach based on overall expression should have greater power to detect net expression changes 
in common immune cell types or large changes in expression of highly specific genes, but will have 
less power to detect smaller expression changes within less numerous cell subtypes. The cell subtype 
origins of the top transcripts reported here now need to be identified. Additionally, the microarray 
technology used across the participating cohorts was not the same. However, 21 (70%) of the top 
30 meta-analysis results were independently replicated between the platforms, which suggests 
that the top (most strongly associated) results are very robust to cohort and array differences. Also, 
the current analysis has identified expressed genes statistically associated with muscle strength, 
but future work will be needed to identify the mechanisms underlying these associations, and 
whether these act on muscle directly or through indirect pathways, perhaps with effects on central 
command, cerebellar coordination or neural transmission. Finally, work is needed on whether the 
identified strength associated gene expression transcripts are predictive of subsequent changes in 
strength or functional decline.
CONCLUSIONS
In this first large-scale transcriptome wide study in human blood, we have identified robust 
associations between the expression of 221 genes and muscle strength in adults. Several known 
pathways were confirmed, including growth factor-related genes, the innate immune response 
and hemoglobin metabolism. For 115 genes this analysis appears to provide the first published 
link to muscle. The analysis also suggests that parts of the expression signatures may be specific to 
subgroups, notably with 10 genes associated with muscle strength only in younger people. 
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Further work is needed to establish which of the identified genes predict future changes in strength. 
The findings of genes via expression microarrays may help identify key changes in cell subtypes in 
blood contributing to strength, through studies of the cellular origins of gene expression signals. 
Future research should also include longitudinal data to assess whether expression of the identified 
genes predicts poor muscle strength or functional outcomes.
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AbSTRACT
Identifying the downstream effects of disease-associated single nucleotide polymorphisms (SNPs) is 
challenging: the causal gene is often unknown or it is unclear how the SNP affects the causal gene, 
making it difficult to design experiments that reveal functional consequences. To help overcome 
this problem, we performed the largest expression quantitative trait locus (eQTL) meta-analysis so 
far reported in non-transformed peripheral blood samples of 5,311 individuals, with replication in 
2,775 individuals. We identified and replicated trans-eQTLs for 233 SNPs (reflecting 103 independent 
loci) that were previously associated with complex traits at genome-wide significance. Although we 
did not study specific patient cohorts, we identified trait-associated SNPs that affect multiple trans-
genes that are known to be markedly altered in patients: for example, systemic lupus erythematosus 
(SLE) SNP rs4917014 [1] altered C1QB and five type 1 interferon response genes, both hallmarks of 
SLE [2-4]. Subsequent ChIP-seq data analysis on these trans-genes implicated transcription factor 
IKZF1 as the causal gene at this locus, with DeepSAGE RNA-sequencing revealing that rs4917014 
strongly alters 3’ UTR levels of IKZF1. Variants associated with cholesterol metabolism and type 1 
diabetes showed similar phenomena, indicating that large-scale eQTL mapping provides insight 
into the downstream effects of many trait-associated variants.
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Genome-wide association studies (GWAS) have identified thousands of variants that are associated 
with complex traits and diseases. However, because most variants and their proxies are non-coding, 
it is generally difficult to identify the causal genes. Recently, several eQTL-mapping studies [5-8] 
have now shown that the majority of disease-predisposing variants actually affect gene expression 
levels of nearby genes (i.e. cis-eQTLs). A few recent studies have also identified trans-eQTLs [5,9-13], 
revealing the downstream consequences of some variants. However, the total number of reported 
trans-eQTLs is fairly low, mainly due to the severe burden of multiple testing. To improve statistical 
power, we performed an eQTL meta-analysis in 5,311 peripheral blood samples, from seven studies 
using Illumina gene expression arrays (EGCUT [14], InCHIANTI [15], Rotterdam Study [16], Fehrmann 
[5], HVH [17-19], SHIP-TREND [20], and DILGOM [21]) and replication analysis in another 2,775 
samples. We aimed to ascertain to what extent SNPs affect genes in cis and trans and whether eQTL 
mapping in peripheral blood could reveal important downstream pathways that may be putative 
drivers of disease processes.
Our genome-wide analysis identified cis-eQTLs for 44% of all tested genes (6,418 genes at probe-
level false discovery rate (FDR)<0.05 and 4,690 genes with more stringent Bonferroni multiple 
testing correction, Table 1, Supplementary Table 1, Supplementary Figures 1-3). Our trans-eQTL 
analysis focused on 4,542 SNPs that have been implicated in complex disease or traits (derived 
from the “Catalog of Published GWAS”). In the discovery dataset, we detected trans-eQTLs at 
FDR<0.05 for 1,513 significant trans-eQTLs that include 346 unique SNPs (8% of all tested SNPs, 
Table 1, Supplementary Table 2, Supplementary Figure 4 and 5). These SNPs affect the expression 
of 430 different genes (a more stringent Bonferroni correction revealed 643 significant trans-eQTLs, 
including 200 unique SNPs and 223 different genes).
We used stringent procedures for trans-eQTL detection (Supplementary methods), and various 
benchmarks to ensure reliability: for 26 trans-eQTL genes the eQTL SNP affected multiple probes 
within these genes (Supplementary Table 3), always with consistent allelic directions, suggesting 
that our probe filtering procedure was effective in preventing false-positive trans-eQTLs. We 
observed uniform directionality for 90% of the tested trans-eQTLs across all studies within our 
discovery meta-analysis (Supplementary Figure 5). We did not find evidence that the eQTLs were 
driven by differences in age or blood cell-counts between individuals (Supplementary Results and 
Supplementary Table 4, Supplementary Figure 6). However, we cannot exclude this possibility 
entirely because FACS analyses on individual cell-types had not been conducted.
To ensure reproducibility of the trans-eQTLs of our current meta-analysis, we performed various 
analyses. We replicated previously reported blood trans-eQTLs [5] (Supplementary Table 5, 
Supplementary Results and Supplementary Figure 7) and replicated trans-eQTLs from our discovery 
meta-analysis in two independent studies of peripheral blood gene expression (52% in KORA F4 
[22], N=740 samples and 79% in BSGS [23], N=862 samples, FDR<0.05, Supplementary Figure 8). 
Irrespective of significance, 91% and 93% of all 1,513 significant trans-eQTL SNP-probe combinations 
showed consistent allelic direction in these replication cohorts as compared to the discovery analysis. 
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A meta-analysis of these two replication studies improved replication rates: 89% of the 1,513 trans-
eQTLs were significantly replicated (FDR<0.05), 99.7% of which showed a consistent allelic direction. 
Irrespective of significance, 97% of the trans-eQTLs showed a consistent allelic direction in this 
replication meta-analysis (Supplementary Figure 8). 
Table 1. Results of the cis- and trans-eQTL mapping analyses.
Summary statistics Cis-eQTLs Trans-eQTLs
Number of SNPs tested that pass QC 1,962,237 4,542 (of which 2,082 are associated with complex 
traits at genome-wide significance, P<5 × 10-8)
Number of probes tested that pass QC 29,891 34,061
Number of genes tested 14,542 16,332
Number of probes not mapping to genes 9,260 18,018
Number of statistical tests performed 11,172,453 153,134,630
Significance thresholds Cis-eQTLs Trans-eQTLs
Meta-analysis  
Z-score
Meta-analysis  
P-value
Meta-analysis  
Z-score
Meta-analysis  
P-value
FDR<0.05 significance 3.824 1.31 × 10-4 5.022 5.12 × 10-7
Bonferroni significance 5.867 4.5 × 10-9 6.287 3.3 × 10-10
cis-eQTL analysis fDR<0.05  
significance
bonferroni 
significance
Number of significant unique SNP-Probe pairs 664,097 395,543 
Number of significant unique eQTL SNPs 397,310 266,036
Number of significant unique eQTL probes 8,228 5,738
Number of significant unique eQTL genes 6,418 4,690
Number of significant unique eQTL probes not mapping to genes 636 326
Trans-eQTL analysis fDR<0.05 
significance
bonferroni 
significance
Number of significant unique SNP-Probe pairs 1,513 643 
Number of significant unique eQTL SNPs 346 200
Number of significant unique eQTL probes 494 240
Number of significant unique eQTL genes 430 223
Number of significant unique eQTL probes not mapping to genes 35 13
We found that some trans-eQTLs could also be detected in three cell-type-specific datasets (283 
monocyte samples [9], 282 B-cell samples [9] and 608 HapMap lymphoblastoid cell-line (LCL) samples 
[24]; Supplementary Figures 9 and 10). Despite the different tissue of these three studies, we were still 
502007-L-bw-Peters
3
133
Combining genetic & genomic approaches
able to significantly replicate 7%, 4% and 2% of the trans-eQTLs (FDR<0.05), respectively. As 95% of 
the trans-eQTL SNPs explained less than 3% of the total expression variance (Supplementary Figure 
11), we lack statistical power to replicate most trans-eQTLs in these smaller replication cohorts.
We subsequently confined further analyses to 2,082 different SNPs that have been found associated 
with complex traits at genome-wide significant levels (‘trait-associated SNPs’, reported P<5 × 10-8, 
out of 4,542 unique SNPs that we tested). These 2,082 SNPs showed a significantly higher number of 
trans-eQTL effects as compared to the 2,460 tested SNPs with reported disease associations at lower 
significance levels (P=8 × 10-22, Supplementary methods and results, Supplementary Figure 12): 254 
of these 2,082 SNPs show a trans-eQTL effect in the discovery analysis (reflecting 1,340 SNP-probe 
combinations, of which we significantly replicated 1,201 SNP-probe combinations, reflecting 233 
different SNPs and 103 independent loci in blood). For 671 out of these 1,340 trans-eQTLs (50%) 
the trait-associated SNP was either the strongest trans-eQTL SNP within the locus (or in strong LD 
with the strongest trans-eQTL SNP) or unlinked to the strongest trans-eQTL SNP (Supplementary 
results and Supplementary Table 6). We observed that the 2,082 trait-associated SNPs were six 
times more likely to cause trans-eQTL effects than randomly selected SNPs (matched for distance 
to gene and allele frequency, P=5.6 × 10-49, Supplementary methods and results, Supplementary 
Figure 13). SNPs, associated with (auto)immune or hematological traits were twice as likely to cause 
trans-eQTLs, as compared to other trait-associated SNPs (P=5 × 10-25, Supplementary methods and 
results). We observed that trait-associated SNPs that also cause trans-eQTLs more often affect the 
expression levels of nearby transcription factors in cis, as compared to trait-associated SNPs that do 
not affect genes in trans (Fisher’s exact P=0.032; Supplementary results), suggesting that some of 
the trans-eQTLs arise due to altered cis gene expression levels of nearby transcription factors.
We also examined genomic SNP properties of the trans-eQTLs: these SNPs (and their perfect 
proxies based on data from the 1000 Genomes Project [25-26]) are significantly enriched (Fisher’s 
exact P<0.05) for mapping within miRNA binding sites (Figure 1A). They map to regions showing 
strong enrichment (fold-change>2.5) of histone enhancer signals in K562 (myeloid) and GM12878 
(lymphoid) cell-lines (Figure 1B), when compared to six non-blood cell-lines. This myeloid and 
lymphoid enhancer enrichment supports the validity of our blood-derived trans-eQTLs. These 
enrichment results suggest tissue specificity, which is supported by our inability to replicate a strong 
trans-eQTL that was previously identified in adipose tissue for SNP rs4731702 [13] that is associated 
with both type 2 diabetes and lipid levels.
These trans-eQTLs can provide insight into the pathogenesis of disease. Although RNA microarray 
studies have revealed dysregulated pathways for many complex diseases, it is often unclear what 
comes first: whether the associated SNPs first cause defects in the pathways whose dysregulation 
ultimately leads to disease, or whether the SNPs first cause disease that then perturbs these pathways. 
One example is SLE, an auto-immune disease resulting in inflammation and tissue damage.
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figure 1. Trans-eQTL SNPs are enriched for functional elements. We investigated whether the trans-eQTL 
SNPs are enriched for certain functional elements. We used the online tools SNPInfo, SNPNexus, and HaploReg 
that rely upon data from, amongst others, the ENCODE project. (A) We observed that trans-eQTL SNPs are 
enriched for mapping within miRNA binding sites (b) trans-eQTL SNPs show strong enrichment (as annotated 
using HaploReg) for enhancer regions that are present in K562 (myeloid) and GM12878 (lymphoid) cell-lines 
(error bars represent one standard deviation).
It is known that SLE patients show markedly increased type 1 interferon (IFN-α) levels, increased 
expression of IFN-α response genes [4,27-28] and decreased complement C1q expression. We 
observed that four common SLE associated variants do indeed affect IFN-α response genes in cis 
(IRF5, IRF7, TAP2 and PSMB9;Supplementary Table 1). However, as most SLE-associated SNPs do not 
map near complement or IFN-α response genes, we assessed whether these SNPs might affect 
complement or IFN-α response genes in trans. This was the case for rs4917014, for which the SLE 
risk allele (rs4917014*T, showing genome-wide significance in Asian populations and nominal 
significance in European populations [1,24]) not only increased expression of five different IFN-α 
response genes (HERC5, IFI6, IFIT1, MX1 and TNFRSF21; Figure 2), but also decreased expression 
of three different probes in CLEC10A. In addition, we observed a nominal significant association 
of rs4917014*T with decreased expression of C1QB (P=5.2 x 10-6, FDR=0.28), a subunit of the first 
component of complement C1q, which has an established protective role in lupus. The complete 
deletion of C1q practically assures the development of SLE [29,30]. CLEC10A and CLEC4C belong 
to the C-type lectin family, which also includes mannose-binding lectins (MBL). While, to our 
knowledge, CLEC10A and CLEC4C have not been studied in the context of SLE, the role of MBL is 
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similar to C1q and is a risk factor for the development of autoimmunity in both humans and mice [3]. 
The rs4917014 trans-eQTLs were well replicated in the peripheral blood and monocyte replication 
datasets and reinforce the role of altered IFN-α mediated pathway, C-type lectin and C1q gene 
expression in SLE. In addition, people who do not have SLE, but who carry the rs497014*T risk allele 
already show these pathway alterations, which indicates these affected pathways are not solely a 
consequence of SLE, but could well precede SLE onset.
We next investigated the underlying mechanisms of the effects exerted by rs4917014. IKZF1 is 
the only gene residing within the rs4917014 locus. Being a transcription factor (Ikaros family zinc 
finger 1), cis-regulatory effects of rs4917014 on IKZF1, that would translate in altered IKZF1 protein 
levels, could provide a working mechanism for the detected trans-eQTLs. However, since our meta-
analysis initially did not show a cis-eQTL on the Illumina probe for IKZF1 that is located near the 5’ 
untranslated region (UTR) of IKZF1, we investigated the 3’-UTR by using DeepSAGE next-generation 
RNA-sequencing data of 94 peripheral blood samples. The variant rs4917014*T strongly increased 
the 3’-UTR expression levels of IKZF1 (Spearman correlation=0.45, P=6.29 x 10-6, Zhernakova et al, 
submitted). We then used ChIP-seq data from the ENCODE-project [31] and observed significantly 
increased IKZF1 protein binding to the genomic DNA locations where the upregulated trans-eQTL 
genes map (Wilcoxon P-value=0.046), compared to IKZF1 binding to all other genic DNA. We also 
observed increased IKZF1 binding to the other SLE cis-genes outside of the IKZF1 locus (Wilcoxon 
P-value=4.3 × 10-4), thereby confirming the importance of IKZF1 in SLE. IKZF1 is important for other 
phenotypes as well: another, unlinked intronic variant within IKZF1, rs12718597, is associated with 
mean corpuscular volume (MCV) [32] and affects the 5’ end of IKZF1 in cis. As IKZF1 knock-out mice 
show abnormal erythropoiesis [33], this suggests a causal role for IKZF1 in MCV as well. However, 
although rs12718597*A increases expression of 31 trans-genes and decreases expression of another 
19 trans-genes, none of the SLE trans-genes overlap the MCV trans-genes. The latter are mainly 
involved in hemoglobin metabolism and do not show an increased IKZF1-binding signal, Wilcoxon 
P=0.35. In summary, these results indicate that IKZF1 has multiple functions and that different SNPs 
near IKZF1 elicit function-specific effects.
We identified other trans-eQTLs showing similar phenomena: we observed that rs174546 (located in 
the 3’-UTR of FADS1, and associated with metabolic syndrome [34], LDL and total cholesterol levels 
[35,36]) affects C11orf10, FADS1 and FADS2 in cis and LDLR in trans. LDLR encodes the LDL receptor 
and contains common variants that are also associated with lipid levels [36] (Figure 3). LDLR gene 
expression levels correlated negatively (P<3.0 × 10-4) with total, HDL and LDL cholesterol levels in 
the tested cohorts (Rotterdam Study and EGCUT, Supplementary Table 7), indicating that peripheral 
blood is a useful tissue for gaining downstream insight into the effects of lipid SNPs.
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figure 2. Independent trans-eQTL effects emanating from the IKZf1 locus. Systemic lupus erythematosus 
SNP rs4917014 and unlinked mean corpuscular volume SNP rs4917014 both affect expression of IKZF1 in cis. 
rs12718597 affects 50 trans-genes (mostly involved in hemoglobin metabolism) while rs4917014 affects eight 
different genes in trans: the rs4917014*T risk allele increases expression of genes involved in type I interferon 
response. At a somewhat lower significance threshold of FDR 0.28 rs4917014*T decreases complement C1QB 
expression. Both processes are hallmark features of SLE.
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figure 3. Cholesterol SNP rs174546 affects LDLR in trans. The rs174546*T allele is known to be associated 
with a decrease in serum LDL cholesterol and triglycerides levels. It increases the expression levels of three 
genes in cis, but also increases gene expression levels of LDLR that encodes the LDL receptor.
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For 21 different complex traits, we found that at least two unlinked variants that are associated 
with these diseases, affected exactly the same gene in trans. When taking an equally sized, but 
permuted list of trans-eQTLs we would on average find only one complex trait where two unlinked 
SNPs affected the same gene in trans (Figure 4, Supplementary Table 8, Methods). Although most 
of these traits are hematological (e.g. mean platelet volume or serum iron levels) we also observed 
this convergence for blood pressure, celiac disease, multiple sclerosis, and type 1 diabetes (T1D). 
rs3184504 (located in an exon of SH2B3) and its near-perfect proxy rs653178 (located in an intronic 
region of ATXN2 on chromosome 12) are associated with several auto-immune diseases including 
T1D [37,38], T1D auto-antibodies [37,38], celiac disease [8,39], hyperthyroidism [40], vitiligo [41], 
rheumatoid arthritis [39] and other complex traits such as blood pressure [42,43], chronic kidney 
disease [44], and eosinophil counts [45].
figure 4. for 21 complex traits, pairs of unlinked trait-associated SNPs affect the same downstream genes. 
We observed that for 21 different traits, there were pairs of unlinked SNPs that have previously been reported 
to be associated with these traits and which also affect exactly the same downstream genes in trans, whereas 
this is rarely observed when using an equally sized, but permuted list of trans-eQTLs.
We observed a cis-eQTL on SH2B3 (FDR<0.05) and fourteen trans-eQTL genes (FDR<0.05, Figure 
5), all highly expressed in neutrophils. Since these trans-eQTLs could potentially appear due to the 
known effect of rs3184504 on differences in cell-count proportions [45], we correlated trans-gene 
expression levels with cell counts in two cohorts (the Rotterdam Study and EGCUT) but did not 
observe significant correlations (Supplementary Table 6). These fourteen trans-eQTLs describe 
different biological functions: T1D disease risk allele rs3184504*T decreases expression levels 
of nine genes, most of which are involved in toll-like receptor signaling [46] (C12orf75, FOS, IDS, 
IL8, LOC338758, NALP12, PPP1R15A, S100A10 and TAGAP) and increases expression of five genes 
involved in interferon-γ response (GBP2, GBP4, STAT1, UBE2L6 and UPP1). We observed that another 
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T1D risk allele, rs4788084*C [37,38] on chromosome 16, increases expression of GBP4 and STAT1 
as well (Figure 5), revealing how different T1D risk alleles converge: they both cause an increase of 
interferon-γ response gene expression.
In summary, our eQTL meta-analysis revealed and replicated downstream effects for 233 trait-
associated SNPs. We have highlighted only a few here and shown that trans-eQTL mapping in blood 
for lipid and immune-mediated disease variants yields downstream insight which is biologically 
meaningful. Our results on IKZF1 show that the two unlinked SLE and MCV variants near this gene 
give strikingly different yet biologically meaningful trans-regulatory effects. Future, larger-scale 
trans-eQTL analysis in blood will likely uncover many more of these regulatory relationships.
METHODS
Study populations
We performed a whole-genome eQTL meta-analysis of 5,311 samples from peripheral blood, divided 
over a total of nine datasets from seven cohorts, including EGCUT [14] (N=891), InCHIANTI [15] 
(N=611), Rotterdam Study [16] (N=762), Fehrmann [5] (N=1,240 on the Illumina HT12v3 platform 
and N=229 on the Illumina H8v2 platform), HVH [17-19] (N=43 on the Illumina HT12v3 platform 
and N=63 on the Illumina HT12v4 platform) SHIP-TREND [20] (N=963), and DILGOM [21] (N=509). 
Gene expression data for each dataset was obtained using either PAXGene (Becton Dickinson) or 
Tempus tubes (Life Technologies), followed by hybridization to Illumina whole-genome Expression 
BeadChips (HT12v3, HT12v4 or H8v2 arrays). The gene expression platforms were harmonized by 
matching probe sequences across the different platforms. Mappings for these sequences were 
obtained by mapping the sequences against the human genome build 36 (Ensembl build 54, Hg18) 
using BLAT, BWA and SOAPv2 sequence alignment programs. Highly stringent alignment criteria 
were used to ensure that probes map unequivocally to one single genomic position. Genotype 
data was acquired using different genotyping platforms, and harmonized by imputation, using the 
HapMap2 [47] Central European population as a reference. Each dataset was individually checked 
for sample mix-ups using MixupMapper [48]. For a full description of the individual datasets, results 
of the sample mix-up analysis, specifics on the gene expression platforms and probe mapping 
procedure and filtering, see Supplementary methods.
Gene expression normalization
Gene expression data was quantile-normalized to the median distribution, and subsequently 
log2 transformed. The probe and sample means were centered to zero. Gene expression data was 
then corrected for possible population structure by removal of four multi-dimensional scaling 
components using linear regression. We reasoned earlier that normalized gene-expression data 
still contains large amounts of non-genetic variation5. After population stratification correction, 
principal component analysis (PCA) was therefore performed on the sample correlation matrix. 
We performed a separate QTL analysis for each principal component (PC), to ascertain whether 
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genetic variants could be detected that affect the PC. If we found an effect on the PC, we did not 
correct the expression data for these components, to ensure we would not unintentionally remove 
genetic effects from the expression data. Significance of these associations was established by 
controlling the false discovery rate (FDR), testing each association against a null-distribution created 
by repeating the analysis 100 times (permuting the sample labels for each iteration [49]). PCs that 
did not show significance at the FDR threshold of 0.0 were removed from the gene expression data 
by linear regression. In all but two very small datasets, the first 40 PCs were removed (excluding 
those components per cohort that showed a QTL effect). We observed that the removal of these 
40 components revealed the highest number of eQTLs in each dataset. Although PC correction 
may remove some eQTL effects, we observed that the majority (95% when removing 35 PCs and 
90% when removing 40 PCs) of trans-eQTL effects was independent of the number of PCs removed 
(Supplementary Figure 14).
eQTL mapping
After normalization of the data, we performed both cis- and trans-eQTL mapping. eQTLs were deemed 
cis-eQTLs, when the distance between the SNP chromosomal position and the probe midpoint was 
less than 250 kilobases (kb), while eQTLs with a distance greater than five megabases (mb) were 
defined as trans-eQTLs. Only SNPs with a minor allele-frequency (MAF)>0.05 and a Hardy-Weinberg 
equilibrium P-value>0.001 were included in the analyses. Since most cohorts had generated the 
gene expression data using the HT12v3 platform, we chose to only include probes that were 
present on this platform. We only tested SNP-probe pairs when the SNP passed quality control in 
at least three cohorts. Furthermore, in order to reduce issues with respect to computational time 
and multiple testing, we confined our trans-eQTL analysis to those SNPs present in the “Catalog of 
Published GWAS” (http://www.genome.gov/gwastudies/, accessed July 16th, 2011). We reasoned that 
for genes with strong cis-eQTL effects, the cis-eQTL effect may obscure the detectability of trans-
eQTL. Therefore, we used linear regression to remove cis-eQTL effects prior to trans-eQTL mapping 
and observed a 12% increase in the number of detected trans-eQTLs (Supplementary Figure 15). For 
each cohort, eQTLs were mapped using a Spearman’s rank correlation on the imputed genotype 
dosage values. We used a weighted Z-method for subsequent meta-analysis [50]. To get a realistic 
null-distribution, we permuted the sample identifiers labels of the expression data and repeated this 
analysis ten times (Supplementary Figure 16). In each permutation the sample labels were permuted. 
We then corrected for multiple testing by controlling the FDR at 0.05, by testing each p-value in the 
real data against a null-distribution created from the permuted datasets [49] (see Supplementary 
methods). It has been suggested that false-positive eQTL effects can arise due to polymorphisms 
in the probe sequences [51,52]. Therefore, we tested whether a significant cis-eQTL SNP was in LD 
(r2>0.2) with any SNP in the cis-probe sequence, using the Western European subpopulations of the 
1000 genomes project [25] (2011-05-21 release, 286 individuals, excluding Finnish individuals) as a 
reference. If we observed this to be the case the respective cis-eQTLs were removed. Furthermore, 
for each trans-eQTL we investigated whether portions of the probe sequence could map in the 
vicinity of the trans-eQTL SNP (which in fact would imply a cis-eQTL, rather than a trans-eQTL effect). 
Therefore, we tried to map the trans-eQTL probe sequences, using very permissive settings, within 
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a 5 mb window of the trans-eQTL SNP. SNP-probe combinations where the probe mapped with at 
least 15 bp within the 5 mb window, were deemed false-positive and removed from further analysis. 
After this filtering we recalculated the FDR for both the cis- and trans-eQTL results.
Trans-eQTL replication
Replication of the trans-eQTL results was carried out in five independent datasets from four cohorts, 
including data obtained from lymphoblastoid cell lines (HapMap3, N=604 [24]), B-cells and monocytes 
(Oxford [9], N=282 and N=283, respectively), and whole peripheral blood (KORA F4 [22], N=740, and 
BSGS [23], N=862). All the cohorts applied the same methodology as used in the discovery phase to 
normalize the gene expression data, check for sample mix-ups and perform trans-eQTL mapping, 
including 10 permutations in order to establish the FDR threshold at 0.05. Finally, we performed a 
sample-size weighted Z-score meta-analysis on the two peripheral blood replication cohorts (KORA 
and BSGS). Further details on these datasets can be found in the Supplementary methods.
Enhancer enrichment and functional annotation
To determine whether the significant trans-eQTL SNPs were enriched for functional regions on the 
genome, we annotated the trans-eQTL SNPs using SNPInfo [53], SNPNexus [54,55], and HaploReg [56], 
which integrate multiple data sources (such as ENCODE project data [31], Ensembl [57], and several 
micro-RNA databases). We limited these analyses to those trans-eQTL SNPs that were previously 
shown to be associated with complex traits at genome-wide significance levels (‘trait associated 
SNPs’, reported P<5 × 10-8). These SNPs were subsequently pruned (using PLINK’s -clump command, 
using an r2<0.2). We used the permuted trans-eQTL data to get realistic null-distributions for each 
of these tools: we selected equally sized sets of unlinked SNPs (r2<0.2 in the Western-European 
subpopulations of the 1000 genomes project [25], 2011-05-21 release, 286 individuals, excluding 
Finnish individuals) that showed the highest significance in the permuted data, ensuring that only 
trait-associated SNPs are included in the null-distribution, as it is known that trait-associated SNPs 
in general already have different functional properties than randomly selected SNPs [58] (e.g. trait-
associated SNPs typically map in closer proximity to genes than random SNPs). We also ensured that 
none of the SNPs in the null-distribution were affecting genes in trans, or were linked to those SNPs 
(r2<0.2 in 1000 genomes). We then identified perfect proxies (r2=1.0 in 1000 genomes). For SNPInfo 
and SNPNexus, we calculated the enrichment for each functional category using a Fisher’s exact 
test. We determined the enhancer enrichment in nine different cell-types using HaploReg, where we 
averaged the enhancer enrichment over the ten permutations.
Convergence analysis
We determined which unlinked trait-associated SNPs show eQTL effects on exactly the same gene: 
per trait, we analyzed the SNPs that are known to be associated with this trait and assessed whether 
any unlinked SNP pair (r2<0.2, distance between SNPs>5Mb) showed a cis- and/or trans-eQTL effect 
on exactly the same gene, as previously described [5]. To determine whether the number of traits for 
which we observed this phenomenon was higher than expected by chance, we re-ran this analysis 
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20 times, each time using a different set of permuted trans-eQTLs, equal in size to the non-permuted 
set of trans-eQTLs.
SLE IKZf1 ENCODE ChIP-seq Analysis
We used IKZF1 ChIP-seq signal data obtained from the ENCODE-project [31] (IKZF1 ChIP-seq 
data acquired and processed by UCSC, ENCODE March 2012 Freeze). For every human gene 
we determined the average signal (corrected for gene size), corrected for GC-content bias, and 
performed a Wilcoxon Mann-Whitney test to see whether the upregulated genes (MX1, TNFRSF21, 
IFIT1/LIPA, HERC5, CLEC4C, IFI6) showed a higher ChIP-seq signal compared to all other human genes.
Data availability
We have made a browser available for all significant trans-eQTL and cis-eQTL at http://www.
genenetwork.nl/bloodeqtlbrowser. This browser also provides all trans-eQTLs that we detected at a 
somewhat less stringent false discovery rate of 0.5, to enable more in-depth post-hoc analyses.
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AbSTRACT
background: Non-coding RNAs are thought to be important regulators of gene expression. However, 
not much is known about this regulator potential. Genetic variants in or close to non-coding RNAs 
may influence the expression of their target genes. We aimed to identify genetic variants in non-
coding RNAs that affect gene expression levels in trans. 
Methods: We selected 38,545 SNPs in (or close to) exons of long non-coding RNAs (lncRNAs) which 
were likely to have functional consequences. We performed an expression quantitative trait locus 
(eQTL) analysis in peripheral blood samples of 652 individuals using RNA sequencing (RNA-seq) 
data, with replication in an additional 1,464 samples measured with RNA-seq. Significant findings 
were replicated in an RNA-array based trans-eQTL meta-analysis of 5,716 samples. 
Results: We identified and replicated 2,678 trans-eQTLs for 1,320 lncRNAs SNPs. The majority of 
the identified trans-effects were located on the same chromosome as the analyzed SNP. When we 
selected only inter-chromosomal trans-eQTLs, we identified 195 trans-eQTLs: they are linked to 127 
unique SNPs, and some affect multiple genes in trans. For example, the cis-eQTL SNP of lncRNA 
RP11-611L7.1 (rs13227497) is associated with the expression of KNS1, PI3, and ALDH1A2 in trans. 
SNPs in these genes are known to be associated with severe hand osteoarthritis, stress, and chronic 
pain. 
Conclusion: Our trans-eQTL analysis for SNPs in non-coding RNAs provide new evidence 
for associations between SNPs in non-coding RNAs and gene expression levels on different 
chromosomes, indicating that trans-eQTLs give insight into new target genes of the non-coding 
RNAs.
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INTRODUCTION
The first expression-quantitative trait locus (eQTL) meta-analyses in peripheral blood identified large 
numbers of common genetic variants regulating gene expression levels of nearby genes (cis-eQTLs) 
[1-6]. A few studies focused on trans-eQTLs (genetic variants influencing gene expression levels that 
reside further away on the chromosome or on a different chromosome), revealing the downstream 
consequences of genetic variants [1-3,5-9]. However, most trans-eQTL studies focused on SNPs that 
were previously found to be associated with diseases or traits. 
Non-coding RNAs are thought to be involved in regulating gene expression. Dysregulation of 
non-coding RNAs influence tumorigenesis and neurological, cardiovascular, and developmental 
disease [10]. However, for most non-coding RNAs, mechanisms are unknown. In the current study, 
we systematically investigated the cis- and trans-eQTL effects of single nucleotide polymorphisms 
(SNPs) in non-coding RNAs. We focused on long non-coding RNAs (lncRNAs): they are non-protein 
coding RNA molecules longer than 200 nucleotides, and many have been found to function as 
co-regulators [11-15]. They modify transcription factor activity and regulate the activities of other 
co-regulators. 
Genetic variants in or close to lncRNAs may affect the non-coding RNA function in different ways: 
the SNP may alter the binding efficiency of the lncRNA to the mRNA targets, or the SNP may change 
the expression of the lncRNA, which in turn may affect the expression of the target mRNA genes, or 
the SNP may affect the maturation efficiency of the lncRNA, which will influence the expression of 
the target mRNA genes. 
We aimed to identify SNPs in (or close to) lncRNA having trans-eQTL effects. They may highlight new 
biological pathways and hypotheses for future studies. 
METHODS
Study design
We performed the initial eQTL analysis in 652 human peripheral blood samples of the Rotterdam Study, 
a population-based cohort study in the district of Rotterdam, the Netherlands [16]. The Rotterdam 
Study has been approved by the Medical Ethics Committee of the Erasmus MC and by the Ministry 
of Health, Welfare and Sport of the Netherlands , implementing the “Wet Bevolkingsonderzoek: ERGO 
(Population Studies Act: Rotterdam Study)”. All participants provided written informed consent to 
participate in the study and to obtain information from their treating physicians. 
We replicated the significantly associated eQTLs in a meta-analysis using RNA-sequencing data of 
1,464 samples from peripheral blood, divided over three independent cohort studies including 
CODAM [17] (n=184), LL [18,19] (n=626), and LLS [20] (n=654). 
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For the replicating trans-eQTLs, we additionally checked whether the effects were similar in a meta-
analysis using RNA-array data. We ran a meta-analysis including 5,716 peripheral blood samples, 
divided over seven independent cohort studies: DILGOM [21] (n=509), EGCUT [22] (n=891), 
FEHRMANN [1] (n=1,240), INCHIANTI [23] (n=611), KORA [24] (n=740), RS [25] (n=762), and SHIP-
TREND [26] (n=963). 
Gene expression profiling
Whole blood was collected (PAXGene Tubes – Becton Dickinson) and total RNA was isolated (PAXGene 
Blood RNA kits – Qiagen). To ensure a constant high quality of the RNA preparations, all RNA samples 
were analyzed with the Labchip GX (Calliper) according to the manufacturer’s instructions. Samples 
exhibiting a RQS<7 were excluded from further analyses. 
For RNA-sequencing, we removed globin RNA from the total RNA (Ambions GLOBINclear kit), and 
generated mRNA focused libraries for RNA sequencing (Illumina’s TruSeq Stranded Total RNA Library 
Prep Kit). We performed paired-end sequencing (2 x 50 bp) using Illumina’s Hiseq2000, and pooled 
10 samples per lane. We generated read sets per sample (CASAVA) and retained the reads passing 
the Illumina’s Chastity Filter for further processing.
For the RNA-arrays, we hybridized the RNA to Illumina Whole-Genome Expression Beadchips 
(HT12v2 or HT12v4) using the protocol specified by the manufacturer. 
RNA sequencing – preprocessing and alignment
To process the RNA-sequencing data, we used a pipeline developed by the BIOS consortium [27]. In 
short, the quality of the sequencing reads was checked using FastQC (v0.10.1), the adaptors were 
removed using cutadapt v1.1 [28], and the low quality ends of the reads were trimmed using sickle 
v1.200 [29]. 
The sequencing reads were mapped to the human genome v19 (hg19) using STAR v2.3.125 [30], 
and we estimated expression on the exon, transcript and gene level using Ensembl v71 annotation 
[31]. Post-processing steps were done with the Picard Tools software [32]. Overlapping exons were 
merged into meta-exons and expression was quantified for the whole meta-exon. This resulted in 
base counts per exon or meta-exon. Gene expression levels were calculated as the sum of expression 
values of all exons of each gene. 
To normalize the gene expression levels, we divided the summed expression values by the gene 
length and the total number of reads per sample. We then used the Trimmed Mean of M-values 
(TMM) normalization method [33] to estimate scale factors between the samples. Finally, gene 
expression values were log2 transformed and standardized, and the first 25 principal components 
were removed, identical to the RNA array preprocessing steps [3].
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Genotypes
The samples were genotyped using the Illumina 550K or the Illumina 610K arrays, and genotypes 
were imputed up to the 1000 Genomes Project (1000G) reference panel (phase Iv3) using MACH. 
The dataset was checked for sample mixups using MixupMapper [34]. There were no mix-ups in this 
dataset. 
SNP selection for RNA sequencing
Of the 33,867,639 imputed variants, we selected 8,866,155 SNPs with a good imputation quality 
(QUAL>0.9) and a minor allele-frequency (MAF)>1%. To select the SNPs in lncRNA, we downloaded 
the genomic positions of all lncRNAs in the GENCODE v19 [35] database (n=23,898), and intersected 
the positions of the 8,866,155 good quality SNPs with the positions of the 23,898 lncRNA transcripts. 
998,182 SNPs mapped in the lncRNAs, of which 51,968 SNPs mapped in the coding regions, of 
which 31,243 had a MAF>5% (SNPs with 0.01<MAF<0.05 were excluded). Additionally, we checked 
whether there are SNPs regulating the lncRNAs in cis using the cis-eQTL meta-analysis results of the 
BIOS consortium [27], and we identified 7,302 cis-eQTL SNPs. In total, we included 38,545 SNPs in or 
close to lncRNAs that are expressed in whole blood, which had a MAF>5%. 
eQTL mapping
After normalization of the data, we performed both cis- and trans-eQTL mapping on the selected 
SNPs using the eQTL mapping pipeline developed by Westra et al. [3]. eQTLs were defined as cis-
eQTLs, when the distance between the SNP chromosomal position and the probe midpoint was less 
than 250 kilobases (kb), while eQTLs with a distance greater than five megabases (mb) were defined 
as trans-eQTLs. 
eQTLs were mapped using a Spearman’s rank correlation on the imputed genotype dosage values. 
To control the false discovery rate (FDR) below 0.05, we created a null distribution by permuting 
sample labels of the expression data, repeating that five (for the trans-analysis) or ten (for the cis-
analysis) times. 
Trans-eQTL replication
All RNA-sequencing cohorts (CODAM, LLD, and LLS) applied the same methodology as used in the 
initial eQTL analysis to process the RNA sequencing and the genotype data. Finally, we performed 
a sample-size weighted Z-score meta-analysis on the three replication cohorts. Further details on 
these datasets can be found in the BIOS consortium manuscript [27]. We will further refer to this 
dataset as the BIOS-replication dataset. 
Replication in RNA-array data
We performed a trans-eQTL meta-analysis in RNA-array cohorts (n=5,716). For the RNA-array cohorts, 
we selected the SNPs located in (or close to) exons of the lncRNAs that are present on the gene 
expression array: of the 8,866,155 SNPs with a good imputation quality (QUAL>0.9) and a minor 
allele-frequency (MAF)>1%, 18,986 SNPs mapped in exons of lncRNAs. Additionally, we included 749 
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SNPs which are known regulators of the lncRNAs [3]. In total, we included 7,950 SNPs in or close to 
lncRNAs that are expressed in whole blood, which had a MAF>5% (SNPs with 0.01<MAF<0.05 were 
excluded). All RNA-array cohorts applied the same methodology as used previously [3], including 
normalization and standardization, checking for sample mix-ups, principal component removal, and 
trans-eQTL mapping (including 10 permutations in order to establish the FDR threshold at 0.05). We 
performed a binary sample-size weighted Z-score meta-analysis on the RNA-array cohorts. We will 
further refer to this dataset as the CHARGE-replication dataset. 
Pseudogenes
Because of ambiguous alignments in pseudogenes (which are very similar to their host gene), we 
filtered out trans-eQTLs in pseudogenes. To identify the pseudogenes, we used the GENCODE v19 
[35] database, and intersected our trans-eQTL results with the list of 14,206 pseudogenes. In total, 
we excluded 1,395 trans-eQTLs in pseudogenes. 
Data processing
All data processing was performed on the Dutch Life Science Grid. Further details about the grid can 
be found in the BIOS consortium manuscript [27]. 
RESULTS
Trans-eQTLs
In the lncRNA eQTL analysis, we tested the associations between 38,545 SNPs and 60,310 gene 
transcripts (Supplementary Table 1). We identified 58,327 cis-eQTLs and 4,556 trans-eQTLs effects 
(at FDR<0.05) (Table 1). 
Table 1. The number of cis- and trans-eQTLs. Number of significant cis- and trans-eQTLs (FDR<0.05) in 
discovery and replication
eQTL effort # eQTLs # SNPs # probes
cis-eQTLs
Discovery (initial eQTL analysis) 58,327 19,172 13,229
BIOS-replication 49,754 (85.3%) 16,917 10,562
trans-eQTLs
Discovery (initial eQTL analysis) 4,556 1,969 1,294
BIOS-replication 4,073 (89.4%) 1,700 1,064
bIOS-replication
In the BIOS replication, we focused on the 4,556 trans-eQTLs, and we replicated 89.4% (4,073 
trans-eQTLs) with consistent allelic directions in the replication cohorts as compared to the 
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discovery cohort. We found 873 inter-chromosomal trans-eQTLs (the SNP was located in a different 
chromosome than the probe) and 3,200 trans-eQTLs with the SNP located in the same chromosome, 
of which 986 extended one megabase (mb) distance. After removing the trans-eQTLS driven by 
pseudogenes, we kept 2,678 trans-eQTLs: 195 inter-chromosomal trans-eQTLs, 576 trans-eQTLs with 
the SNP on the same chromosome with a distance >1mb, and 1,907 trans-eQTLs with the SNP on the 
same chromosome with a distance between 250kb and 1mb (Table 2).
Table 2. The number of replicating trans-eQTLs not driven by pseudogenes. Number of significant trans-
eQTLs (FDR<0.05) splitted by trans-eQTL type
Type of trans-eQTL # trans-eQTLs
Inter-chromosomal trans-eQTLs 195
# unique SNPs 127
# unique genes 76
Trans-eQTLs with SNP-gene distance >1mb 576
# unique SNPs 232
# unique genes 127
Trans-eQTLs with SNP-gene distance <1mb and >250kb 1,907
# unique SNPs 1,115
# unique genes 563
Total number of trans-eQTLs 2,678
# unique SNPs 1,320
# unique genes 723
Inter-chromosomal trans-eQTLs 
We focused on the 195 significant inter-chromosomal trans-eQTLs which are caused by 127 unique 
SNPs (Supplementary Table 2): 105 SNPs are located in exons of 46 unique lncRNAs and 22 SNPs are 
known cis-eQTL SNPs for 18 unique lncRNAs [27]. Three lncRNAs (SNHG7, ZNF571-AS1, and Z84812.4) 
carry more than ten different SNPs with trans-eQTL effects. The lncRNA SNHG7 is very interesting, 
because Boone et al. [36] recently showed that SNHG7 belongs to the five most highly expressed 
and consistently regulated lncRNAs. It is a member of the small nucleolar host gene family, and 
its expression decreases by IGF1 signaling. Boone et al. propose that SNHG7 is a putative lncRNA 
oncogene that is controlled by IGF1 signaling in a feedback mechanism to prevent hyperproliferation, 
and that this regulation can be lost in the development or progression of breast cancer. 
The 127 unique SNPs for which we found trans-eQTL effects were enriched for associations with 
immune-related diseases. In GWAS, these SNPs have been associated with diseases like celiac 
disease and Epstein-Barr virus immune response [37]. 
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The 72 unique genes for which we found trans-eQTL effects were enriched for associations with 
blood- and immune related diseases: SNPs in these genes have been associated with disease like 
celiac disease, hematological traits, response to anti-retroviral therapy in HIV-1 infection, HIV-1 
control, IgG glycosylation, immune response to smallpox, obesity related traits, and QT interval [37]. 
lncRNA RP11-56L13.1 affects phosphatase gene DUSP22
Two interesting trans-eQTL findings are the SNPs rs4247499 and rs148368513 in the first (rs4247499) 
and last (rs148368513) exon of the intergenic lncRNA RP11-56L13.1. The SNPs are in linkage (r2=0.84 
and D’=0.95), and both SNPs affect the gene expression levels of DUSP22 (p=8.82E-24 and 6.64E-23), 
and the SNPs do not have any other cis- or trans-eQTL effect. 
The DUSP22 gene belongs to the tyrosine-protein phosphatase family and three SNPs located close 
to DUSP22 have been linked to celiac disease, hematological traits, and response to anti-retroviral 
therapy in GWAS [37]. The risk alleles of the SNPs in the lncRNA RP11-56L13.1 (rs4247499*T and 
rs148368513*T) increase the expression of the DUSP22 gene. To our knowledge, the lncRNAs and 
the two SNPs have never been studied in the context of celiac disease, hematological traits, or 
response to anti-retroviral therapy. 
rs13227497 and severe osteoarthritis 
Another interesting results is the SNP rs13227497, which is known to be associated with the 
intergenic lncRNA RP11-611L7.1 in cis (p=8.85E-102) [27]. In our trans-eQTL analysis, we observed 
the risk allele (rs13227497*A) to be associated with higher levels of the KCNS1 gene (p=1.77E-14), 
the PI3 gene (p=3.72E-14), and the ALDH1A2 gene (p=4.26E-9). KCNS1 encodes a potassium channel 
alpha subunit, and a missense SNP in KCNS1 (rs734784) is known to be associated with chronic 
pain [38]. The PI3 gene is a serine-type endopeptidase inhibitor and is regulated by NF-κB. NF-κB is 
involved in cellular responses to stimuli such as stress and free radicals. The ALDH1A2 gene encodes 
retinaldehyde dehydrogenase 2 (RALDH2), an enzyme that catalyzes the synthesis of retinoic acid. 
Common variants within the ALDH1A2 gene have been associated with severe osteoarthritis of the 
hand [39]. Because severe osteoarthritis goes hand In hand with chronic pain and stress, this lncRNA 
might affect these genes in one pathway. 
lncRNA RP11-34P13.14 regulated by SNPs on 2 chromosomes
A third example is the lncRNA RP11-34P13.14, which is associated with five different SNPs on two 
different chromosomes (chr7 and chr16). Two SNPs on chromosome 7 are located in the first exon of 
another lncRNA AC093627.7 (rs79615415 and rs147418006) and one SNP (rs143579933) is a cis-eQTL 
SNP of this lncRNA. The two other SNPs (rs4785780 and rs12923514) on chromosome 16 are located 
in an intron of the PRDM7 gene, which is involved in transcription regulation [40]. All risk alleles 
are associated with higher levels of the lncRNA RP11-34P13.14, and only the SNPs on chromosome 
16 show additional cis-effects. These results indicates a complex network where one lncRNA RP11-
34P13.14 is regulated by trans-eQTL SNPs in another lncRNA and another gene; the PRDM7 gene. 
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CHARGE-replication with RNA-array data
In the CHARGE replication (based on RNA-array data), 41 of the 195 trans-eQTL SNP-gene 
combinations could be tested because of different SNP inclusion criteria (see methods). For two 
SNPs (4.9%), we replicated the trans-eQTLs effects (Table 3 and Supplementary Table 3). 
Table 3. Number of trans-eQTLs in the CHARGE-lookup. Number of SNPs and probes tested in the RNA array 
meta-analysis 
Summary statistics # inter-chromosomal trans-eQTLs
RNA-seq 195
RNA-array – # of tested combinations 41
RNA-array – # of replicating trans-eQTLs 2 (4.9%)
The first replicating trans-eQTL is the SNP rs7440274, which is located in the last exon of the lncRNA 
ZNF718 on chromosome 4. The minor allele G (MAF=19.1%) is associated with lower expression 
levels of the PHKB gene (on chromosome 16) in RS (beta=-5.88, p=3.9E-9), BIOS (beta=-6.21, 
p=5.37E-10), and in the CHARGE meta-analysis (beta=-7.81, p=5.81E-15). The PHKB gene encodes 
the beta subunit of phosphorylase kinase, and earlier studies reported mutations in the PHKB gene 
resulting in glycogen storage disease [41]. 
The second replicating trans-eQTL is the SNP rs12939138, which is located in the last exon of the 
lncRNA RP11-1094M14.11 on chromosome 17. The minor allele T (MAF=4.3%) is associated with 
higher expression levels of the PTGS1 gene (on chromosome 9) in RS(beta=5.33, p=9.65E-8), BIOS 
(beta=5. 90, p=3.68E-9), and in the CHARGE meta-analysis (beta=7.15, p=8.58E-13). The activity of 
the PTGS1 enzyme is known to be inhibited by the nonsteroidal anti-inflammatory drugs (NSAID) 
such as aspirin [42,43].
DISCUSSION
In this trans-eQTL study for SNPs thought to affect the function of non-coding RNAs, we identified 
and replicated 2,678 trans-eQTLs In (or close to) lncRNAs. We focused on the 195 inter-chromosomal 
trans-eQTLs. In the CHARGE replication based on RNA-array data, we replicated only 4.9% of the 
inter-chromosomal trans-eQTLs. 
We described three inter-chromosomal trans-eQTL examples for which we identified potentially 
new associations with target genes. The SNPs in lncRNA RP11-56L13.1 are linked to DUSP22, and 
three SNPs close to DUSP22 are known to be associated with celiac disease, hematological traits, 
and response to retroviral therapy. Therefore, it might be interesting to study this lncRNA in relation 
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to these diseases. The SNP rs13227497 (a cis-eQTL SNP for lncRNA RP11-611L7.1) was associated 
with higher expression levels of KCNS11, PI3, and ALDH1A2, and SNPs in these genes are known 
to be associated with osteoarthritis related phenotypes. And five different SNPs on two different 
chromosomes were associated with higher expression levels of the lncRNA RP11-34P13.14. This 
might indicate a complex network where one lncRNA is regulated by different trans-eQTL SNPs on 
different chromosomes. In summary, these results indicate that the lncRNAs might be important for 
regulating one or more target genes which may belong to one pathway. 
We replicated two of 41 (4.9%) trans-eQTL combinations tested in the CHARGE meta-analysis which 
was based on RNA-array data. The low percentage of replication could be explained by the different 
measurement techniques used. The RNA-arrays use 3’probes, and measure the relative amount of 
gene expression levels of a complete gene transcript. In contrast, with RNA-seq we measure the 
absolute number of reads mapping to each individual exon across the gene of interest. Therefore, the 
concordance between RNA-seq and RNA-arrays is not perfect. For the two replicating trans-eQTLs, 
we could say that these trans-eQTLs represent very robust signals: independent of the measurement 
technique used, the genes seem to be regulated by the lncRNA SNPs. Given the enormous size of 
the possible combinations for SNPs and targets (potentially detected trans-eQTLs), this level of 
replication is highly statistically significant. 
To be able to replicate more trans-eQTLs, the RNA-seq alignment should be more similar to the 
RNA-array design: instead of using all exons in a gene, we could target the 3’ exon only (like the 
RNA-array). This might improve the correlation between the gene expression levels measured with 
RNA-arrays and RNA-seq. 
How the lncRNAs are regulating the mRNA expression is still unclear: only a small number of lncRNAs 
have been functionally well-characterized. Next to analyzing the effect of SNPs in lncRNAs on genome-
wide expression levels, we could study the interactions between lncRNAs and proteins using RNA 
immuneprecipitation sequencing (RIP-seq). RIP-seq is an antibody-based technique used to map in 
vivo  RNA-protein interactions. The RNA binding protein (RBP) of interest is immunoprecipitated 
together with its associated lncRNAs for identification of bound transcripts. With RIP-seq, we will gain 
more insight about the interactions between individual proteins and specific lncRNA molecules. This 
technique has been used to identify chromatin-modifying complexes interacting with lncRNAs like 
Kcnq1ot1, Airn, Xist, and HOTAIR [44]. 
A potential limitation of our study is that we relied on Spearman’s correlation to identify eQTLs. 
Spearman’s correlation assumes constant change over genotype (by adding one minor allele very 
step), which may not always be correct. We did run random forests which increased the number 
of significant eQTLs enormously. However, the replication rate for the random forests was worse. 
Although we chose to apply Spearman’s correlation in our study, we recognize that more complex 
models should be investigated in the future. 
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To fully understand the functional mechanisms of lncRNAs, we could perform targeted perturbations 
to determine the role of the specific lncRNAs. By repressing the levels of the functional lncRNA, 
the dynamics behavior of the interactions can be studied. However, the reduced expression levels 
should have phenotypically measurable consequences. 
In summary, our analysis revealed and replicated 195 inter-chromosomal trans-eQTL effects for 
127 unique SNPs in (or close to) lncRNAs. Our complete list of trans-eQTLs provides new biological 
pathways and hypotheses for future studies. Larger trans-eQTL analyses will likely uncover many 
more of these regulatory relationships. Functional experiments would help to give more insight into 
the biological mechanisms underlying the trans-eQTL associations.
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SUPPLEMENTARy TAbLES
Supplementary Table 1. The number of SNPs and probes tested.
Summary statistics cis-eQTLs trans-eQTLs
Number of SNPs tested 38,545 38,545
Number of probes tested 60,310 60,310
Number of SNP-probe combinations tested 564,525 2,324,648,950
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AbSTRACT
Objectives: Chronic widespread pain (CWP) is a common disorder affecting ~10% of the general 
population and has an estimated heritability of 48-52%. In the first large-scale genome-wide 
association study (GWAS) meta-analysis, we aimed to identify common genetic variants associated 
with CWP. 
Methods: We conducted a GWAS meta-analysis in 1,308 female CWP cases and 5,791 controls of 
European descent, and replicated the effects of the genetic variants with suggestive evidence for 
association in 1,480 CWP cases and 7,989 controls. Subsequently, we studied gene expression levels 
of the nearest genes in two chronic inflammatory pain mouse models, and examined 92 genetic 
variants previously described associated with pain. 
Results: The minor C-allele of rs13361160 on chromosome 5p15.2, located upstream of CCT5 and 
downstream of FAM173B, was found to be associated with a 30% higher risk of CWP (MAF=43%; 
OR=1.30, 95%CI=1.19-1.42, P=1.2 x 10-8). Combined with the replication, we observed a slightly 
attenuated OR of 1.17 (95%CI=1.10-1.24, P=4.7 x 10-7) with moderate heterogeneity (I2=28.4%). 
However, in a sensitivity analysis that only allowed studies with joint-specific pain, the combined 
association was genome-wide significant (OR=1.23, 95%CI=1.14-1.32, P=3.4 x 10-8, I2=0%). 
Expression levels of Cct5 and Fam173b in mice with inflammatory pain were higher in the lumbar 
spinal cord, not in the lumbar dorsal root ganglions, compared to mice without pain. None of the 92 
genetic variants previously described were significantly associated with pain (P>7.7x10-4). 
Conclusions: We identified a common genetic variant on chromosome 5p15.2 associated with joint-
specific CWP in humans. This work suggests that CCT5 and FAM173B are promising targets in the 
regulation of pain.
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INTRODUCTION
Chronic widespread pain (CWP) is a common disorder, affecting about 10% of the general population 
[1]. The prevalence of CWP increases with age for both men and women, but is more common in 
women at any age [1]. CWP represents a major underestimated health problem and is associated 
with substantial impairment and a reduced quality of life. It has been related to a number of physical 
and affective symptoms such as fatigue, psychological distress and somatic symptoms [1,2]. Chronic 
musculoskeletal pain is one of the most common conditions seen in rheumatology clinics and 
accounts for 6.2% of the total healthcare costs in the Netherlands every year [3]. Further research is 
needed to be able to understand the causal mechanisms and optimal treatment for CWP patients. 
CWP causally relates to an initial local pain stimulus, such as an acute injury or athletic injuries or 
another pain state such as low back pain or local pain due to osteoarthritis (OA) or rheumatic arthritis 
(RA) [4-6]. However, most injured subjects do not develop chronic widespread pain, and only a part 
of patients with OA or RA develop CWP. We therefore hypothesize that several discrete stimuli may 
initiate CWP via a common final pathway that involves the generation of a central pain state through 
the sensitization of second order spinal neurons. 
CWP is a complex trait since both environmental and genetic factors play a role in the etiology. 
Heritability estimates of twin studies suggest that 48%-52% of the variance in CWP occurrence 
is due to genetic factors implying a strong genetic component [7]. A number of studies have 
examined genetic variants for CWP. These candidate gene studies examined polymorphisms 
in genes involved in both the peripheral and the central nervous system [8]. In particular, genes 
involved in neurotransmission (pathway of dopamine and serotonin [9-19]), and genes important 
for the hypothalamic-pituitary-adrenal (HPA) axis have been considered [20]. A number of genetic 
variants in these candidate genes were found to be associated with CWP, individual pain sites, or 
experimental pain. However, no consistent significant associations have been demonstrated. 
The most studied gene in relation to pain is COMT (catechol-O-methyltransferase); an enzyme that 
degrades neurotransmitters including dopamine. The variant allele of rs4680 (or V158M) results in 
reduced enzymatic activity due to its effect on thermostability [21], and has been associated with 
reduced opoid activity in response to painful stimuli resulting in increased pain sensitivity [22]. But 
also for COMT, no consistent results have been observed in genetic association studies [13,23-29]. 
Overall, the results have been conflicting which is likely due to the modest sample sizes used 
and paucity of replication. In general, candidate studies are biased by previous knowledge of the 
etiology of the disease under study. Since knowledge about the pathophysiology of CWP is poor, 
the chances of success using this approach are low. Therefore our objective was to identify genetic 
variants involved in CWP by means of a large-scale hypothesis-free genome-wide association study 
(GWAS) meta-analysis including 2,788 cases and 13,780 controls. To our knowledge, this is the 
first study presenting a large-scale GWAS meta-analysis of chronic pain. The prevalence of CWP is 
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approximately two times higher in women than in men and there is strong evidence that women 
tolerate less thermal and pressure pain than men [30]. Therefore only women were included in this 
study to reduce heterogeneity and thereby increase power. 
MATERIALS AND METHODS
We performed a meta-analysis (stage 1) of GWAS data of 1,308 female Caucasian CWP cases and 
5,791 female Caucasian controls, derived from five studies, and focussed our follow-up efforts on 
the SNPs with suggestive evidence of association (P<1 x 10-5) with CWP (stage 2). The study outline 
is summarized in Figure 1. 
figure 1. Study outline. 
CWP = chronic widespread pain; GWAS = genome-wide association study.
Phenotype
Chronic Widespread Pain (CWP) was defined as subjects having pain in the left side of the body, in the 
right side of the body, above waist, below waist, and in the axial skeleton (following the Fibromyalgia 
Criteria of the American College of Rheumatology [2]). Controls were defined as subjects not having 
CWP. Subjects using analgesics (ATC-code: N02 [31]) were excluded from the control group. Detailed 
descriptions of the study specific inclusion criteria are presented in Supplementary Table 1. 
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Study Design Summary
We combined the summary statistics of GWAS in a meta-analysis comprising 1,308 CWP female 
Caucasian cases and 5,791 female Caucasian controls (stage 1). We focussed our follow-up efforts on 
the SNPs with suggestive evidence of association (P<1 x 10-5) with CWP in 1,480 CWP cases and 7,989 
controls available for replication (stage 2). 
Subjects
A full detailed description of all study cohorts is presented in Table 1 and in the Supplementary 
Methods section. For the stage 1 analysis, we included studies from the Netherlands: the Erasmus 
Rucphen Family study (ERF study) [32], Rotterdam Study I, II and III (RS-I, RS-II and RS-III) [33]; and 
the United Kingdom: TwinsUK [34,35]. All studies were approved by their institutional ethics review 
committees and all participants provided written informed consent. For our stage 2 analysis, 
we sought follow-up samples with pre-existing GWAS in-silico data (stage 2a) as well as de novo 
genotyping (stage 2b). The studies are from the United Kingdom: the British 1958 Birth Cohort 
(1958BC) [23,36-38], the Chingford Study (CHINGFORD) [39,40], the Dyne Steel DNA Bank for Aging 
and Cognition (DSDBAC) [41], the EPIdemiological study of FUNctional Disorders (EPIFUND) [20], and 
the Hertfordshire Cohort Study (HCS) [42]; from Iceland: the Age, Gene/Environment Susceptibility 
Study (AGES) [43]; from the United States: Framingham Osteoarthritis Study (FOA) [44]; from the 
Netherlands: the Genetics osteoARthritis and Progression Study (GARP) [45]; and from Germany: the 
Study of Health In Pomerania (SHIP) [46,47]. All studies were approved by the local ethics committees 
and all participants provided written informed consent. 
Genotyping, Quality Control and Imputation
Genotyping of the stage 1 cohorts was done by Illumina Infinium HumanHap550 Beadchip 
(RS-I and RS-II), the Illumina Infinium HumanHap610 (RS-II, RS-III, and TwinsUK), or the Illumina 
Infinium HumanHap300 (ERF and TwinsUK). More details about the genotyping, Quality Control, 
and Imputation are shown in the Supplementary Methods section. Complete information on 
genotyping protocols and QC measures for all stage 1 cohorts is described in the Supplementary 
Material (Supplementary Table 2).Detailed descriptions of the QC and imputation procedures are 
provided in the Supplementary Material (Supplementary Table 3).
Genotypes of the stage 2a studies (1958BC, AGES, DSDBAC, FOA, GARP, and SHIP) were obtained 
from SNP arrays and imputed data. Where unavailable, proxy SNPs were selected based on high 
linkage disequilibrium. The stage 2b studies (CHINGFORD, EPIFUND, and HCS) performed de novo 
genotyping, using both Sequenom iPLEX and TaqMan-based assays (Supplementary Methods). 
Genotyping platforms, calling algorithms, quality control before imputation, imputation methods, 
and analysis software used were all study-specific (Supplementary Tables 4 and 5). The explicit 
number of follow-up SNPs genotyped in the different studies and whether the original or a proxy 
SNP was used is summarized in Supplementary Table 6. 
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GWAS-analysis in the Stage 1 Studies
CWP was analyzed as a binary trait (cases versus controls) using logistic regression under an 
additive model with adjustment for age and BMI (Supplementary Table 7). To adjust for population 
substructure, we included the 4 most important PCs as covariates in the regression analysis of RS-I, 
RS-II, and RS-III. These PCs were derived from an multidimensional scaling analysis of identity-by-
state distances, using PLINK software [48]. Detailed descriptions of the GWAS methods are provided 
in Supplementary Table 8).
Stage 1 GWAS Meta-Analysis
P-values for association were combined using the Meta-Analysis Tool for genome-wide association 
scans (METAL) [49]. The genomic control method [50] as implemented in METAL was used to 
correct for any residual population stratification or relatedness not accounted for by the four most 
important PCs. A P-value<5 x 10-8 was considered genome-wide significant while a P-value<1 x 10-5 
was considered suggestive [51]. Power calculations were performed using CaTS software (www.sph.
umich.edu/csg/abecasis/CaTS/). Using Bonferroni correction (P<5 x 10-8), power calculations showed 
that we had approximately 80% power to detect an odds ratio (OR) of 1.30 for SNPs with a minor 
allele frequency (MAF) of 0.43, given a disease prevalence of 10% for 1,308 cases and 5,791 controls 
in the discovery group. Using a P-value<1 x 10-5, we had 80% power to detect an OR of 1.25. 
SNP selection for replication
We aimed to select SNPs for replication (stage 2) that were enriched for signals of association with 
CWP. All SNPs with suggestive evidence for association in the stage 1 analyses were selected and 
separated into independent loci by taking the most significantly associated SNP and eliminating all 
SNPs that have a HapMap CEU pair-wise correlation coefficient r2>0.8 with that SNP using the PLINK 
software.
Meta-analysis of stage 1 and stage 2 results
We combined the stage 1 and stage 2 association results to derive a combined meta-analysis for the 
suggestively associated loci. METAL was used to conduct a fixed-effects meta-analysis as in stage 
1. Estimated heterogeneity variance and forest plots were generated using Comprehensive Meta-
Analysis (www.meta-analysis.com). 
functional analysis of associated SNPs
To determine whether the associated SNPs have any regulatory effect on gene expression levels, we 
checked their effect (and the effect of the linked SNPs) on the expression levels of their neighbouring 
genes. We used the 1000 genomes data in the SNAP software [52,53] to identify those SNPs having a 
linkage disequilibrium (LD) thresholds of r2>0.1. We searched two publicly available eQTL databases: 
the NCBI GTEx (Genotype-Tissue Expression) eQTL Browser (http://www.ncbi.nlm.nih.gov/gtex/
GTEX2/gtex.cgi) and the expression Quantitative Trait Loci database (http://eqtl.uchicago.edu/cgi-bin/
gbrowse/eqtl/). We used SIFT [54] to predict whether the coding non-synonymous variant causing an 
amino acid substitution affects protein function.
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RNA expression analyses in mice
For functional follow-up, two independent mouse models of inflammatory pain were studied. The 
first model was based on carrageenan injections; female C57Bl/6 mice received an intraplantar 
injection of 20 μl λ-carrageenan (2% (w/v), Sigma-Aldrich) in saline in both hind paws [55]. The 
second model was based on Complete Freund’s Adjuvant (CFA) injections; male C57Bl/6 mice 
(Harlan Laboratories) received an intraplantar injection of 20 μl CFA (Sigma-Aldrich) in saline in both 
hind paws [56]. Controls were injected with saline only. At day 3 (after CFA injection) or day 6 (after 
carrageenan injection), thermal sensitivity (heat withdrawal latency time) was measured using the 
Hargreaves (IITC Life Science, Woodland Hills, CA) test as described [57]. Intensity of the light beam 
was chosen to induce heat withdrawal latency time of approximately 8 seconds at baseline. 
After measurement the mice were sacrificed and the lumbar (L2-L5) spinal cord and the dorsal root 
ganglions (DRG) (L2-L5) were isolated. These areas of spinal cord and DRG were selected because 
pain transmission from the hind paws is mediated via primary sensory neurons that have their cell 
bodies in the lumbar DRG, and transmit the signal to the lumbar spinal cord through sensory fibres 
in the dorsal roots. Total RNA was isolated and mRNA levels of Cct5 and Fam173b were measured in 
the spinal cord and the DRG. For more details, see the Supplementary Methods section. 
All experiments were performed in accordance with international guidelines and approved by the 
experimental animal committee of University Medical Center Utrecht (carrageenan experiment) 
or the United Kingdom Home Office Animals (Scientific Procedures) Act 1986 (CFA experiment). 
Mice used for the carrageenan experiment were bred and maintained in the animal facility of the 
University of Utrecht (the Netherlands).
Systematic review of genetic variants previously described
We systematically searched for associations earlier reported with pain in the HugeNavigator 
PhenoPedia Database [58]. We used the search term “pain” and checked all publications for genes 
and SNPs associated with pain at least twice. Genes and SNPs associated with drug therapy, 
facial pain, migraine, and postoperative pain were excluded. For all reported SNPs, we examined 
their association with CWP in our stage 1 meta-analysis. The significance threshold was set at 
P<8 x 10-4 using Bonferroni correction for 65 independent genetic loci. Again, power calculations 
were performed using CaTS software (www.sph.umich.edu/csg/abecasis/CaTS/). With an alpha level 
of 8 x 10-4, power calculations showed that we had approximately 80% power to detect an OR of 1.22 
for SNPs with an minor allele frequency of 20% or higher. 
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RESULTS
GWAS meta-analysis for CWP
The Manhattan plot and Quantile-Quantile (QQ) plot of the initial stage 1 meta-analysis are presented 
in Figure 2. In total, 2,224,068 SNPs (directly genotyped or imputed) were tested for association. The 
overall genomic control lambda (λGC) was 1.007, indicating no significant population stratification. 
We identified two SNPs which were genome-wide significant (P<5 x 10-8), and another 39 SNPs 
with suggestive evidence for association (P<1 x 10-5) located in ten independent genomic regions. 
The most significant association was observed for two imputed highly correlated SNPs (r2=0.97) 
located upstream of the Chaperonin-Containing-TCP1-complex-5 gene (CCT5) and downstream of 
the FAMily with sequence similarity 173, member B gene (FAM173B) (rs13361160, P=1.2x10-8 and 
rs2386592, P=2.6 x 10-8). For both SNPs, the minor allele (MAF=43%) was associated with a 30% 
higher risk for CWP (OR=1.30, 95%CI=1.19-1.42). 
Meta-analysis of GWAS replication
For the ten independent SNPs with suggestive evidence, we pursued in silico replication data 
in six studies (stage 2a: 1,203 CWP cases and 5,032 controls) and performed de novo genotyping 
in subjects from three additional studies (stage 2b: 277 CWP cases and 2,957 controls) (detailed 
description of the studies is presented in Table 1 and Supplementary Methods). The summary results 
of the stage 1 and 2 meta-analysis are presented in Table 2. 
After combining the results of stage 1 and stage 2, the top SNP was rs13361160 (OR=1.17, 
95%CI=1.10-1.24, P=4.7 x 10-7, I2=28.4%). Figure 3 shows a forest plot of the association of rs13361160 
with CWP across the stage 1 and stage 2 studies. The overall effect in the replication studies (stage 
2 studies) was in a consistent direction but not significant (OR=1.06, 95%CI=0.98-1.16, P=0.16). In 
the combined analysis, moderate heterogeneity was observed (I2=28.4%). Supplementary Table 1 
shows the different pain assessment methods used in the different studies to define CWP. Since four 
out of five stage 1 studies included joint-specific pain only (ERF, RS-I, RS-II, and RS-III), we performed 
a sensitivity analysis in which stage 2 cohorts using non-joint pain were excluded (1958BC, DSDBAC, 
EPIFUND, HCS, and SHIP). This resulted in a combined OR of 1.23 (95%CI=1.14-1.32, P=3.4 x 10-8, 
I2=0%). An overview of the results of the combined meta-analysis and the separate stage 1 and stage 
2 analyses is presented in Table 3. 
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figure 2. Genome-wide association results for chronic widespread pain (CWP) (stage 1). (A) Manhattan 
plot showing the p value of association tests for about 2 million SNPs with CWP in the stage 1 meta-
analysis. SNPs are plotted on the x-axis according to their position on each chromosome. On the y-axis, the 
association P-values with CWP are shown (as −log 10 P-values). The grey solid horizontal line represents the 
P-value threshold of 5 × 10-8 (genome-wide significance). The grey dashed horizontal line represents the 
p value threshold of 1 × 10-5 (the level for suggestive evidence): SNPs in loci reaching 1 × 10-5 were tested 
for replication. (b) Quantile-quantile (QQ) plot of SNPs. The blue area represents the 95%CI around the test 
statistics. A QQ plot compares the additive model statistics to those expected under the null distribution 
using fixed effects for all analysed HapMAP CEU imputed SNPs passing quality control criteria. 
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Table 3. Top hit association results. 
Type of Analysis Stage 1 Stage 2 Stage 1 & 2 (combined)
SNP tested Adjustments OR  
(95%CI)
P OR  
(95%CI)
P OR  
(95%CI)
P
rs13361160 Age, BMI, and 4 PCs 1.30 (1.19-1.42) 1.18 x 10-8 1.06 (0.98-1.16) 0.16 1.17 (1.10-1.24) 4.67 x 10-7
minor allele = C, other allele = T, MAF=43.5%
Sensitivity analysis: joint pain only
rs13361160 Age, BMI, and 4 PCs 1.30 (1.19-1.42) 1.18 x 10-8 1.10 (0.97-1.25) 0.15 1.23 (1.14-1.32) 3.43 x 10-8
minor allele = C, other allele = T, MAF=43.5%
In both analyses the effect estimates of the models refer to the minor allele (=effect allele). BMI = body mass index; MAF = minor allele 
frequency; OR = odds ratio; 95%CI = 95% confidence interval; P = P-value.
figure 3. forest plot of the association of rs13361160 SNP with chronic widespread pain (CWP). Study 
specific estimates and summary association between rs13361160 and CWP are shown. 
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functional analysis of rs13361160 and rs2386592
The SNPs rs13361160 and rs2386592 (r2=0.97) are annotated to the 5p15.2-region and located 81 kb 
upstream of CCT5 and 57 kb downstream of FAM173B (Figure 4). We tested whether rs13361160 
and rs2386592 and their linked SNPs (r2>0.1) affected gene expression levels of CCT5 or FAM173B. 
In total, we identified 130 SNPs in LD with our top SNPs of which two SNPs were located in the 
coding region: one synonymous SNP rs1042392 in the CCT5 gene (r2=0.16, D’=0.85) and one non-
synonymous SNP rs2438652 in the FAM173B gene (r2=0.17, D’=1.0) (Supplementary Table 9). The 
minor allele of rs2438652 causes a threonine-to-methionine substitution (T75M) which is thought 
to be functionally neutral. SNPs rs13361160 and rs2386592 were not recorded as influencing the 
expression levels of CCT5 and FAM173B, however, the linked intronic SNP rs2445871 (r2=0.14 for 
both) had a direct eQTL effect on FAM173B expression levels in liver tissue [59].
figure 4. Regional plot of locus 5p15.2. On the x-axis, SNPs are plotted according to their position in a 
400-kb window around rs13361160. On the y-axis, the association p values with chronic widespread pain are 
shown (as −log 10 p values). The purple diamond highlights the most significant SNP rs13361160. Blue peaks 
indicate recombination sites, and the SNPs surrounding the most significant SNP are color coded to identify 
their strength of linkage disequilibrium with the most significant SNP (pairwise r2 values of the HapMap CEU 
samples). Genes and the direction of transcription are shown at the bottom of the plot. 
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RNA expression analysis in mice
We studied gene expression levels of the two nearest genes Cct5 and Fam173b in the lumbar 
spinal cord and the dorsal root ganglions (DRG) in two independent mouse models of chronic 
inflammatory pain. In both the carrageenan treated group and the Complete Freund’s Adjuvant 
(CFA) treated group, mice had shorter heat withdrawal latency times than mice injected with saline 
only, confirming enhanced pain sensitivity (P<0.001) (Supplementary Figure 1). 
The results from the multivariate analysis using the two genes (Cct5 and Fam173b examined as 
dependent variables), the different treatments (saline, carrageenan, and CFA) and the different tissues 
(DRG and spinal cord) confirmed that there is a significant treatment effect for Cct5 F(2,25)=3.399, 
p=0.0049, as well as for Fam173b F(2,25)=4.911, p=0.016. Moreover, both genes showed a significant 
tissue effect (Cct5: F(1,25)=13.595, p=0.001, and Fam173b: F(1,25)=13.522, p=0.001), as well as a 
significant interaction between tissue and treatment (Cct5: F(2,25)=6.424, p=0.006, and Fam173b: 
F(1,25)=4.196, p=0.027) (Figure 5). These findings indicate that in spinal cord but not in DRG both 
Fam173b and Cct5 expression levels were upregulated in response to two different inducers of 
inflammatory pain. DRG Fam173b and Cct5 expression levels in CFA/carrageenan-treated mice 
were indistinguishable from saline-treated mice.
figure 5. Quantitative PCR analysis of gene expression levels in the lumbar (L2–L5) spinal cord (A) and the 
dorsal root ganglions (DRG) (b) of mice after intraplantar saline (n=3), carrageenan (n=4), and Complete 
freund’s Adjuvant (CfA) (n=4) injection. Spinal cord and DRG were collected and analyzed for RNA levels of 
Cct5 and Fam173b. Data were normalized for Gapdh and β-actin (housekeeping genes) expression. Data are 
expressed as mean±SEM, *=p<0.05.
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Candidate SNPs previously associated with chronic pain.
We examined whether genetic variants previously described for association with pain were 
associated with CWP in our large stage 1 meta-analysis. We identified a total of 44 genes of which 
136 SNPs had been reported at least twice with any pain phenotype (excluding facial pain, migraine, 
postoperative pain, and response to drug therapy), and we examined the association of these 
136 SNPs with CWP in the GWAS stage 1 meta-analysis. Out of 136 candidate SNPs, we were able to 
check 92 common SNPs (MAF>5%) in 65 independent genetic loci (Supplementary Table 10). Five 
SNPs had a too low MAF (<=5%) and 39 SNPs were not genotyped or imputed in our meta-analysis. 
None of the earlier reported SNPs passed the significance threshold (P<8 x 10-4). Interestingly, the 
strongest associated SNPs are located in three genes that have been reported to be associated 
with pain phenotypes most frequently: COMT (Catechol-O-MethylTransferase), GCH1 (GTP cyclo-
hydrolase 1), and OPRM1 (mu opioid receptor). The effects of the SNPs in GCH1 are in the same 
direction as earlier reported [60-62]: individuals having the minor allele for rs10483639, rs4411417 
or rs752688 have 15% less pain than those exhibiting the common alleles. The effect of the SNP 
rs599548 in OPRM1 is also in the same direction as earlier reported [63]: those having the minor 
allele for rs599548 have 19% more pain than those exhibiting the major allele. The two COMT SNPs 
are in weak linkage disequilibrium with the well-known amino-acid changing variant rs4860, but 
previously have not been reported to be significantly associated with pain [23,64]. We have found a 
protective effect for the minor allele of rs2020917 (those having a minor allele have 15% less pain) 
and an adverse effect for the minor allele of rs5993883: those having the minor allele of rs5993883 
have 14% more pain.
DISCUSSION
In this study, we identified a genetic variant near CCT5 and FAM173B to be associated with CWP. 
Chronic pain coincided with higher RNA-expression of Cct5 and Fam173b in the lumbar spinal cord 
of mouse models of inflammatory pain. This finding indicates that both genes in the 5p15.2 region 
are regulated in the context of inflammatory pain.
Interestingly, Bouhouche et al. [65] reported a human pedigree in which a CCT5 mutation caused 
hereditary sensory neuropathy (OMIM=610150), a syndrome characterized by a sensory deficit 
in the distal portion of the lower extremities, chronic perforating ulcerations of the feet, and 
progressive destruction of underlying bones. Symptoms can include pain and numbness, tingling 
in the hands, legs or feet, and extreme sensitivity to touch. CCT5 is a subunit of the chaperonin 
containing t-complex polypeptide 1 (TCP-1) which assists in protein folding and assembly in the 
brain [66]. CCT5 interacts with the serine/threonine-protein phosphatase 4 catalytic subunit PP4C 
[67-69]. Zhang et al. [70] confirmed that protein phosphates like PPP4C may have a regulatory effect 
on the central sensitization of nociceptive transmission in the spinal cord. Interestingly, sensitization 
is thought to contribute to chronic inflammatory pain [71]. Since the function of the FAM173B gene 
is not yet known, it is difficult to postulate the mechanism by which this gene could influence CWP. 
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Further research into the genes in this locus is needed to ascertain whether either or both CCT5 and 
FAM173B are driving the observed association.
By combining the effects across the different stage 2 studies, moderate heterogeneity was observed 
in the meta-analysis. This heterogeneity might be caused by different pain assessment methods 
used by the stage 2 cohorts. In particular, four cohorts asked the participants about joint pain 
specifically, while the other five also included non-joint pain. When the non-joint pain phenotype 
were excluded, the heterogeneity across the cohorts reduced to 0% and the overall P-value for 
rs13361160 now reached genome-wide significance by combining the stage 1 and stage 2 effects. 
This might suggest that indeed phenotype heterogeneity was introduced by including non-joint 
pain. In general, it is anticipated that pain is a very complex trait, with different ethiological pathways 
introducing phenotypic heterogeneity. 
A limitation of our study is that we were not able to examine possible phenotype subgroups, such as 
individuals with rheumatic arthritis (RA), a chronic systemic inflammatory disorder that principally 
affects the synovial joints. Stratifying these groups of individuals might serve to increase power to 
find genetic loci. We here decided to analyse all CWP cases together, based on the hypothesis that 
several discrete stimuli need to initiate CWP via a common final pathway that involves the generation 
of a central pain state through the sensitization of second order spinal neurons. In addition, the 
prevalence of RA is very low (about 0.5-1%) [72], and the earlier defined GWAS hits for RA (i.e., the 
HLA-locus) [73] were not in our top list. So, we assume the results were not dominated by this small 
number of individuals with RA. 
It would be helpful to dissect the phenotype of pain into quantitative sub-phenotypes, for example, 
by measuring pain sensitivity and pain thresholds for temperature or pressure [74], or by examining 
functional MRIs [75]. The use of quantitative and possibly more objective pain measurements in 
response to painful stimuli (rather than reported pain) will be of pivotal importance for future 
pain research. Because we have focused on the clinical pain definition using questionnaires and 
pain homunculus, we accept that we may have missed true pain susceptibility alleles. However, 
this study represents the largest genome-wide meta-analysis looking into the genetics of human 
chronic widespread pain to date. The experiments in two independent mouse models of chronic 
inflammatory pain showed that the expression of Cct5 and Fam173b were higher in the lumbar spinal 
cord of mice with chronic inflammatory pain but not in de dorsal root ganglions (DRG). In the spinal 
cord, the expression profiles of both genes were upregulated in response to two different inducers 
of inflammatory pain. These findings indicate that both genes in the 5p15.2 region are co-regulated 
in the spinal cord during inflammation-induced pain in both independent pain models, thereby 
possibly contributing to the neurobiology of pain. In the lumbar DRG, containing the cell bodies of 
the primary sensory neurons that detect pain signals from the hind paws, Cct5 and Fam173b gene 
expression levels did not change by inflammation. Because of these complementary results from the 
two independent tissues (spinal cord and DRG), we hypothesize that the 5p15.2 region is likely to 
play a role in spinal central pain processing and not in regulating primary sensory neuron responses. 
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In the study of candidate genes previously reported to be associated with a pain phenotype, we 
showed that none of the 92 studied variants were significantly associated with CWP in our GWAS 
meta-analysis. This can be explained by the fact that many of the previous reported loci were studied 
in relative modest sample sizes and in a large variety of pain phenotypes [76]. Power calculations 
show that we had approximately 80% power to detect an odds ratio (OR) as low as 1.22 for SNPs with 
an allele frequency of 20% or higher. So, even in this large meta-analysis power was still modest to 
detect small ORs and we therefore cannot exclude smaller effect sizes of the tested variants, resulting 
in lack of reproducibility [77]. This lack of reproducibility of SNPs in candidate genes in large GWAS 
meta-analyses has been shown before for other phenotypes such as BMD [78]. It is interesting to 
note that among the candidate SNPs, the strongest associated ones were located in the three most 
studied pain genes COMT, GCH1, and OPRM1. The directions of the effects of these SNPs were the 
same as reported earlier, which would support true associations. 
In conclusion, our study reports a GWAS meta-analysis on CWP. We identified the genetic variant 
rs13361160 at the 5p15.2 locus, located 81kb upstream of the CCT5 gene and 57kb downstream 
of the FAM173B gene, to be associated with CWP. We showed an increase in expression levels of 
Cct5 and Fam173b in the spinal cord of inflammatory pain models of mice, and since these genes 
both seem to influence the central mechanism of sensitization, they may represent a novel pathway 
involved in pain sensation. 
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AbSTRACT
Introduction: Chronic pain and pain sensitivity are complex traits with a variety of potential 
determinants. Although not yet fully elucidated, pain sensitivity and the risk for chronic pain are 
thought to be partly genetic. In our study, we attempt to further elucidate the genetic predisposition 
of pain sensitivity. 
Methods: In a total number of 3,795 participants from the Rotterdam study (a large prospective 
population based cohort) heat pain thresholds (HPT) were determined. We estimated the total 
additive genetic influence on HPT measurements due to common genetic variation using GCTA, and 
we performed a genome wide association study (GWAS) to identify new loci associated with HPT 
in the general population. Finally, we reviewed the literature for previously reported DNA variants 
associated with experimental pain thresholds and tried to replicate these findings in our dataset. 
Results: The overall heritability estimate of HPT was 19%. In individuals without chronic pain, this 
estimate was 32% compared to 9% in individuals with chronic pain. In addition, the heritability 
was higher in women compared to men. Our GWAS revealed one genome-wide significant signal 
(1:176688345:D) which is located in the twelfth intron of the PAPPA2 gene (p= 2.48E-08). Additionally, 
we found six suggestive signals (P<1.0E-06). Genetic variants previously associated with pain 
sensitivity were not replicated in our study.
Conclusion: A significant proportion of the variability of HPT is explained by genetics. The extent 
to which HPT is genetically determined is higher when individuals do not experience chronic pain. 
Future genetic studies on pain sensitivity should take the presence of chronic pain into account 
since it influences the phenotype substantially. This largest genetic screen for pain sensitivity up to 
date provides new potential genetic loci for further research. 
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INTRODUCTION
Chronic pain and pain sensitivity are complex traits with a variety of potential determinants. The 
development of chronic pain and an increased sensitivity by sensitization of the nervous system 
are unintended consequences after tissue damage. In this scenario, the pain is prolonged or more 
severe compared to what might be expected during a normal healing process [1].
A wide variety of risk factors have been described for the development of chronic pain. One of 
them is an intrinsic high pain sensitivity, which can be assessed by experimental pain sensitivity 
measurements [2]. In theory, experimental pain sensitivity is less sensitive to bias due to disease 
or tissue damage, compared to more subjective pain phenotypes such as pain severity scores [3]. 
There are many different measurements to determine pain sensitivity, such as pain thresholds and 
tolerance for different stimuli. The heat pain threshold (HPT) is one of the most studied measurements 
for pain sensitivity: the HPT is noninvasive and can be used for measuring pain sensitivity and pain 
thresholds. Measurements can be done over multiple body points, and the temperature and the 
duration of the pain stimulus can be highly controlled [3]. Finally, there is good reproducibility 
between two sessions [4]. 
The proportion of genetic influence on pain has been under debate. In previous studies, the heritability 
of pain sensitivity and chronic pain has been estimated in classical twin studies. A review by Nielsen 
et al. [5] showed that the heritability estimates of specific pain phenotypes differ: for example, 
back and neck pain have heritability estimates ranging from 0% to 68% [6-13], osteoarthritis has 
heritability estimates ranging from 0% to 53% [14,15], and irritable bowel syndrome has heritability 
estimates ranging from 0% to 48% [16-20]. The heritability of experimental pain sensitivity has been 
studied scarcely, with only three previous study reports. All three reports had a twins design and 
used various experimental designs, such as cold pressor tests and heat pain thresholds [21-23], and 
relatively small sample sizes were used. Consequently, heritability estimates ranged between 0% and 
60%. Other studies investigating the genetic background of pain sensitivity focused on candidate 
genes previously described to play a role in pain, or studied the genetic variants in modestly sized 
pain patient populations [24-36]. 
In a previous study by our group, we investigated the genetic background of chronic widespread pain 
[37]. Although we identified a DNA variant to be associated with CWP, we also identified significant 
heterogeneity among phenotype definitions among the cohorts. As for other complex traits, it 
would be helpful to dissect the pain phenotype into quantitative underlying endophenotypes, such 
as intrinsic pain sensitivity, which can be measured by experimental pain thresholds. The present 
study therefore focuses on experimental HPT as an endophenotype underlying the development 
of chronic pain.
The aim of the current study was to further elucidate the genetic predisposition of pain sensitivity, 
defined as the HPT. In the Rotterdam Study, a large prospective population based cohort, we 
502007-L-bw-Peters
202
Chapter 4
estimated the heritability of the HPT and the influence of gender and the presence of chronic pain 
on the heritability of the trait. We performed a genome wide association study (GWAS) to search for 
potential new genetic markers associated with HPT in a general population. And finally, we reviewed 
the literature for significantly pain sensitivity associated variants and we tried to replicate those 
findings in our population.
METHODS
Study population
This study is performed within the Rotterdam Study (RS), a large prospective population-based 
cohort study of men and women aged 45 years and over. The study design and rationale are 
described elsewhere in detail [38]. In summary, determinants, incidence and progression of chronic 
disabling diseases in the elderly are studied. The first cohort (RS-I) within the Rotterdam study started 
in 1990 and included 7,983 individuals ages 55 years and older. In 1999, an additional 3,011 subjects 
were included in Rotterdam study II (RS-II). The third cohort (RS-III) was invited in 2005, adding 
3,932 individuals aged 45 years and over. All participants were examined in detail at baseline and 
at subsequent follow up visits, which took place approximately every six years. In summary, a home 
interview and extensive set of examinations at the research center was performed. For the present 
study, we used data from 3,795 participants for whom data on experimental pain sensitivity, data on 
the presence of chronic pain and genetic information were available. The Rotterdam Study has been 
approved by the Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare 
and Sport of the Netherlands, implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies 
Act: Rotterdam Study)”. All participants provided written informed consent to participate in the study 
and to obtain information from their treating physicians. 
Genotyping
Genotyping was done using Illumina Infinium HumanHap550 Beadchips (RS-II), or the Illumina 
Infinium HumanHap610 Beadchips (RS-III). Details about genotyping and Quality Control have been 
described previously [37]. In short, a total of 2,612 subjects were genotyped in RS-II (Illumina 550 
duo) and a total of 3,523 subjects in RS-III (Illumina 610 quad). Exclusion criteria were a call rate 
<98%, Hardy-Weinberg P-value <10-6 and minor allele frequency <0.01%, autosomal heterozygosity, 
sex mismatch and outlying identity-by-state clustering estimates. A total of 2,157 for RS-II and 3,048 
for RS-III passed genotyping quality control. Data was imputed with the 1000-Genomes reference 
panel (phase 1, version 3) using MACH version 1.0.15/1.0.16 [39]. A total number of 30,072,738 SNPs 
were available for association analysis. 
Experimental pain sensitivity assessment: Heat pain threshold measurement
In the 3,795 participants of the Rotterdam study included in this study, quantitative sensory testing 
was conducted. We used a commercially available thermo-sensory analyzer, the TSA II (Medoc 
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Advanced Medical Systems, Durham, NC). The measurement probe had a surface of 30x30mm, and 
was placed on the inner site of the non-dominant forearm.
During the HPT measurement, the starting temperature of the probe was 32 degrees Celsius. Then, 
the probe would increase in temperature with 1.5 degrees per second until the participant ended 
the test or the maximum temperature of 50 degrees Celsius was reached. The participant was asked 
to push a large red ‘quiz button’ and therewith end the measurement at the moment the stimulus 
started to feel unpleasant or painful. After each measurement, the temperature returned to 32 
degrees Celsius before the next measurement started. The HPT measurement was repeated five 
times in a row. For the analysis, the average temperature of the last three measurements was used.
Heritability estimation
To quantify the proportion of HPT variance explained by genetic variants, we used the restricted 
maximum likelihood (REML) method. This method is able to quantify heritability estimates 
attributable to all genetic variants and is implemented in the Genome-wide Complex Trait Analysis 
(GCTA) package [40]. We created one genetic relationship matrix (GRM) file for the unrelated 
participants in our RS-II and RS-III populations, and included all genotyped SNPs. This resulted in 
a GRM file of 495,775 SNPs for 3,795 samples. No pairs of individuals exceeded the GCTA standard 
cutoff coefficient of 0.025 for genetic relatedness. A P-value<0.05 was considered to be statistically 
significant in this analysis.
The mean HPT (as described before) was used as phenotype and adjustments were made for age 
and gender. 
Additional analyses were performed in which we stratified both for gender and the presence of 
chronic musculoskeletal pain.
Genome Wide Association Study (GWAS) and meta-analysis
We performed two GWAS for HPT: one in RS-II and one in RS-III. We used MACH2QTL via GRIMP [41], 
which uses the genotype dosage values (0-2 as a continuous variables) as the predictor in a linear 
regression framework. HPT was used as the outcome measurement and adjustments were made for 
age, gender and the presence of chronic pain. In addition, the GWAS was repeated in participants 
without chronic pain.
Quality control was done with EasyQC [42]. The effective allele count was calculated for all SNPs by 
2*minor allele frequency*R2(correlatedness of the data)*sample size. SNPs with an effective allele 
count >5 were included in the meta-analysis. An effective allele count of >5 represents minor alleles 
appearing at least 5 times in the study population. 
The summary statistics of the results of the GWAS in RS-II and RS-III were meta-analyzed using 
METAL (www.sph.umich.edu/csg/abecasis/metal) after genomic control correction to the standard 
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errors and p-values. METAL applies an inverse-variance methodology assuming fixed effects with 
Cochran’s Q and I2 metrics to quantify between-study heterogeneity.
For the GWAS, the statistical significant threshold was set on 5.0E-08. SNPs with a P-value<1.0E-06 
were called suggestive signals. 
Systematic review of genetic variants previously described 
We systematically searched the literature for previous associations with experimental pain 
thresholds. We used the Human Genome Epidemiology (HuGe) Navigator Phenopedia database 
for this [43]. This database provides a comprehensive archive of studies assessing the associations 
between phenotypes and genetic variants and this database is continuously updated.
The phenopedia tool provides a list of genes previously associated with your phenotype of interest, 
and includes links to the articles in which these associations were published. We used the search 
term ‘pain threshold’ on 16 September 2014. All publications were manually screened for the 
phenotype studied and the SNPs identified. We only included the studies which investigated the 
association of genetic variants with measures of quantitative sensory testing. The SNPs selected for 
the analysis were those described to be significantly associated with the pain threshold phenotype. 
Additionally, an rs-id needed to be available. 
For all reported SNPs, we examined their association with HPT in our GWAS meta-analysis results. 
The significance threshold was set at P-value<0.05.
RESULTS
Population characteristics
For this study, 1,326 individuals from the third follow up visit of RS-II and 2,469 individuals from the 
second follow up visit of RS-III were included in whom HPT measurements and genotype information 
was available. Characteristics are shown in Table 1. The participants from RS-II were significantly 
older and had a lower percentage of women. The prevalence of chronic pain was significantly higher 
in RS-II and mean HPT measures were slightly lower in RS-II compared to those in RS-III.
Table 1. Study population characteristics.
Total RS-II RS-III
N= 3,795 1,326 2,469
Age, mean (SD) 65.9 (7.5) 72.6 (5.2) 62.3 (6.0)
Women, % (n) 56% (2,125) 54% (716) 57% (1,407)
Chronic pain present, % (n) 44% (1,670) 47% (623) 42% (1,037)
Heat pain threshold, mean (SD) in degrees Celsius 47.5 (3.0) 47.3 (3.2) 47.7 (2.8)
RS-II = Rotterdam Study II; RS-III = Rotterdam Study III; SD = standard deviation; n = sample size. 
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Heritability estimation
In the complete population, the GCTA estimate of genetic influence due to the additive effect 
of common SNPs was 19% (SE 0.09; P-value=0.02). Since gender is one of the major factors 
determining HPT, we subsequently stratified the population according to gender. We oberved the 
heritability estimate in women to be 35% (SE 0.20; P-value 0.04), while it was 9% in men (SE 0.28; 
P-value 0.38). Chronic pain is known to influence HPTs significantly through central sensitization. 
Therefore, we studied the heritability of HPT separately in individuals with and without chronic pain. 
For individuals with chronic pain, the heritability was estimated to be 8% (SE 0.20; P-value=0.35). 
For individuals without chronic pain, this estimate was higher and statistically significant with 32% 
(SE 0.17; P-value=0.03).
GWAS meta-analysis
A total of 30,072,738 markers were tested for the association with HPT in our population of in total 
3,795 individuals. Genomic control inflation factors for the P-values in RS-II and RS-III were low 
(λ=1.01 and 1.001 respectively). The Quantile-Quantile plot indicated no substantial population 
stratification due to cryptic relatedness, population substructure or other biases (Figure 1). The 
results of the GWAS meta-analysis are summarized in a Manhattan Plot of the P-values (Figure 2). 
figure 1. Quantile-quantile plot (Q-Q plot) for the GWAS meta-analysis with HPT. This plot compares 
additive model statistics to those expected under the null distribution using fixed-effects for all analyzed 
1000G imputed SNPs passing the quality control. Analysis adjusted for the presence of chronic pain.
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figure 2. Manhattan plot of the P-values of the GWAS meta-analysis of HPT in RS-II and RS-III. Analysis 
adjusted for the presence of chronic pain. The red line represents the line for genome wide significance 
(P-value=5.0E-08), the blue line represents the line for suggestive signals (P-value=1.0E-06).
We identified one SNP on chromosome 1 to be genome-wide significant (P-value <5.0E-08). This 
SNP represents a deletion located on position 176,688,345 on chromosome 1 (P-value=2.48E-08). 
It is a relatively rare deletion (minor allele frequency=0.02), and it is located in the twelfth intron of 
the PAPPA2 gene. The PAPPA2 gene encodes for a protein which is thought to be a local regulator 
of insulin-like growth factor (IGF) bioavailability. IGF is implicated in nociceptive (pain) sensitivity of 
primary afferent neurons [44]. Additionally, the deletion is located 140kb downstream of the ASTN1
gene. ASTN1 (or astrotactin 1)  is a neuronal adhesion molecule required for migration of young 
postmitotic neuroblasts in cortical regions of developing brain, including cerebrum, hippocampus, 
cerebellum, and olfactory bulb [45].
Next to the genome-wide significant hit, we found six other suggestive signals with a P-value<1.0E-06 
(Table 2). Five of six top SNPs have relative low allele frequencies (MAF<0.05). 
We found one locus to be suggestive in both the analyses: in the original GWAS (adjusting for 
chronic pain), the intronic SNP rs187924640 (MAF=0.015) was a suggestive hit (p=2.56E-07), and 
in the sensitivity analysis (excluding chronic pain cases) this SNP was also close to significance 
(P-value=8.23E-07). The PRKC1 gene encodes for the protein kinase C iota type, which is implicated 
in the regulation of neuronal growth and specification [46-48].
502007-L-bw-Peters
4
207
Genomic analysis integration for age-related musculoskeletal comorbidities
Ta
bl
e 
2.
 G
en
om
e 
W
id
e 
A
ss
oc
ia
tio
n 
A
na
ly
si
s ‘
H
ea
t P
ai
n 
Th
re
sh
ol
d’
 a
dj
us
te
d 
fo
r p
re
se
nc
e 
of
 c
hr
on
ic
 p
ai
n,
 to
ph
its
 s
ig
na
ls
 P
-v
al
ue
<1
.0
E-
06
M
ar
ke
r
Ch
r
Po
s
Co
de
d 
al
le
le
O
th
er
 
al
le
le
A
f
be
ta
St
dE
rr
P-
va
lu
e 
(a
ll 
pa
rt
ic
ip
an
ts
)
P-
va
lu
e 
(n
o 
pa
in
 c
as
es
)
Po
si
tio
n
G
en
e
1:
17
66
88
34
5:
D
1
17
66
88
34
5
D
I
0.
02
-2
.0
9
0.
38
2.
48
E-
08
1.
11
E-
05
in
tr
on
 1
2
PA
PP
A2
rs
13
04
96
46
21
43
65
18
46
T
G
0.
98
1.
52
0.
29
1.
84
E-
07
1.
24
E-
05
in
tr
on
 2
AB
CG
1
rs
18
79
24
64
0
3
16
99
48
81
7
T
G
0.
02
-1
.5
7
0.
31
2.
56
E-
07
8.
23
E-
07
in
tr
on
 1
PR
KC
I
rs
51
27
66
10
97
22
83
38
C
G
0.
10
0.
60
0.
12
5.
41
E-
07
2.
96
E-
04
in
tr
on
 1
SO
RB
S1
rs
74
37
10
79
12
10
84
04
4
A
G
0.
06
-0
.8
1
0.
16
5.
98
E-
07
2.
00
E-
04
in
tr
on
 1
RA
D
52
rs
14
14
93
09
1
1
84
37
57
70
A
C
0.
04
-1
.0
9
0.
22
6.
81
E-
07
7.
60
E-
04
in
tr
on
 1
5
TT
LL
7
rs
72
39
18
4
18
67
12
90
23
T
G
0.
96
0.
91
0.
19
9.
94
E-
07
3.
52
E-
03
in
tr
on
 1
D
O
K6
Ch
r =
 c
hr
om
os
om
e;
 P
os
 =
 p
os
iti
on
; C
od
ed
 a
lle
le
 =
 e
ffe
ct
 a
lle
le
; A
F 
= 
al
le
le
 fr
eq
ue
nc
y 
of
 co
de
d 
al
le
le
; B
et
a 
= 
eff
ec
t s
iz
e 
of
 e
ffe
ct
 a
lle
le
; S
td
Er
r =
 st
an
da
rd
 e
rr
or
 o
f t
he
 e
ffe
ct
. 
502007-L-bw-Peters
208
Chapter 4
Systematic review of genetic variants previously described 
In the HuGe navigator, the search term ‘Pain threshold’ provided a total of 60 publications describing 
44 different genes. After selection for pain threshold phenotypes and SNPs having an rs-id, we 
were left with fifteen publications. In these articles, nine SNPs in six different genes (COMT, DRD3, 
OPRK, OPRM1, SLA6A4 and HTR1A) were previously reported to be significantly associated with pain 
threshold phenotypes. The selected SNPs, the direction of the effect in the previous articles and the 
results in our GWAS study are shown in Table 3. None of the nine SNPs were significantly associated 
with HPT in our GWAS meta-analysis results. 
Table 3. Associations of HPT with the candidate gene SNPs.
Coded 
allele
Other 
allele
Af beta P-value 
(all participants)
Effect direction 
in literature*
References
COMT
rs4680 A G 0.55 -0.09 0.18 -, -, -, -, - [25-27,31,34]
DRD3
rs6280 T C 0.69 0.02 0.77 - [35]
OPRK
rs6473799 A G 0.77 0.09 0.27 - [36]
rs7016778 A T 0.88 0.15 0.17 + [36]
rs7824175 C G 0.92 -0.01 0.94 - [36]
rs9479757 A G 0.10 -0.05 0.69 + [30]
OPRM1
rs1799971 A G 0.89 0.02 0.82 +,+ [24,28]
SLC6A4
rs25531 T C 0.93 0.025 0.89 +, + [29,33]
HTR1A
rs6295 C G 0.50 0.04 0.63 + [32]
* A negative direction (-) means a higher sensitivity for QST coinciding with a lower HPT; A positive direction (+) means a lower 
sensitivity for QST coinciding with a higher HPT. Coded allele = effect allele; AF = allele frequency of coded allele; Beta = effect size of 
effect allele. 
DISCUSSION
In this population based study, we aimed to identify the genetic background of an experimental 
measure of pain sensitivity, the heat pain threshold (HPT). We observed an overall heritability 
estimate of 19% which was dependent on gender and the presence of chronic pain. We performed a 
genome wide association study (GWAS) to search for potential new loci and found seven interesting 
new loci. In a candidate SNP approach, we were not able to replicate the earlier associated SNPs with 
the HPT in our study.
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Although not yet fully elucidated, a significant proportion of the variability of HPT is explained by 
genetics. The method we used to measure heritability is different from twin and pedigree analysis. 
Our method uses only common DNA variants in linkage with the genotyped SNPs (on the Illumina 
SNP arrays) to estimate heritability, while family-based studies use all genetic variants, including 
rare variants [40,49]. Since there are less SNPs included in our analysis, the heritability of the trait will 
be underestimated. The GCTA method has been applied to other complex traits like height, and in 
this study a heritability of 55% for height was observed [50]. This is much lower than the heritability 
estimates based on twin studies, in which 89-93% of the height variance can be explained by 
genetics [51]. Therefore, we expect the heritability estimate of the HPT to be higher than the 19% 
we identified. 
The advantage of GCTA is that this method is able to estimate the heritability in a large sample of 
unrelated individuals, which makes it more generalizable to a general population [52]. 
Interestingly, we found an evident difference in the heritability estimate of HPT between genders 
and between individuals with and without chronic pain. In women and in individuals without 
chronic pain, the phenotypic variance is explained genetically for one third. In men and in individuals 
with chronic pain, the heritability estimate was not significant. In our study sample, almost 20% 
of all men reached the maximum threshold of 50 degrees Celsius for the HPT. As a consequence, 
part of the variability of the HPT-measurement is lost, which results in lower power to measure 
heritability in this part of the population. Another explanation could be that the HPT in men is 
influenced by other, not yet identified, factors. Our results also showed that heritability of HPT is 
much higher in individuals without chronic pain compared to those that have pain. It is known that 
experimental pain sensitivity (like HPT) is influenced by the presence of chronic pain, caused by 
central sensitization of the nervous system [1]. We hypothesize that the presence of chronic pain 
overrides the subtle genetic effects observed in the general population. This may be one of the 
reasons why former studies were not able to find consistently influencing genes for pain sensitivity 
phenotypes. Therefore, the presence of chronic pain should be taken into account when performing 
genetic analysis on HPT and potentially for other pain sensitivity thresholds in future studies.
To the best of our knowledge, we here present results from the largest genetic study on experimental 
pain performed up to date. In the GWAS for the HPT adjusted for chronic pain, there was one deletion 
(1:176688345:D) on chromosome 1 which reached genome wide significance (p=2.48E-08). This 
deletion is located in the twelfth intron of the PAPPA2 gene, of which the encoded protein is thought 
to be a local regulator of insulin-like growth factor (IGF) bioavailability. IGF is implicated to play a 
role in the nociceptive (pain) sensitivity of primary afferent neurons. Neurotrophy, neurogenesis and 
metabolic functions are shown to be influenced by IGF in the adult brain [53]. In vitro, upregulation 
of IGF showed a higher sensitivity of primary afferent neurons [54,55]. Additionally, the deletion 
is located 140kb downstream of the ASTN1 gene. ASTN1 (or astrotactin 1)  is a neuronal adhesion 
molecule required for migration of young postmitotic neuroblasts in cortical regions of developing 
brain, including cerebrum, hippocampus, cerebellum, and olfactory bulb [45]. Trafficking of the 
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ASTN1 protein is regulated by the ASTN2 gene [56]. Interestingly, an SNP within ASTN2 (rs4836732) 
was found to be associated with the pain-related phenotype total hip replacement in women 
(p=6.11E-11) [57].
One suggestive hit, located within the PRKCI gene, was associated with HPT in both the overall 
analysis (including all participants) and the sensitivity analysis (without chronic pain cases). The 
PRKCI gene encodes the protein kinase C iota gene, which has been found to regulate neuronal 
growth in the hippocampus in embryonic rats, specification of neurons during development in 
cerebellar purkinje cells in zebrafish and inhibiton of spinal cord precursors, also in zebrafish [46-48]. 
These functional associations indicate that the PRKCI gene might in fact be influencing neuronal 
functioning.
Although very interesting, our GWAS findings need to be replicated in an independent cohort, 
before definite conclusions can be drawn. Since the power to detect SNPs associated with our 
phenotype was relatively low (n=3,795), there might be some false positive hits. Additionally, there 
might be interesting signals among the suggestive SNPs and replication should demonstrate the 
true signals. After replication of our findings, functional testing of candidate genes would help to 
give more insight into the biology of HPT.
In the study of candidate genes previously reported to be associated with pain sensitivity 
measurements, we showed that none of the SNPs was significantly associated with HPT in our GWAS 
meta-analysis, although our sample size was at least 10 times larger. This can be explained by the 
fact that many of the previous reported loci were investigated in small populations of pain patients. 
This could indicate that the associations found are more associated to the pain syndrome than the 
pain sensitivity itself. The lack of reproducibility of SNPs in candidate genes in large GWAS meta-
analyses has been shown before for other phenotypes such as BMD [58].
In conclusion, our study reports a heritability estimate for HPT of 19%. We identified significant 
influences of gender and chronic pain on the heritability estimates of HPT. Therefore, future 
genetic studies on pain sensitivity should be adjusted for gender and the presence of chronic 
pain, or individuals with chronic pain should be excluded from the analysis. This will result in a 
more homogenous pain phenotype and this will increase the chances of finding new genetic loci 
involved. The exact genes influencing HPT remain not fully elucidated, but this study provides new 
potential genes for further research.
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AbSTRACT
Objective: To identify molecular biomarkers for early knee osteoarthritis (OA), we examined whether 
joint effusion in the knee associated with different gene expression levels in the circulation.
Materials and Methods: Joint effusion grades measured with magnetic resonance (MR) imaging and 
gene expression levels in blood were determined in women of the Rotterdam Study (N=135) and 
GARP (N=98). Associations were examined using linear regression analyses, adjusted for age, fasting 
status, RNA quality, technical batch effects, blood cell counts, and BMI. To investigate enriched 
pathways and protein-protein interactions, we used the DAVID and STRING webtools. 
Results: In a meta-analysis, we identified 257 probes mapping to 189 unique genes in blood that 
were nominally significantly associated with joint effusion grades in the knee. Several compelling 
genes were identified such as C1orf38 and NFATC1. Significantly enriched biological pathways were: 
response to stress, gene expression, negative regulation of intracellular signal transduction, and 
antigen processing and presentation of exogenous pathways. 
Conclusion: Meta-analyses and subsequent enriched biological pathways resulted in interesting 
candidate genes associated with joint effusion that require further characterization. Associations 
were not transcriptome-wide significant most likely due to limited power. Additional studies are 
required to replicate our findings in more samples, which will greatly help to understanding the 
pathophysiology of OA and its relation with inflammation, and may result in biomarkers urgently 
needed to diagnose OA at an early stage.
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INTRODUCTION
Osteoarthritis (OA) is a common, age-related, degenerative disease of the synovial joints. It is 
characterized by cartilage degradation, osteophyte formation, subchondral bone changes, and 
synovitis [1]. These characteristics can lead to joint space narrowing, pain, and loss of function, 
until at the end-stage of the disease total joint replacement is required. OA is a leading cause of 
morbidity and disability and carries high socioeconomic costs. With increasing obesity and age in 
the population, a massive rise in morbidity and costs attributed to OA is expected. To be able to 
change from symptomatic treatment at late disease state and total joint replacement towards early 
(secondary) prevention, it is very important to identify new osteoarthritic disease stage markers 
that could be measured in the early stages of OA. These markers should function as new targets or 
biomarkers for early disease treatment and prevention. 
Radiography is routinely used to support in the diagnosis of OA. However, radiographic imaging is 
inadequate to detect and monitor biochemical changes within joint tissues which can occur long 
before symptoms are present. Magnetic resonance (MR) imaging is a non-invasive 3D imaging 
method with high tissue contrast that has been successfully used to visualize osteoarthritic changes 
[2]. Additionally to radiographic osteophyte formation and joint space loss, joint effusion can be 
assessed. Joint effusion is the presence of increased intra-articular fluid [3], which has been positively 
associated with knee pain in knee OA patients [4]. Joint effusion is known to be related with joint 
inflammation [5] and a recent study showed that occurrence of joint effusion is a strong predictor for 
development of incident radiographic OA [6].
As inflammation is increasingly considered to be an important pathway in the OA pathophysiology, 
efforts have been made to identify pro- and anti-inflammatory mediators (such as cytokines) which 
enable monitoring of the OA disease course [7-9]. With the aim to better understand the downstream 
consequences of inflammation in the knee, we compared gene expression levels in the blood of 
participants with different grades of joint effusion, as assessed by MR imaging. Ramos et al. already 
identified specific gene expression networks in blood associated with OA status [10]. Therefore, it 
could be advocated that blood expression profiles may reflect predisposition to OA. And because 
blood is a readily accessible tissue, gene expression levels associated with joint effusion may serve 
as molecular biomarkers for early detection of OA. We examined in two cohort studies whether joint 
effusion grades on MR imaging of the knee were associated with specific gene expression levels in 
the peripheral circulation, and subsequently performed a meta-analysis. Analysis for enrichment 
was performed to determine whether particular pathways were overrepresented among the genes 
associated with joint effusion.
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MATERIALS AND METHODS
Subject selection
The Rotterdam Study (RS) is a large prospective, population-based cohort study in the district of 
Rotterdam, the Netherlands, investigating the prevalence, incidence, and risk factors of various 
chronic disabling diseases among elderly Caucasians aged 45 years and over. A detailed description 
of the design and rationale of the Rotterdam Study has been published elsewhere [11]. We invited the 
first 1,116 women aged 45-60 years visiting the research center to join a sub-study investigating early 
signs of knee osteoarthritis (knee OA). Participants were evaluated for the self-reported presence of 
rheumatoid arthritis (RA) and these cases were excluded. An additional exclusion criterion was the 
presence of any contra-indications for MR imaging, including weighing more than 150 kilograms. 
In total, 891 participants were included. For this study, we selected participants having both gene 
expression data and good quality knee MR imaging data available. In total, we could include 135 
participants. The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the 
“Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. All participants provided 
written informed consent to participate in the study and to obtain information from their treating 
physicians. 
The Genetics, Arthrosis and Progression study (GARP) consists of 191 sibling pairs (n=382) of white, 
Dutch ancestry. All participants (age range 40-78 years; mean age 60 years) are clinically and 
radiographically diagnosed with primary, symptomatic OA at multiple joint sites in the hand, or in at 
least two joints of the following locations: hand, spine (cervical or lumbar), knee, or hip [12]. Patients 
with secondary OA, such as inflammatory joint disease, major developmental diseases, bone 
dysplasia, major local factors or metabolic diseases as hemochromatosis were excluded. Sib pairs 
(n=105) with at least one subject with symptomatic hip or knee OA (but not in a radiographic end-
stage) were eligible for the MR imaging sub-study [13]; in 5 out of 210 patients no MR imaging (one 
due to claustrophobia, one with a large knee that did not fit into the knee coil) or an MR imaging of 
insufficient quality (due to motion artefacts in three patients) was available. For this study, a subset 
of 98 women (including 28 sibs) was selected for which both gene expression data and knee MR 
imaging data were available. The GARP study has been approved by the Medical Ethics Committee 
of the Leiden University Medical Center, the Netherlands. All participants provided written informed 
consent to participate in the study.
Knee OA definition
In both RS and GARP, radiographs were scored to examine knee OA. Knee OA was defined as at 
least one definite osteophyte and definite joint space narrowing or at least two definite osteophytes 
(Kellgren and Lawrence (K/L) score ≥2). 
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MR acquisition
In the RS, all participants were scanned on a 1.5 T MRI scanner (General Electric Healthcare, 
Milwaukee, Wisconsin, USA) with an 8-channel cardiac coil, so that two knees could be scanned 
at once without repositioning the subject. The protocol consisted of a sagittal fast spin echo (FSE) 
proton density and T2 weighted sequence (repetition time (TR)=4,900 ms; echo time (TE)=11/90 
ms, flip angle of 90-180, slice thickness 3.2 mm, field of view 15 cm2), a sagittal FSE T2 weighted 
sequence with frequency selective fat suppression (TR/TE=6800/80 ms, flip angle=90-180, slice 
thickness=3.2 mm, field of view=15 cm2), a sagittal spoiled gradient echo sequence with fat 
suppression (TR/TE=20.9/2.3 ms, flip angle=35, slice thickness=3.2 (1.6) mm, field of view=15 cm2) 
and a fast-imaging employing steady-state acquisition (FIESTA) sequence (TR/TE=5.7/1.7 ms, flip 
angle=35, slice thickness=1.6 mm, field of view=15 cm2). This FIESTA sequence was acquired in the 
sagittal plane. Total scanning time was 27 minutes for two knees per patient. 
Acquisition of MR imaging in GARP was performed using a 1.5 – T MR imaging scanner (Philips 
Medical Systems, Best, The Netherlands) using a 4-channel transmit/receive knee coil as described 
elsewhere [13]. The following images were obtained: coronal proton density- and T2-weighted dual 
spin echo (SE) images (with TR=2,200 ms; TE=20/80 ms; 5 mm slice thickness; 0.5 mm intersection 
gap; 16 cm field of view; 206 x 256 acquisition matrix); sagittal proton density- and T2-weighted dual 
SE images (TR=2,200 ms; TE=20/80 ms; 4 mm slice thickness; 0.4 mm intersection gap; 16 cm field 
of view; 205 x 256 acquisition matrix); sagittal three-dimensional (3D) T1-weighted spoiled gradient 
echo (GE) frequency selective fat-suppressed images (TR=46 ms; TE=2,5 ms; flip angle 40°; 3.0 mm 
slice thickness; slice overlap 1.5 mm; no gap; 18 cm field of view; 205 x 256 acquisition matrix); and 
axial proton density- and T2-weighted turbo spin echo (TSE) fat-suppressed images (TR=2,500 ms; 
TE=7.1/40 ms; echo train length 6,2 mm slice thickness; no gap; 18 cm field of view; 205 x 256 
acquisition matrix). Total acquisition time (including the initial survey sequence) was 30 min for 
one knee per patient. Since the original purpose of the MR imaging study in GARP was to assess 
progression of OA, only one knee was imaged and no images were obtained of a knee that already 
had a maximum K/L score of 4 [2]. 
Semi-quantitative joint effusion scoring
In RS, a trained reader (who was blinded for any clinical, radiographic and genetic data) scored all 
MR images of the knees with the semi-quantitative Knee Osteoarthritis Scoring System (KOSS), 
described in detail elsewhere [2]. The joint effusion grades in the tibiofemoral joint (TFJ) and the 
patellofemoral joint (PFJ) were scored together (grade 0-3): 0=joint effusion absent, 1=small joint 
effusion, 2=moderate joint effusion, and 3=massive joint effusion. The scores of the left and the 
right knee were summed, resulting in one grade per person ranging from 0 to 6. An experienced 
musculoskeletal radiologist, also blinded for any clinical, radiographic and genetic data, scored 
a random sample of MR images to determine the inter-observer reliability. The inter-observer 
reliability was moderate to good with an intra-class correlation coefficient (ICC) of 0.83. 
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In GARP, MR images were also scored according to KOSS [2] by three readers with 3, 15, and 25 years of 
experience in consensus, blinded to clinical, radiographic and genetic data, as described previously 
[13]. Presence of joint effusion was evaluated on T2-weigthed coronal, sagittal and axial sequences. 
A small, physiological sliver of synovial fluid was not recorded. A small effusion (grade 1) was present 
when a small amount of fluid distended one or two of the joint recesses, moderate effusion (grade 
2) when more than two recesses were partially distended, and massive (grade 3) when there was 
full distension of all the joint recesses. As in RS, the grades were scored semi-quantitatively ranging 
from 0 to 3.
Because we used non-contrast-enhanced MR imaging in both GARP and RS, we could not measure 
synovial thickness reliably. 
Gene expression levels 
In RS, whole-blood was collected (PAXGene Tubes – Becton Dickinson) and total RNA was isolated 
(PAXGene Blood RNA kits - Qiagen). To ensure a constant high quality of the RNA preparations, all RNA 
samples were analyzed using the Labchip GX (Calliper) according to the manufacturer’s instructions. 
Samples with an RNA Quality Score >7 were amplified and labelled (Ambion TotalPrep RNA), and 
hybridized to the Illumina HumanHT12v4 Expression Beadchips. Processing of the Rotterdam Study 
RNA samples was performed at the Genetic Laboratory of Internal Medicine, Erasmus University 
Medical Center Rotterdam, and the dataset has been deposited in the GEO database under the 
accession number GSE33828 [14].
For GARP, generation of gene expression levels in peripheral blood mononuclear cells (PBMCs) has 
been described elsewhere [10]. Gene expression data has been deposited in the GEO database 
under the accession number GSE48556. 
Both RS and GARP samples were scanned on the Illumina iScan System (combined with an 
AutoLoader) using Illumina iScan image data acquisition software. Illumina GenomeStudio software 
(version 1.9.0) was used to generate output files for statistical analysis using R [15]. To identify 
transcripts that had detectable quantitative expression, we used the detection P-values reported 
by Illumina’s GenomeStudio software. The detection P-value represents the confidence that a given 
transcript is expressed above the background defined by negative control probes. We called a 
transcript significantly expressed when the detection P-value was <0.05 in more than 50 percent 
of all samples. All other transcripts were excluded from analysis. Because of this stringent detection 
P-value cut-off, the overall false-positive rate is very small (we won’t get false positive genes), 
whereas the false-negative rate might be higher (so we could lose some joint effusion associated 
genes, i.e., genes that are expressed at high joint effusion grades specifically). 
Statistical- and functional analysis
Raw gene expression intensities were normalized by quantile-normalization to the median 
distribution; gene expression levels were subsequently log2-transformed. To minimize the influence 
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of the overall signal levels, which may reflect RNA quantity and quality rather than a true biological 
difference between individuals, the probe means and sample means were centered to zero, and 
sample variance was linearly scaled, such that each sample had a standard deviation of one 
(standardization). To identify transcripts that were differentially expressed with joint effusion grades, 
we used four different linear regression models (lm): 
 – Model 0: unadjusted: lm (probe ~ joint effusion grade) 
 – Model 1: adjusted for age + fasting status + RNA quality score (RQS) + batch + cell counts
 – Model 2: adjusted for Model 1 + body mass index (BMI)
 – Model 3: adjusted for Model 1 + BMI + nonsteroidal anti-inflammatory drug (NSAID) intake
BMI was measured at the research centers (as weight in kg divided by height2 in meters), and NSAID 
intake was extracted from the pharmacy records (RS) or collected via questionnaires (GARP). Because 
it is known that BMI is associated with markers of inflammation [16,17], and because additional 
adjustments for NSAID use (model 3) hardly changed the effect sizes and standard errors of the 
results as shown in the Supplementary Tables (S1-S2), we used model 2 for the meta-analysis and 
follow-up analyses. Notably, the analysis in GARP was also adjusted for sib ship in addition to age, 
batch, and BMI. In GARP, no adjustments were included for fasting status since blood was collected 
for all participants without fasting. Furthermore, gene expression levels were assessed from PBMCs 
and the RNA integrity number (or RQS) was at least 8.3 (36 random samples were analyzed) [10].
To be able to meta-analyze the results of both studies, we combined the 12,843 Illumina HT12v4 
probes (RS) and the 12,246 Illumina HT12v3 probes (GARP) based on chromosomal position and 
nucleotide sequence: 9,507 probes (representing 7,408 unique genes) were similar between the two 
gene expression platforms and could be meta-analyzed. 
We ran sample size weighted meta-analyses based on P-values and the direction of the effects. By 
using the P-values and the effect direction, a Z-statistic characterizing the evidence for association 
was calculated. The Z-statistic summarized the magnitude and the direction of the effect. An overall 
Z-statistic and P-value was calculated from the weighted sum of the individual statistics. Weights 
were proportional to the square-root of the number of individuals examined in each sample and 
standardized such that the squared weights sum to 1. We used the Meta-Analysis Tool for genome-
wide association scans (METAL) [18] for this. METAL has been developed for meta-analyzing genetic 
genome-wide association studies. Because we are dealing with gene expression levels and not SNPs, 
we changed the SNPID column to probe IDs and assigned all probes a minor allele A and a major 
allele G, a minor allele frequency=0.10, and a + strand. For the positions, the probe chromosomes 
and the midpoint position of the probes were used. Sample sizes, effect directions, and P-values were 
extracted from the linear regression model results files. Probes with a meta-analysis P-value<6.75E-06 
(0.05 / 7,408 genes tested) were considered transcriptome-wide significantly associated with the 
joint effusion grades in the knee. 
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Pathway analyses
Pathway analysis was done with the DAVID tool; the Database for annotation, visualization and 
integrated discovery [19]. We included all nominal significant genes (meta-analysis P-value<0.05), 
and checked for enrichment of any biological processes identified in the gene ontology database. 
Analysis of protein interaction networks
To investigate protein interactions among the nominal significant genes, we used the Search Tool 
for the Retrieval of Interacting Genes/Proteins [20], which is available online. With the “enrichment” 
option, we checked for enrichment of protein-protein interactions and “GO biological processes”. 
RESULTS
Subjects
The complete characteristics of the included subjects of both RS and GARP are shown in Table 1 and 
Figure 1. In both RS and GARP, mean age of the subjects with and without joint effusion was not 
significantly different (ANOVA P-value RS=0.146, ANOVA P-value GARP=0.181). Mean BMI seemed 
to be higher with higher joint effusion grades, but due to small sample sizes this difference was not 
significant (ANOVA P-value RS=0.069, ANOVA P-value GARP=0.487). 
Table 1. Subject characteristics of RS and GARP. *this can be in one or two knees.
RS GARP
Grade # Mean Age 
(±SD)
Mean bMI 
(±SD)
# knee OA* # Mean Age 
(±SD)
Mean bMI 
(±SD)
# knee OA*
Grade 0 65 54.0 (3.4) 26.6 (4.6) 3 47 60.7 (6.9) 26.5 (3.8) 21
Grade 1 30 55.1 (3.9) 28.0 (5.3) 1 46 58.9 (6.6) 25.8 (3.9) 30
Grade 2 30 54.8 (3.8) 26.9 (4.4) 1 5 58.3 (8.9) 27.2 (7.3) 4
Grade 3 6 56.2 (2.1) 29.8 (4.9) 1 0 - - -
Grade 4 4 52.0 (4.2) 36.8 (10.1) 1 0 - - -
Grade 5 0 - - 0 - - -
Grade 6 0 - - 0 - - -
Total 135 54.5 (3.6) 27.4 (5.2) 7 98 59.7 (6.8) 26.1 (4.0) 55
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figure 1. Joint effusion grades in subjects without knee OA (A) and samples with knee OA (b).
Results within the Rotterdam Study
Of the 7,408 genes tested, CLEC4A (C-type lectin domain family 4, member A) demonstrated 
the strongest association with joint effusion grades in the knee (effect size=0.407 (SE=0.120); 
P-value=9.57E-04). In total, 310 probes (representing 251 unique genes) were nominally significant. 
The top 50 results are shown in Supplementary Table 1. 
Results within GARP
In GARP, the lowest P-value was found for the DNA-damage-inducible transcript 4 (DDIT4) gene 
(effect size=-1.425 (SE=0.411); P-value=5.21E-04). In total, 439 probes (representing 331 unique 
genes) were nominally significant (Supplementary Table 2). 
Meta-analysis of the Rotterdam Study and GARP
In general, the top five genes of GARP and RS were different. To identify a common transcriptional 
signature for joint effusion, we performed a meta-analysis across RS and GARP. The top 20 results are 
shown in Table 2. All 257 nominally significant probes (representing 189 unique genes) are shown in 
Supplementary Table 3. The lowest P-value was found for the C1orf38 (Chromosome 1 Open Reading 
Frame 38) gene, also called THEMIS2 (Thymocyte Selection Associated Family Member 2) or ICB-1
(Induced by Contact to Basement membrane) (Z-score=-3.356; P-value=7.90E-04). Gene expression 
levels of C1orf38 were lower in samples with higher joint effusion grades in both whole blood and 
PBMCs (Supplementary Figure S1). Also the DYNLL2 gene (Dynein, Light Chain, LC8-Type 2), the 
NFATC1 gene (Nuclear factor of activated T-cells, cytoplasmic 1), and the RBM4 gene (RNA Binding 
Motif Protein 4) were nominally associated, with respectively higher (DYNLL2 and NFATC1) and lower 
(RBM4) gene expression levels correlating with advanced joint effusion grades (Supplementary 
Figure S2-4). 
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figure 2. Protein-protein interactions determined with STRING showing interactions between the 
178 nominally associated genes (P-value<0.05), marking proteins involved in antigen processing and 
presentation of exogenous antigens in red (GO:0019884). Disconnected proteins are hidden. 
Pathway-analysis of genes nominally significant in the meta-analysis
Using the 257 nominally associated probes (P-value<0.05), 178 genes were recognized by the webtool 
DAVID. The most significant GO terms identified were: intracellular protein transport (GO:0006886: 
13 of 374 genes, P-value=4.5E-04, Fold Enrichment (FE)=3.4), response to stress (GO:0006950: 34 of 
1685 genes, P-value=1.5E-04, FE=2.0), antigen processing and presentation of exogenous antigens 
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(GO:0019884: 4 of 14 genes, P-value=3.5E-04, FE=27.8), but the three GO terms did not survive the 
Benjamini Hochberg multiple testing correction. Additionally, one KEGG pathway was nominally 
significantly enriched: antigen processing and presentation (hsa04612: 5 of 83 genes, P-value=0.0127, 
FE=5.4). 
Using the webtool STRING, we did not find significantly enriched protein-protein interactions within 
the network of 178 genes (P-value=0.386, observed interactions=58, expected interactions=55). 
However, STRING confirmed two significantly enriched biological pathways identified with DAVID: 
response to stress (45 of 1685 genes, P-value=6.23E-03) and antigen processing and presentation of 
exogenous antigens (10 of 14 genes, P-value=3.44E-02). The protein-protein interactions are visualized 
in Figure 2. Proteins involved in the antigen processing and presentation of exogenous antigens 
pathway (GO:0019884) are marked red, highlighting a cluster of three proteasomes (PSMA3, PSMD6, 
and PSME1) important for the antigen processing pathway.
DISCUSSION
We examined whether joint effusion grades in the knee were associated with specific gene 
expression levels in the circulation, which could potentially serve as molecular biomarker to indicate 
OA in the early stage. We identified 257 nominally associated probes (P-value<0.05) mapping to 
189 unique genes. C1orf38, DYNLL2, and RBM4 were among the 5 most significant genes in the 
meta-analysis. Additional adjustments for BMI and NSAID intake did not notably affect the results, 
suggesting that the associations are consistent across all BMI ranges and in both users and non-
users of NSAIDs. Subsequent pathway analyses with DAVID revealed nominal significant enrichment 
of genes involved in response to stress, gene expression, negative regulation of intracellular signal 
transduction, and antigen processing and presentation of exogenous antigens pathways. The 
biological pathways response to stress and antigen processing and presentation of exogenous 
antigens were confirmed with a second pathway analysis tool STRING. 
C1orf38 is a protein-coding gene and is highly expressed in several blood cells (monocytes, dendritic 
cells, NK-cells, T-cells, B-cells). The gene is induced by interferon-gamma (IFN-γ), an important 
cytokine that orchestrates many distinct cellular processes regarding inflammation [21]. Therefore, 
C1orf38 could be an interesting candidate for further research.
Cytoplasmic dynein consists of a molecular complex of several proteins including DYNLL2, and it is 
thought to play a role in movement and positioning of a wide range of organelles and complexes 
in the cell [22]. Notably, recent studies showed that DYNLL2 inhibits inflammation and may also 
inhibit osteoclastogenesis and bone resorption via regulation of NFκB transcription activity [23]. This 
would suggest that the higher expression of DYNLL2 in association with higher joint effusion grades 
is rather consequence than cause, however, this remains to be established. 
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RBM4 is thought to play a role in alternative splice site selection during pre-mRNA processing, and 
seems to be important for the regulation of the translation of pro-inflammatory genes [24].
Of note is the association of higher joint effusion grades with higher expression levels of NFATC1 
(nuclear factor of activated T cells 1). Besides its function in bone remodeling through calcium/
calcineurin signaling, NFATC1 belongs to a family of transcription factors that play a central role in 
inducible gene transcription during immune response [25]. Although no significant differences were 
found in NFATC1 gene expression between OA-affected and unaffected tissues using microarray 
analyses [26-29], a slight but significant reduction was detected by RT-qPCR in OA affected cartilage 
[30]. In addition, Jeffries and colleagues [31] found changes in DNA methylation profiles, and it was 
shown that cartilage-specific ablation of NFATC1 predisposes to development of early onset OA too 
[30]. Since the expression of NFATC1 is positively associated with joint effusion it could be speculated 
that, in line with the increased expression of DYNLL2, upon occurrence of joint effusion specific 
pathways are activated to protect against development of OA. Consistent with this hypothesis, 
we observed that increased expression of NFATC1 in association with joint effusion is much more 
pronounced in subjects without knee OA in GARP. Therefore, NFATC1 might be a useful biomarker 
for early detection of OA. However, this should be confirmed in a longitudinal study tracking the 
development of the disease.
The pathway enrichment analysis results were consistent with known inflammatory disease 
mechanisms including response to stress and gene expression. Cellular stress and inflammation 
are known to reciprocally activate or inhibit each other, depending on the immune cell type and 
the stress-inducing signals [32]. Additionally, we identified the pathways negative regulation of 
intracellular signal transduction (GO:1902532) and antigen processing and presentation of exogenous 
antigens (GO:0019884). Hanada et al. [33] already highlighted a key role for the intracellular signal 
transduction pathways of the pro- and anti-inflammatory cytokines which activate inflammatory 
transcription factors such as NF-κB, Smad, and STATs. The antigen processing machinery can be easily 
linked to the inflammatory response too [34].
STRING showed the interaction between 3 proteasomes identified in the analysis (PSMA3, PSMD6, 
and PSME1). Proteasomes are important for degrading intracellular proteins, and recently it has 
been shown that mutations and polymorphisms in the proteasome are associated with several 
inflammatory and auto-inflammatory diseases [35]. Therefore, these genes could also be interesting 
targets for future studies.
Despite the identification of several compelling potential markers for early OA, major drawback of 
the current study was the relatively small sample size (n=233). Although gene expression data and 
knee MR images are available in larger datasets, the number of samples in which both measurements 
were determined is unfortunately limited. In addition, the data of the two cohorts (RS and GARP) was 
rather heterogeneous in particular due to the fact that in RS joint effusion grades were combined for 
two knees (sum of left and right knee), while in GARP joint effusion was determined in one randomly 
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selected knee. Moreover, GARP is a cohort of clinical OA cases while RS is a population-based cohort 
study, in which no selection was made for OA cases specifically: in RS only seven out of 135 subjects 
(5.2%) were diagnosed with radiographically evident knee osteoarthritis, while in GARP 55 out of 
98 subjects (56.1%) had knee OA. Furthermore, in RS the analyses were adjusted for fasting status 
(134 of 135 subjects fasted overnight) and RNA quality scores, while in GARP non-fasting subjects 
were used and RNA quality scores were available in a small subset only. Finally, gene expression 
levels in RS were determined in whole blood, while in GARP PBMCs were used. Although a previous 
study showed that expression levels differ across different RNA sources (whole blood, PBMCs, and 
lymphoblastoid cell lines), phenotype-based differential expression analyses results were consistent 
in whole blood and PBMCs [36]. Taken together, it is likely that cohort heterogeneity has resulted in 
limited power due to which no transcriptome-wide significant probes were identified. Earlier studies 
confirmed the good quality and reproducibility of our gene expression arrays [10,27,37]. Another 
potential limitation of our study is that we did not assess recent traumatic knee injuries: traumas can 
increase joint effusion and dilute our associations.
In conclusion, joint effusion grades in the knee on MR imaging were nominally associated with the 
expression levels of 189 unique genes in blood and the identified genes were mainly involved in 
inflammation. Although the associations presented in this manuscript were not transcriptome-wide 
significant, the meta-analysis and subsequent enriched biological pathways resulted in compelling 
candidate genes such as C1orf38 and NFATC1 that could be further characterized in future research. 
Additional studies are needed to replicate our findings as well as to identify other genes which will 
greatly help in understanding the pathophysiology of OA and its relation with inflammation, and 
may result in biomarkers urgently needed to diagnose OA at an early stage.
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The overall objective of this thesis was to discover novel genomic factors involved in ageing and 
age-related diseases by integrating different genomic approaches. We assessed the effects of 
genetic variants, gene expression levels, and DNA methylation levels on age-related phenotypes, 
and additionally we combined the different levels of -omics data (genomics, epigenomics, and 
transcriptomics). In this chapter, the challenges of population-based genomic studies are placed in 
a broader context. Furthermore, suggestions for future research are given. 
POPULATION bASED STUDIES
When searching for novel genomic factors, there are a number of advantages of using large scale 
population based cohort studies. The size of the studies is very important: when studying genetics 
and genomics, large studies are required to identify the subtle individual effects of each of the 
genetic variants. A large population-based study is a good representation of the individuals living in 
a certain area, and both healthy and diseased subjects are included. In the Rotterdam Study, not only 
the number of subjects is large, but also the number of traits (phenotypes) studied in these samples. 
This makes it possible to study ageing in a broader context, adjust for many confounders, and study 
interactions between different phenotypes. Another advantage of population-based cohort studies 
is the longitudinal design: the period of follow-up gives the opportunity to not only study disease 
states in a cross-sectional fashion, but also answer research questions on incidence and progression 
of disease, and importantly, longitudinal data can be used to study causality. A longitudinal design 
also allows to introduce novel measurements in an already running cohort study with all available 
(historic) measurements.
The main disadvantage of large population based cohort studies is the fact that the study is not 
specifically designed for one’s phenotype of interest. This is specifically a problem if the phenotype 
has a low prevalence. Examples of low prevalence diseases are Behcet’s disease, Crohn’s disease, 
Cystic Fibrosis, and Prader-Willi syndrome. Because of the low prevalence, only a handful of cases will 
be identified in the Rotterdam Study. With such low numbers of cases, one cannot properly study 
the genetics and genomics of a disease. 
Another disadvantage of large population based studies is that, because of the large sample size, 
some measurements (e.g., RNA sequencing) remain too expensive to be applied to the complete 
study population and so subsets have to be selected. Therefore, selection bias can be a problem, 
and the power for analyses is reduced, or the measurements are done with a less expensive (and less 
accurate) method. In summary, robust, fast and easy-to-integrate measurements are most beneficial 
in large population-based studies. 
Many recently started studies make use of electronic health records (ehealth records) of the general 
practitioners and hospitals in a certain area. Additionally, dental records, pharmacy dispensing 
records, education and environmental records, and social services records can be included. In 
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comparison with population-based studies, these studies do not have to invest in research centers 
and repeated measurements. However, these studies will not gain information about the health 
status of subjects not visiting the general practitioner and/or hospital. Therefore, population-based 
cohort studies are still very important. 
In the United Kingdom, they started a national health resource, called the UK Biobank, which is 
partly funded by the Scottish and Welsh government. They recruited 500,000 people aged between 
40 and 69 years in 2006-2010 from across the country to participate, with the aim to improve the 
prevention, diagnosis, and treatment of a wide range of serious and life-threatening illnesses. In 
addition to baseline measurements, participants complete detailed web-based questionnaires 
and confirm integrating their ehealth records [1]. Combining health measurements and ehealth 
records on a nation-wide level will be very valuable to better understanding of the pathogenesis 
of diseases. There are many more world-wide initiatives like the UK Biobank, for example, Genomics 
England, the Million Veteran Progam (USA), the Regeneron 100k-patient genomics study, and 
23andme. 23andme is designed a bit different, because the participants pay to join this study: 
the company sells personal ancestry information based on your genetic variants [1], and uses the 
genetic information in combination with additional questionnaires for further research. Most data 
of these large initiatives is accessible: all researchers can apply to use the resources for health related 
research that is of public interest. 
COMbINING DIffERENT MEASUREMENT PLATfORMS 
A main driving force in genomics has been the development of novel technology, which allows new 
discoveries. This also introduces challenges when combining data. Examples are the introduction 
of next generation sequencing technology around 2010, just after microarray technology became 
main stream in genomics. When combining data of multiple large population-based studies in a 
meta-analysis approach, similar genomic data (e.g., gene expression levels) can be measured with 
different platforms. For example, genome-wide gene expression levels can be measured with RNA 
sequencing or gene expression microarrays, and microarrays are available from several different 
companies, such as Illumina (San Diego, CA, USA), Affymetrix (Santa Clara, CA, USA), and Agilent 
Technologies (Santa Clara, CA, USA). 
Combining different microarray platforms
The different microarray platforms use different probes and cover different genes. For example, the 
Affymetrix gene expression levels are based on multiple probes per gene, while the Illumina genes 
are covered by one or two probes at the 3’ end of the transcript. Additionally, both array platforms 
use different annotation files. We decided to combine the different platforms using gene-based 
levels for both platforms (using average gene expression levels per gene). For non-matching genes, 
we examined the physical location of the probes (on the array) and intersected these to gain more 
overlapping genes. 
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Combining microarray data and RNA-seq
Additionally, different measurement techniques have different resolutions and quality. For example, 
RNA-seq measures read counts for each gene expressed, while microarrays use pre-designed 
complement sequence detection probes catching the relative amount of expressed genes, which 
give a level of hybridization signal. By analyzing microarray data, cross-hybridization, non-specific 
hybridization, and the limited detection range are important technical issues. The RNA-seq analysis 
does not rely on pre-designed probes, but has difficulties with alignment (for example, pseudogenes 
can strongly impact the alignment). These differences have impact on what expression levels can be 
measured, i.e., it has been shown that RNA-seq is superior in detecting low abundance transcripts (if 
sequenced at high sequencing depth), differentiating biologically critical isoforms, and allowing the 
identification of genetic variants [2]. 
The main advantage of combining data of different measurement platforms is that the significantly 
associated genes represent very robust signals. Independent of the technique used to measure the 
gene expression levels, the gene seems to be important for the phenotype of interest. However, 
the concordance between RNA-seq and microarrays is far from perfect yet. There are batch 
effects because of different laboratories producing the data and different production schemes of 
companies making the essential consumables. Such technological variation needs to be recognized 
and controlled for as much as possible by standardization and harmonization. In addition, the 
analysis pipeline for RNA-seq data is still in development. For a better concordance, we need to align 
the RNA-seq reads to the 3’exons only (like the Illumina array). This might improve the correlation 
between the gene expression levels measured with the microarrays and RNA-seq. 
The Illumina Infinium Human Methylation 450K beadChip array
In this thesis, the Illumina Infinium Human Methylation 450K Beadchip array was used for measuring 
DNA methylation levels in all CHARGE cohorts. The methylation arrays offer a fast and cost-effective 
solution for profiling a relatively large number of CpG sites in one analysis. However, the Illumina 
450K array contains only 1.7% of the 28.2 million known CpG sites [3]. The definitions of the CpG 
locations are visualized in Figure 1. In Table 1, the locations of the CpGs on the Illumina 450K array 
(according to the Illumina 450K annotation file) and the locations of all known CpGs [4] are provided. 
For both groups of CpGs, we intersected the CpG positions with the locations of the 28,691 CpG 
islands (UCSC Genome Browser hg19, track “CpG islands”) and their shores and shelves. 
Islands were defined based on UCSC criteria: CG content >50%, a CpG observed/expected ratio >0.6, 
and length >200bp. Shores were defined as the 2kb up- and downstream of the CpG islands, and the 
shelves were defined as the 2kb up-and downstream of the shores.
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figure 1. The definition of CpG islands and their flanking shores and shelves (image adapted from Illumina’s 
450K datasheet). 
Table 1. The number of CpGs in CpG islands, in shores, in shelves, and off island on the Illumina 450K array 
compared to all known CpGs. 
CpG location All known CpGs (28.2M) (%) CpGs on 450K array (%)
CpGs in CpG islands 2,089,538 (7.4%) 150,254 (30.9%)
CpGs in shores 2,023,011 (7.2%) 112,110 (23.1%)
CpGs in shelves 1,184,491 (4.2%) 47,109 (9.7%)
CpGs off island 22,920,408 (81.2%) 176,039 (36.3%)
SUM 28,217,448 (100%) 485,512 (100%)
As presented in Table 1, the CpGs on the 450K methylation array are extremely enriched for CpGs in 
CpG islands and their flanking shores and shelves (96% of the CpG islands are covered) compared 
to all known CpGs. Illumina selected the content of the array with the guidance of a consortium 
of methylation experts comprising 22 members representing 19 institutions worldwide. At that 
point in time, it was thought that CpG islands were the most relevant areas of the genome involved 
in regulatory processes. Based on current knowledge, we know that CpG island methylation only 
accounts for a fraction of the variation in gene expression, and methylation in other domains like 
enhancers is hypothesized to play a far larger role than previously anticipated [5]. Table 2 shows 
how many of the CpGs on the 450K array are present in active promoters and/or enhancers for three 
different blood cell types: primary T-cells (tissue E034), primary B-cells (tissue E032), and primary 
monocytes (tissue E029). 
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Table 2. The number of CpGs in functional regions across different blood cell types. The active enhancer 
and promoter regions in each blood cell type were defined by the NIH Roadmap Epigenomics Consortium 
[6]. We intersected the locations of the CpGs with the positions of the active enhancers and promoters in 
three blood cell types: primary T-cells (tissue E034), primary B-cells (tissue E032), and primary monocytes 
(tissue E029). The number (and the percentage) of CpGs located in active enhancers and promoter regions 
is shown. 
blood cell type Enhancers Promoters Enhancer & Promoter Other locations
All known CpGs (28.2M)
Primary T-cells 2,131,734 (7.6%) 1,732,227 (6.1%) 1,121 (<0.01%) 24,352,366 (86.3%)
Primary B-cells 1,981,933 (7.0%) 1,616,856 (5.7%) 1,087 (<0.01%) 24,617,572 (87.2%)
Primary monocytes 1,979,686 (7.0%) 1,585,502 (5.6%) 1,080 (<0.01%) 24,651,180 (87.4%)
450K array (485,512)
Primary T-cells 77,348 (15.9%) 142,941 (29.4%) 67 (0.01%) 265,156 (54.6%)
Primary B-cells 74,730 (15.4%) 135,747 (28.0%) 65 (0.01%) 274,970 (56.6%)
Primary monocytes 67,405 (13.9%) 133,054 (27.4%) 74 (0.02%) 284,979 (58.7%)
As shown in Table 2, the number of CpGs in functional regions are quite similar across the three 
different blood cell types tested: of all known CpGs, about 7% is located in enhancer regions and 
about 6% is located in promoter regions. Less than 0.01% of the CpGs is located in a regions with 
both enhancer and promoter activity. As expected, the CpGs on the 450K array are enriched for 
promoter regions (approximately 28% of the CpGs on the array are located in promoter regions). In 
addition, the 450K array is also enriched for CpGs in functional enhancer regions: about 15% of the 
CpGs on the array are located in enhancers. 
But of course, the array also misses many CpGs located in enhancers and promoters. Of the 2 million 
CpGs located in active enhancer regions, we measured only 73,000 CpGs on the 450K array (3.6%) 
(Table 2). These 73,000 CpGs tag 23.8% of the active enhancers in blood. 
The same is true for the promoter regions: of the 1.6 million CpGs located in active promoter regions, 
we measured only 137,000 CpGs on the 450K array (8.3%) (Table 2). These 137,000 CpGs tag 64.3% 
of all active promoter regions in blood. 
Therefore, all epigenetic results presented in the manuscript in chapter 2.1 on the analysis of 
gene expression and DNA methylation with ageing are biased towards the content of the 450K 
methylation array. Because of the pre-selection of the 450K CpGs, the design of the array was not 
hypothesis neutral and we missed many of the regulatory regions. 
A new methylation array: the Illumina Infinium MethylationEPIC beadChip 
Very recently, Illumina introduced a new human methylation array, which is called the Illumina 
Infinium MethylationEPIC BeadChip. This array builds upon the 450K array (with >90% of the original 
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CpGs) plus an additional 350,000 CpGs in enhancer regions. These enhancer regions have been 
identified in the ENCODE project and the FANTOM5 project across multiple tissue types. The 
additional CpGs will definitely improve the coverage of the potentially functional enhancer regions. 
However, both methylation arrays are not able to measure allele specific methylation: the arrays 
measure the methylation percentage at a certain CpG site, and not which allele is methylated. 
Additionally, the Illumina arrays are not able to measure two CpGs close to each other. Because 
DNA methylation is dynamic data (this will be discussed in the next paragraph), it is not possible to 
impute CpGs close to each other: the correlation between CpGs may differ across different tissues 
and time, depending on stimuli.
Other techniques for measuring DNA methylation
To overcome the limitations of the 450K array, next-generation sequencing based modalities could 
be good alternatives. One option is whole-genome bisulfite sequencing (WGBS), which can quantify 
DNA methylation levels of all 28 million CpG sites, together with which allele is methylated [3]: single-
cytosine methylation levels are measured genome-wide. However, WGBS is prohibitively expensive 
for most studies because this method requires resequencing the entire genome at high depth [7]. 
Another option is using Reduced Representation Bisulfite Sequencing (RRBS), but this method is 
also biased towards the CpG islands in the gene promoter and covers only a minor proportion of 
variable CpGs. One of the recent options is methylC-capture (MCC) sequencing. This method can 
be used for measuring both genetic variation and methylation levels: it targets a pre-designed 
selection of CpGs and SNPs in a disease-relevant tissue [8]. For example, the capture panel of Roche 
Nimblegen, Inc. (Madison, WI, USA) targets about five million dynamic CpGs mapping to regulatory 
elements in blood, and includes all SNPs linked to auto-immune diseases. The main disadvantage of 
MCC-sequencing is the fact that analyzing the data is still challenging: the analysis is more complex 
and the data storage is more demanding. Additionally, MMC-sequencing is much more expensive 
than running 450K arrays. 
DyNAMIC DATA
As mentioned before, gene expression levels and DNA methylation are dynamic: they can vary 
between tissues vary in time, and vary between different disease states. In contrast to genetic 
variants where a specific SNP is present or not, gene expression and DNA methylation levels strongly 
depend on the tissue type being measured. A single sequencing experiment in whole blood will 
only offer information regarding that specific tissue (whole blood) at one point in time. This argues 
for studying immune and blood-related phenotypes when analyzing gene expression and DNA 
methylation levels in blood. One should be cautious in relating gene or methylation levels to other 
(not-blood related) phenotypes: the associations could be driven by confounders. 
The eQTL studies (chapter 3.1 and 3.2) showed that gene expression levels in blood are mostly 
regulated by SNPs identified in GWAS studies for immune and blood-related phenotypes (for 
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example, celiac disease, systemic lupus erythematosus (SLE), the cholesterol metabolism, and type 
1 diabetes). And this phenomenon is even stronger in the trans-eQTL analyses: in our blood analysis, 
the trans-eQTLs SNPs are enriched for associations with (auto)immune diseases or hematological 
traits. Blood itself is a heterogeneous collection of cell types, and comparisons between blood cell 
types showed that the number of shared eQTLs varies widely with the cell type and tissues studied. 
For example, a comparison of B-cells and monocytes showed that 21.8% of the detected cis-eQTLs 
were shared and only 7% of the detected trans-eQTLs were shared between tissues [9]. This suggests 
that the genetic regulation in trans is more cell type specific than the regulation in cis, and shows 
that the genetic regulation of gene expression is complex and differs across cell types and tissues. 
MEASUREMENTS IN WHOLE bLOOD
In population-based cohorts, only easily accessible tissues can be gathered, such as blood, urine, 
stool, and saliva. In this thesis, we used genomic data from peripheral blood, which represents a 
heterogeneous pool of different cell types and subtypes with variable patterns of gene expression 
levels [10]. Therefore, cell composition is an important confounder, since gene expression changes 
with cell composition, and cell composition can be altered, for example, depending on collection 
time, collection conditions, and the disease state. 
Complete blood counts
In the Rotterdam Study, the complete blood counts (CBCs) have been measured in the samples. The 
CBCs give important information about the kinds and numbers of blood cells, especially the number 
of white blood cells (WBC): the monocytes, the lymphocytes, and the granulocytes; the number of 
red blood cells (RBC): the erythrocytes; and the number of platelets: the thrombocytes (Figure 2). 
Normal ranges of a complete blood count for healthy males and females are given in Table 4. 
Table 4. Normal ranges of complete blood counts for healthy adults. http://www.mercynorthiowa.com/cbc-
normal-ranges
Normal cell counts per microliter
Type of blood cell Males females
Erythrocytes (RBC) 4.3-5.8 million 3.8-5.2 million
Monocytes (WBC) 200-900 200-900
Lymphocytes (WBC) 800-4,800 800-4,800
Granulocytes (WBC) 0-30 0-30
Thrombocytes (platelets) 150,000-440,000 150,000-440,000
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We used the CBCs to correct for the major differences in cell composition. Of course, these cell 
subset classifications are also artificial: they reflect the current ability to distinguish the cells based 
on specific small sets of available markers. It is becoming clear that each defined subpopulation of 
cells can be further broken down into additional subgroups, as the tools for subset classification 
become more sophisticated [11]. 
Houseman estimates
Houseman et al. [12] developed an algorithm to predict the blood cell type numbers based on 100 
CpG methylation sites present on the Illumina 450K methylation array. The algorithm estimates the 
relative number of CD4+ T-cells, CD8+ T-cells, NK cells, monocytes, granulocytes, using CpG sites 
which are known to be differentially methylated in the different blood cell types. The algorithm was 
validated by predicting the blood cell type profiles of sorted white blood cell samples. The main 
disadvantage of this method is that the algorithm was validated in only 46 sub-cell type samples 
(Table 5). Additionally, in our study we identified that the correlation between the Houseman 
estimates and the measured CBCs is not perfect, in fact not perfect at all: the r2 values ranged 
between 0.27 and 0.57 (in 726 samples of the Rotterdam Study) (Figure 3). These weak correlations 
are alarming results for all transcriptomic and epigenetic analyses adjusting for the Houseman 
estimates, since they can introduce strong biases in the reported associations.
Table 5. The number of validation samples per blood cell type, used by Houseman. 
Sorted white blood cell type # of validation samples
B-cells 6
Granulocytes 8
Monocytes 5
NK cells 11
T cells (CD4+) 8
T cells (CD8+) 5
T cells (NKT) 1
T cells (other) 5
SUM 46
Variations in cell composition reflecting biological differences
The possible effects of different subpopulations of cells on the phenotype should be kept in 
mind while interpreting the association results. Nevertheless, the differences between the cell 
compositions associated with disease could be very interesting too. For example, with ageing it is 
known that the relative abundance of immune cells in blood is shifting: the amount of naïve T-cells 
is decreasing and the amount of highly differentiated effector and memory T-cells is increasing with 
age [13-18]. This is called immunosenescence and reflects the age-associated immune deficiency, 
which is found in long and short-lived species. 
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In our transcriptome-wide association analysis with age (chapter 2.2), we adjusted for the number 
of CBCs. However, the subpopulations of cell (e.g., the naïve versus differentiated T-cells) were not 
measured in the participating studies and could therefore not be adjusted for. Interestingly, we 
could replicate our findings in a number of studies with cell subset specific gene expression levels. 
For example, CD4+ cells, CD8+ cells, CD14+ cells (monocytes), and periperheral blood mononuclear 
cells (PBMCs). Replicating an age-associated gene in a sub cell type suggests that these genes are 
not solely accountable by cell count differences, but also reflect biological functions.
figure 3. The correlation between the measured CBCs (x-axis) and the Houseman estimates (y-axis) for 
granulocytes, monocytes, and lymphocytes. 
It is important to note that not only blood is a heterogeneous collection of different cell types: this 
is also true for other tissues, like brain cells, muscle cells, bone cells, or cartilage cells. Furthermore, 
these tissues are often contaminated with blood cells because of cell isolation difficulties. Therefore, 
the possible effects of different subpopulations of cells must be kept in mind while interpreting 
association results. 
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In this thesis, we identified 1,497 genes to be associated with ageing, of which 134 genes were 
known to belong to an immune function pathway (chapter 2.1). We identified 34 genes that are 
differentially expressed in relation to blood pressure (BP): 21 for systolic blood pressure, 20 for 
diastolic blood pressure, and 5 for hypertension (chapter 2.2). Next to inflammatory response, 
the BP genes also showed enrichment for metabolic processes and transcription regulation. For 
circulating lipid levels, we found 906 genes to be associated: 793 for triglycerides, 489 for HDL 
cholesterol, 5 for LDL cholesterol, and 20 for total cholesterol (chapter 2.3). Genes associated with 
triglycerides and HDL cholesterol were enriched for processes like protein binding, RNA binding, 
and ribosome integrity. LDL cholesterol genes were enriched for apolipoprotein receptor activity 
(initiating changes in cell activity), and the total cholesterol genes were highly enriched for the 
functions related to DNA and RNA binding. The muscle strength analysis identified 221 genes to be 
associated, which were enriched for hemoglobin metabolic process, hemolytic anemia, and innate 
immune response (chapter 2.4).
Across all four phenotypes (ageing, blood pressure, circulating lipid levels, and muscle strength), we 
identified 2,392 unique genes to be differentially expressed with at least one of the phenotypes. 226 
genes (9.4%) were significantly associated with two or more phenotypes. One gene was identified to 
be associated with all four phenotypes: the Perforin 1 (PRF1) gene. Its protein is important for T-cell and 
natural killer (NK) cell mediated destruction of cells. Gene set enrichment analysis of the 226 genes 
(using WebGestalt) identified enrichment for immune system diseases (24 genes, P-value=3.17E-5), 
inflammation (20 genes, P-value=3.17E-5), rheumatoid arthritis (14 genes, P-value=4.3E-5), and 
connective tissue disease (n=15, P=value=6.7E-5). Enriched molecular functions (gene ontology 
terms) were ribosome structure (n=13, P-value=2.33E-5), protein binding (n=119, P-value=0.026), 
and RNA binding (n=24, P-value=0.026). Both the enriched molecular functions and diseases 
emphasize the association of immune activation and cell signaling pathways in whole blood studies. 
For the eQTL analyses, we checked whether the identified eQTLs were driven by differences in age 
or blood cell-counts between individuals (Chapter3.1). We selected 18 phenotypic measurements 
that were available in at least 1,500 samples (including age and CBCs), and we correlated the gene 
expression values with the phenotypic measurement using Spearman’s rank correlation. After 
adjusting for the principal components (PCs) (one of the steps during the eQTL mapping), the 
correlations with age and CBCs were not significant anymore (p=0.31). This indicated that through 
removal of the PCs, we eliminated the differences in blood cell counts. However, we cannot exclude 
this possibility entirely because we did not conduct analyses on individual cell-types. 
As discussed, analyzing genomic features in whole blood cells is more complex than interpreting 
cell-type specific experiments, but it is not necessarily less informative than the analysis of 
subpopulations. Of course, an analysis approach based on overall expression has greater power 
to detect expression changes in common blood cell types, and has less power to detect smaller 
changes in less numerous blood cell types. The cell subtype origins of the phenotype-associated 
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genes reported here now need to be identified by studying the associations in subtype specific 
cohorts. 
MUSCULOSKELETAL COMORbIDITIES
Next to ageing and general age-related phenotypes, we also focused on musculoskeletal 
comorbidities which are the most frequent cause of physical activity limitations. We performed a 
GWAS for chronic widespread pain (CWP) (chapter 4.1) and a GWAS for heat pain thresholds (chapter 
4.2), which is an experimental pain sensitivity marker. Many chronic pain syndromes are known 
to be associated with hypersensitivity to pain [19]. Additionally, we performed a transcriptomics 
study for gene expression levels in the circulation and joint effusion grades in the knee (chapter 
4.3). Joint effusion is known to be related with joint inflammation [20], and is a strong predictor for 
development of incident knee OA [21]. 
In the GWAS meta-analysis for CWP, we found evidence for involvement of the 5p15.2 region 
containing two genes: CCT5 and FAM173B. Although we have not conclusively identfied the causal 
gene in this area, there are some interesting findings which might implicate some candidates. For 
example, In the lumbar spinal cord of mouse models of inflammatory pain, chronic pain coincided 
with higher gene expression levels of both the Cct5 gene and the Fam173b gene. Follow-up studies 
identified that the Fam173b reduction enhanced the resolution of inflammatory pain in this mouse 
model [22]. 
In the heat pain threshold GWAS meta-analysis, we found one deletion (1:176688345:D) to be 
significantly associated. The deletion is located in the twelfth intron of the PAPPA2 gene in the 
1q25.2 region. The PAPPA2 gene is thought to be a regulator of insulin-like growth factor (IGF) 
bioavailability. IGF is important in the nociceptive pain sensitivity (processing harmful pain stimuli) 
of primary sensory neurons in the nerve cells. However, most interestingly we identified that having 
chronic pain substantially influences the heat pain threshold measurements: the genetic heritability 
in samples without pain (based on all genetic variants on the Illumina 550K SNP array) equals 32%, 
while samples having chronic pain have a heritability of only 9%. In addition, the heritability was 
higher in women compared to men. So, this suggests that having chronic pain and being male 
affects the pain sensitivity measurements with respect to the underlying genetic variants. 
Both GWAS studies on pain described in this thesis were the first in its kind, and have been preceded 
by many small candidate gene studies reporting various “significant” associations [23]. However, in 
both GWAS studies, we could not replicate any of the previously reported SNPs associated with 
chronic pain or pain sensitivity, while our meta-analysis sample sizes were much larger than the 
discovery sample sizes. So, most likely the candidate gene studies were all false positives due to 
lack of power. Alternatively, one could speculate that very specific groups of pain patients were 
chosen for the candidate gene studies in which these SNPs have larger effects. Moreover, the lack of 
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reproducibility of SNPs in candidate genes in large GWAS meta-analyses has been shown before for 
many other phenotypes like BMD [24]. 
Last but not least, we tried to identify molecular biomarkers for early knee OA) by examining joint 
effusion grades in the knee and gene expression levels in the circulation. We identified 189 genes to 
be nominally associated with joint effusion in the knee, and several compelling genes were identified 
such as C1orf38 and NFATC1. Significantly enriched biological pathways were: response to stress, 
gene expression, negative regulation of intracellular signal transduction, and antigen processing 
and presentation of exogenous pathways. Additional studies are needed to replicate the findings, 
which may result in biomarkers urgently needed to diagnose OA at an early stage.
CAUSAL DIRECTIONS
Because we studied genetics and genomics of age-related diseases in a cross-sectional design in 
the experiments described in this thesis, it is not possible to determine a causal direction for the 
associations reported. Therefore, the results of genetic and genomic studies need to be considered 
in light of longitudinal and functional evidence. Causality can be better understood by following the 
subjects in time and knowing the biological pathways involved. So, follow-up studies are needed to 
address causation. 
For dynamic data (both gene expression and DNA methylation), a promising approach would be 
to infer causal networks from longitudinal data. After checking for co-regulated genes at one time 
point, the co-regulation can be measured at consecutive time points [25]. The continuity between 
the different time points allows studying the impact of major events. Because longitudinal data for 
both gene expression and DNA methylation data is now becoming available in the Rotterdam Study, 
this will hopefully provide more insight. 
fUTURE DIRECTIONS
The main goal of population-based genetic and genomic studies in cohorts of elderly such as the 
Rotterdam Study is to identify new genes and biomarkers involved in age-related diseases, and 
thereby discovering new pathways to better understand the biological mechanisms of ageing. 
In this thesis, we discovered SNPs and genes to be associated with ageing and age-related 
phenotypes. The sample sizes of the meta-analyses of GWAS data, gene expression levels, and DNA 
methylation levels continue to increase, thereby resulting in even more SNPs and genes associated 
with disease, but with increasingly smaller effect size. Like the GWAS meta-analyses done for 
height [26], waist-hip-ratio [27] and BMI [28] (in more than 250,000 individuals), studies including 
much larger sample sizes will generate even more robust associations and will reduce the noise in 
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the current analyses. And this will also be true for gene expression studies and DNA methylation 
studies: including much larger sample sizes will reduce the noise in the analyses, and will increase 
the number of significant findings. However, as shown in Figure 4, it is not only the sample size 
that determines the number of identified loci. Despite relatively large sample sizes for Alzheimer’s 
disease and osteoarthritis (OA), only a modest number of loci were identified [29]. And the same 
is true for the GWAS studies for chronic widespread pain (CWP) and heat pain thresholds (HPT). In 
general, it is suspected that pain is an extremely heterogeneous phenotype.
For the identification of genome-wide trans-eQTLs, much larger sample sizes are needed too. For 
a genome-wide trans-eQTL analysis, at least 2.5 million SNPs times 60,000 gene expression probes 
need to be tested, resulting in 150 billion tests. The trans-eQTL meta-analysis described in chapter 
3.1 is the largest meta-analysis done until now, including only 5,311 subjects having both genome-
wide SNP data and gene expression data in blood. Therefore, the number of subjects in these 
analyses must increase dramatically to be able to perform the trans-eQTL analysis on all 2.5 million 
SNPs. For many other tissues, trans-eQTL studies have not been performed at all. This is a “big black 
hole”, were additional research is needed to fill the enormous gap. Trans-eQTLs are very important to 
understand the downstream effect of disease variants, especially when the trans-eQTLs affect more 
genes in one pathway. The links between SNP and genes will give rise to new biological networks, 
which will definitely improve our understanding of complex diseases. 
figure 4. The power of genetic studies depends on the sample size and the phenotype (image adapted 
from Van Meurs et al. [29]). The number of GWAS hits (SNPs with a P-value<5E-08) as a function of sample size 
of the discovery cohort for several major complex diseases.
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Because of the introduction of RNA-seq data, the current eQTL studies can now be extended with 
Allele Specific Expression (ASE) studies. At heterozygous positions in the genome, the percentage 
of reads having allele A or B can be determined. Over expression of one allele over the other (called 
ASE) has been observed, and can be assessed on a genome-wide scale. With the RNA-seq technology 
this is possible right now: because of including heterozygous genetic variants in the analysis, there 
are no inter-individual differences resulting in confounding factors. This is more powerful than a 
phenotype-based association analysis, and would be a nice addition to the current eQTL studies 
done. 
It is anticipated that future studies will focus on more target tissues or specific cell types relevant for 
the disease phenotype under study. It is expected that genetic variants will have larger effects on 
gene expression or DNA methylation in the target tissue. For example, single cell RNA sequencing 
can be used to identify the gene expression profiles of one specific cell type of interest. With single 
cell sequencing, the gene expression levels of one specific cell are sequenced, meaning that there 
cannot be issues of heterogeneous cell populations. However, the selection of the single cells is still 
a critical step. Tissues consist of heterozygous cell population, so the selection procedure needs to 
be similar in all participants. Additionally, cells can be in different developmental stages (cells divide, 
cells grow, cells diffentiate, cells die, etc.), so this should be taken into account as well. Otherwise, 
the problem of sequencing heterozygous cell populations will be replaced by the problem of 
sequencing different cell populations across individuals. 
It would be very interesting to get access to primary tissues, such as neuronal, bone and cartilage 
tissues. This will give a better insight into the molecular mechanisms underlying osteoarthritis, 
chronic pain, and pain sensitization. Because this will not be possible in population based cohort 
studies, collaborations with neurology and orthopedics departments are needed. A nice example of 
a project using primary tissues is the Genotype-Tissue Expression Project (GTEx): it is a pioneering 
project obtaining and storing a large range of organs and tissues, and testing them in the lab. These 
tissues were collected and stored through the National Cancer Institute’s cancer Human Biobank 
initiative, and they created a resource that researchers can use to study how inherited changes in 
genes lead to common diseases [30]. 
Another option would be focusing on induced Pluripotent Stem (iPS) cells. iPS cells can be 
generated from adult cells from skin biopsies or blood cells (which can be done in population based 
cohort study) and upon proper stimulation they can give rise to other cell types in the body [31]. 
Highly differentiated somatic cells can be reprogrammed to a pluripotent stage, and these can be 
differentiated again. With this technique one can generate patient specific iPS cells (carrying the 
disease and a certain genetic background as assessed by GWAS or NGS). 
Additionally, the annotation of non-coding transcripts needs to be improved. In this thesis, we 
focused on trans-eQTL effects for SNPs in long non-coding RNAs (lncRNAs), and in this analysis, we 
had many difficulties with the alignment of sequencing reads to the correct genes. This was caused 
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by all kind of transcripts that are very similar to the protein-coding genes, most of them being 
non-functional pseudogenes. More research is needed to improve this annotation. Next to a better 
annotation, it would be very interesting to measure the levels of the non-coding RNAs themselves. 
With the expression levels of lncRNAs, it is possible to examine whether the SNP is really affecting 
the non-coding RNA itself. Of course, these experiments need to be done in the target tissue. 
As discussed before, it would be interesting to implement new DNA methylation measurement 
techniques like whole genome bisulfite sequencing (WBGS), methylC-capture (MCC) sequencing, 
or the Illumina MethylationEPIC Beadchips. These methods are not or at least less biased towards 
the CpG islands and gene promoters. What method to use depends on the financial circumstances 
and the aim of the project. When calculating costs for each method, the analysis time should be 
taken into account: sequencing methods generate a huge amount of data, but data storage and 
analysis are thus more complex. Sequence data have to be analyzed through sophisticated and 
computationally intensive algorithms, while array data can be easily analyzed with freely available 
analysis packages in R. 
For the musculoskeletal comorbidities studied, less heterogeneous phenotype definitions need 
to be defined. The use of quantitative and possibly more objective pain measurements will be of 
pivotal importance to identify further genetic variants underlying chronic pain. With the heat pain 
thresholds GWAS, we used a quantitative measurement for pain sensitivity, but still similarly sized 
replication cohorts are needed that can demonstrate that the identified signals are true signals. For 
the joint effusion study, we experienced similar difficulties: only GARP and the Rotterdam Study 
have both knee MRIs and transcriptome-wide gene expression levels in blood available currently. 
Our results contributed to a better understanding of the molecular mechanisms of ageing and 
age-related comorbidities and the inter-individual differences in these mechanisms in the general 
population. Our lists of genes provide a rich trove of data for future studies, and may serve as a 
roadmap aimed at translating findings into treatment strategies and interventions.
IS AGEING A DISEASE? 
The final question remains whether ageing is programmed by biological clocks operating throughout 
lifespan, or whether ageing is based on accumulation of damage, or a mixture of both mechanisms? 
The studies in this thesis showed that transcriptome-wide gene expression levels measured in 
human blood cells are strongly associated with age, blood pressure, lipid levels, and muscle strength, 
and that DNA methylation changes in the functional regions of the DNA (enhancer regions) co-
occur with these gene expression changes with age. Such enhancer regions could act as dimmer 
switches regulating the expression levels of nearby or distant genes, and the DNA methylation can 
be influenced by environmental factors (for example, changes in diet, exercise, smoking, etc.). These 
findings could offer very nice strategies for interventions (changing to a healthier diet, exercise more 
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regularly, and quit smoking), when we are sure that DNA methylation changes causally alter the 
gene expression levels. Earlier family studies showed that the capacity to survive to high ages is 
heritable: children of 90- and 100-year-olds have lower occurrences of metabolic morbidity (e.g., 
cardiovascular disease, diabetes, hypertension, even osteoarthritis) [32]. Additionally, their insulin 
sensitivity and lipid levels resemble those of the more healthy section of the population [33]. So, 
they are biologically younger than their spouses (age-matched unrelated individuals), and get 
significantly older too [34]. In summary, the theory of ageing being programmed by biological 
clocks feels like the preferred hypothesis: by inheriting the best genetic variants of your parents and 
optimally tuning the environmental factors (a healthy life style, good food patterns), one might be 
able to influence the pace of ageing. 
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Summary 
Although age is the most powerful risk factor for many common diseases, the underlying molecular 
mechanisms are still largely unknown. The overall objective of this thesis was to integrate different 
genetic and genomic approaches to better understand ageing and age-related comorbidities. 
We studied the effects of genetic variants, gene expression levels, and DNA methylation levels on 
age-related phenotypes. Additionally, we combined the different levels of -omics data (genomics, 
epigenomics, and transcriptomics) to identify expression quantitative trait loci (eQTLs) and 
potentially functional CpG-methylation sites regulating gene expression levels. 
In Chapter 2, the results of four transcriptome-wide gene expression meta-analyses are presented. 
In Chapter 2.1, we studied gene expression levels in whole blood of 14,983 persons, and we 
identified 1,497 genes that are differentially expressed with ageing. The age-associated genes were 
enriched for the presence of potentially functional DNA methylation sites (enhancer and insulator 
regions) that associated with both ageing and the gene expression levels of the genes located close 
by. Additionally, we used the gene expression levels to predict the “biological or transcriptomics 
age” of an individual, and we show that the delta age (the difference between the biological age and 
the chronological age) was associated with biological features like blood pressure, cholesterol levels, 
fasting glucose, and body mass index. 
In Chapter 2.2, results of the transcriptome-wide association analysis for blood pressure are shown. 
We performed a meta-analysis in 7,017 persons that did not receive antihypertensive drugs, and 
identified 34 genes that were differentially expressed in relation to blood pressure. Only two genes 
(FOS and PTGS2) have been previously reported to be involved in blood pressure related processes. 
Gene set enrichment analyses suggested that the genes are involved in inflammatory response and 
the apoptosis pathways. The genetic variant rs3184504 in the gene SH2B3 (which was also reported 
in a GWAS to be associated with blood pressure) was found to be a trans-regulator of six of the blood 
pressure associated genes (FOS, MYADM, PP1R15A, TAGAP, S100A10, and FGBP2). 
In Chapter 2.3, we showed that gene expression levels are also associated with circulating lipid 
levels: triglycerides, HDL-cholesterol, LDL-cholesterol, and total cholesterol. In a meta-analysis of 
4,841 fasting individuals that did not receive lipid-lowering medications, we identified 906 genes 
to be associated with levels of at least one lipid trait. We identified a set of basophil and mast cell-
related genes whose expression levels were associated with all four lipid traits. The two genes with 
the smallest P-values were HDC and CPA3: expression levels of these two genes explained 23.1% 
and 18.1% of the total variation in log-transformed triglyceride levels, respectively. Furthermore, 
we identified significant associations between lipid levels and the expression levels of 95 known 
lipid-related genes. 
In Chapter 2.4, we aimed to identify gene expression levels associated with muscle strength. In a 
meta-analysis of 7,781 persons with hand-grip strength measurements, we identified 221 genes to 
be associated. The associated genes were enriched for hemoglobin biosynthesis, innate immune 
activation, and stress response. 115 genes (52%) have not previously been linked to muscle in NCBI 
PubMed abstracts. Ten genes were only associated in younger individuals (<60 years), four genes 
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(ASAP1, GID8, RAC1, and NDUFS1) were only found in males, and one gene (DEFA4) was found in 
females only. 
The relationship between genetic variants (SNPs) and gene expression levels is described in Chapter 
3. In Chapter 3.1, we focused on disease-associated SNPs: we performed the largest eQTL meta-
analysis in peripheral blood samples of 5,311 individuals, and replicated in another 2,775 persons. 
We identified and replicated trans-eQTLs for 233 SNPs (reflecting 103 independent loci), that were 
previously associated with complex traits. We identified trait-associated SNPs that affect multiple 
genes in trans: for example, the SNP rs4917014 (known to be associated with systemic lupus 
erythematosus or SLE) altered the expression levels of the C1QB gene and five type 1 interferon 
response genes, which are hallmarks of SLE. Variants associated with cholesterol metabolism and 
type 1 diabetes showed similar phenomena, indicating that large-scale eQTL mapping provides 
insight into the downstream effects of many trait-associated variants.
Chapter 3.2 describes a trans-eQTL analysis for SNPs in long non-coding RNAs (lncRNA). lncRNAs are 
thought to be important regulators for gene expression. In 652 persons with RNA sequencing data 
and replication in another 1,464 persons (with RNA sequencing data), we identified 2,678 trans-eQTLs 
for 1,320 SNPs in lncRNAs. Of these, 195 lncRNA trans-eQTLs showed inter-chromosomal effects (the 
SNP was located on a different chromosome than the gene). The 195 lncRNA trans-eQTLs are caused 
by 127 unique SNPs, and some affect multiple genes in trans: for example, SNP rs13227497 (a cis-
eQTL SNP for lncRNA RP11-611L7.1) is associated with the expression of KNS1, PI3, and ALDH1A2. 
SNPs in these genes are known to be associated with severe hand osteoarthritis, response to stress, 
and chronic pain. The lncRNA might affect the three genes in one pathway, thereby influencing all 
three phenotypes simultaneously.
In Chapter 4, we integrated genetic and genomic studies for age-related musculoskeletal 
comorbidities. With ageing, musculoskeletal comorbidities have become the most frequent cause 
of physical activity limitations and reduced self-management behavior, thereby causing a reduced 
quality of life. Chapter 4.1 describes the results of the first GWAS study for chronic widespread pain 
(CWP). CWP is a common disorder affecting about 10 percent of the general population. In the 
GWAS meta-analysis of 1,308 female CWP cases and 5,791 female controls, we identified two SNPs 
which were genome-wide significant (representing one locus) and another 39 SNPs with suggestive 
evidence for association (representing nine loci). After replication in another 1,480 female CWP cases 
and 7,989 female controls, we identified the minor C-allele of rs13361160 on chromosome 5p15.2, 
located upstream of CCT5 and downstream of FAM173B, to be associated with a 30% higher risk of 
CWP. Expression levels of Cct5 and Fam173b in mice with inflammatory-induced hyperalgesia were 
higher in the spinal cord, not in the dorsal root ganglions, compared to mice without pain. Both 
CCT5 and FAM173B are novel genes that are associated with CWP but the underlying mechanisms 
involving pain sensitivity should be investigated in more detail. 
In Chapter 4.2 we describe a GWAS of the heat pain threshold (HPT). The HPT is an experimental 
pain sensitivity measurement: a thermo-sensory analyzer probe was placed on the inner site of the 
non-dominant forearm, and the participants were asked to stop the test at the moment the pain 
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stimulus (increase in temperature) started to feel unpleasant or painful. Our GWAS meta-analysis in 
3,795 participants of the Rotterdam study revealed one genome-wide significant SNP rs192745611, 
which is located in the fifth exon of the PAPPA2 gene, of which the encoded protein is thought to 
be a local regulator of insulin-like growth factor (IGF) bioavailability. IGF is implicated to play a role 
in the nociceptive (pain) sensitivity of primary afferent neurons. Neurotrophy, neurogenesis and 
metabolic functions are shown to be influenced by IGF in the adult brain, and in vitro, upregulation 
of IGF showed a higher sensitivity of primary afferent neurons. 
By estimating the heritability of HPT, we found large differences between sexes and persons with 
or without chronic pain: the heritability estimate in females was 35%, compared to 9% in males; 
in persons without chronic pain the heritability estimate was 32%, compared to 8% in persons 
having chronic pain. Therefore, we adjusted the GWAS analysis for both sex and chronic pain status. 
Although very interesting, our GWAS findings need to be replicated in an independent cohort. This 
would give more insight into the underlying mechanisms of the HPT.
Chapter 4.3 describes a transcriptome-wide gene expression meta-analysis for joint effusion grades 
in the knee. Joint effusion is the presence of increased intra-articular fluid, which has been positively 
associated with knee pain in knee OA patients. Joint effusion is known to be related with joint 
inflammation and recent studies showed that the occurrence of joint effusion is a strong predictor 
for the development of incident knee OA. We aimed to identify molecular biomarkers for early 
knee OA, and included 135 females of the Rotterdam Study and 98 females of the GARP study. We 
identified 189 genes in blood that were nominally significantly associated with joint effusion, which 
were significantly enriched for response to stress, gene expression regulation, negative regulation of 
intracellular signal transduction, and antigen processing and presentation of exogenous pathways. 
The lowest P-value was found for the C1orf38, also called THEMIS2 or ICB-1, which is highly expressed 
in several blood cells (monocytes, dendritic cells, NK cells, T-cells, B-cells). The gene is induced by 
interferon-gamma (IFN-γ), an important cytokine that orchestrates many distinct cellular processes 
regarding inflammation. 
Chapter 5 provides a general discussion on the results of the studies in a broader perspective. 
Additionally, several recommendations for future research are presented. 
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Ouderdom komt met gebreken. Maar eigenlijk begrijpen we nog altijd niet zo goed wat er 
nu precies gebeurt in het menselijk lichaam. Het doel van dit proefschrift is veroudering en 
ouderdomsgerelateerde ziektes beter te begrijpen door middel van integratie van genetische en 
genomische studies. We hebben onderzoek gedaan naar genetische variaties (SNPs), genexpressie 
levels en DNA methylering. Bovendien hebben we deze verschillende soorten data met elkaar 
gecombineerd: we hebben onderzocht welke SNPs genexpressie reguleren (dit noemt men eQTLs) 
en we hebben gekeken of genen die geassocieerd zijn met veroudering tegelijk verrijkt zijn met 
mogelijk functionele CpG methyleringssites. 
In Hoofdstuk 2 worden de resultaten van vier verschillende genexpressie studies beschreven. In 
Hoofdstuk 2.1 onderzochten we de genexpressie levels in het bloed van 14.983 mensen. We hebben 
1.497 genen gevonden die op de een of andere manier betrokken zijn bij het verouderingsproces. 
Een deel van deze genen is betrokken bij de energiehuishouding, de vetverbranding en de stevigheid 
en flexibiliteit van cellen. Vervolgens hebben we gekeken naar de DNA methylering (epigenetische 
markers) van deze genen: we zien dat de verouderingsgenen verrijkt zijn met methyleringssites 
in mogelijk functionele gebieden (ook wel enhancer en insulator gebieden genoemd). Deze 
methyleringssites zijn zowel met leeftijd als met de genexpressie levels (van de genen waarin ze 
liggen) geassocieerd. Tot slot hebben we de genexpressielevels gebruikt om voor ieder individu de 
“biologische leeftijd” te voorspellen. We laten zien dat het verschil tussen de “biologische leeftijd” en 
de “echte” of chronologische leeftijd geassocieerd is met bekende risicofactoren, zoals bloeddruk, 
cholesterol levels, bloedsuikerspiegel en de body mass index (BMI). 
In Hoofdstuk 2.2 hebben we de genexpressie levels in het bloed geassocieerd met de bloeddruk. 
In een meta-analyse van 7.017 mensen die geen bloeddruk verlagende medicijnen gebruikten 
hebben we 34 bloeddruk genen blootgelegd. Deze genen zijn geassocieerd met de bloeddruk, 
omdat ze met een verhoogde (of juist verlaagde) bloeddruk een ander signaal gaan afgeven. Van 
slechts twee genen was (wetenschappelijk) al bekend dat ze een relatie hebben met bloeddruk: 
dit zijn FOS en PTGS2. De totale lijst van 34 genen is belangrijk voor de afweer bij ontstekingen en 
voor apoptose (de afbraak van cellen). De SNP rs3184504 in het gen SH2B3 (deze is gevonden met 
een genoomwijde associatie studie (GWAS) naar bloeddruk) lijkt 6 andere bloeddruk gerelateerde 
genen te reguleren (FOS, MYADM, PP1R15A, TAGAP, S100A10 en FGBP2. 
In Hoofdstuk 2.3 worden de genen beschreven die geassocieerd zijn met circulerende lipiden: 
een lipiden profiel meting bestaat uit triglyceriden, HDL-cholesterol, LDL-cholesterol en totaal 
cholesterol. In een meta-analyse van 4.841 nuchtere deelnemers die geen lipiden-verlagende 
medicijnen gebruikten, hebben we 906 genen gevonden die geassocieerd zijn met tenminste één 
type lipide. Ook vonden we een select groepje genen dat geassocieerd was met alle vier de lipides: 
deze genen zijn belangrijk voor mastocyten en basofiele granulocyten. Mastocyten en basofiele 
granulocyten lijken sterk op elkaar: ze spelen een belangrijke rol in de immuunrespons en bij 
allergische reacties. De expressielevels van de meest significante genen (HDC en CPA3) verklaren 
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zo’n 23,1% en 18,1% van de totale variatie in trygliceriden levels. Bovendien konden we voor 96 
bekende lipide genen de associatie met circulerende lipiden bevestigen. 
In Hoofdstuk 2.4 hebben we gekeken of genexpressie levels ook associëren met spierkracht. In een 
meta-analyse van 7.781 mensen met spierkracht-metingen in de hand, hebben we 221 genen in het 
bloed gevonden die geassocieerd zijn met spierkracht. Deze genen zijn belangrijk voor de aanmaak 
van hemoglobine, aspecifieke afweer in het immuunsysteem en de lichamelijke reactie op stress. 
115 genen (52%) zijn niet eerder gevonden in relatie tot spier of spierkracht (als je zoekt in NCBI 
PubMed abstracts). Tien genen werden enkel gevonden in analyses specifiek voor jonge mensen (< 
60 jaar), vier genen (ASAP1, GID8, RAC1 en NDUFS1) werden alleen gevonden in mannen en één gen 
(DEFA4) werd enkel gevonden in vrouwen. 
In Hoofdstuk 3 werd de relatie tussen genetische varianten (SNPs) en genexpressie levels 
onderzocht. In Hoofdstuk 3.1 is specifiek gekeken naar ziekte-gerelateerde SNPs: we hebben een 
zogenaamde “expressie quantitative trait locus” (eQTL) meta-analyse gedaan van 5.311 mensen en 
hebben de resultaten gerepliceerd in 2.775 mensen. We hebben trans-eQTLs gevonden voor 233 
SNPs in 103 onafhankelijke gebieden. We hebben SNPs gevonden die meerdere genen reguleren 
in trans: bijvoorbeeld de SNP rs4917014 (een bekende SNP voor de auto-immuunziekte Lupus 
erythematosus of SLE): deze SNP verandert niet alleen de expressie levels van het IKZF1 gen dichtbij 
(cis-effect), maar verandert eveneens de expressie levels van het C1QB gen en 5 verschillende type 
1 interferon genen. Zowel het C1QB gen als de type 1 interferon genen zijn reeds bekend voor 
de ziekte SLE. Andere fenotypes (zoals het cholesterol metabolisme en type 1 diabetes) lieten 
vergelijkbare resultaten zien. Dit laat zien dat grote eQTL meta-analyses meer inzicht kunnen geven 
in de indirecte effecten van de genetische variaties. 
Hoofdstuk 3.2 beschrijft een trans-eQTL studie specifiek voor SNPs gelegen in “long non-coding” 
RNAs (lncRNAs). lncRNAs heten non-coding RNAs omdat ze niet coderen voor eiwitten. Toch lijken 
ze belangrijk te zijn voor de regulatie van genexpressie. Daarom hebben we een trans-eQTL analyse 
gedaan in 652 mensen en hebben we de resultaten gerepliceerd in 1.464 onafhankelijke mensen. 
We hebben 2.678 trans-eQTLs gevonden voor 1.320 SNPs in lncRNAs. Slechs 195 trans-eQTLs waren 
échte trans-effecten, waarbij de SNP op een ander chromosoom ligt dan het gen. De trans-eQTLs 
werden veroorzaakt door 127 unieke SNPs, waarvan sommige SNPs meerdere genen reguleren. Een 
mooi voorbeeld is SNP rs13227497: deze SNP ligt vlakbij de lncRNA RP11-611L7.1 en reguleert deze 
lncRNA in cis. Daarnaast reguleert de SNP ook de genexpressie levels van KNS1, PI3 en ALDH1A2 in 
trans. SNPs in deze trans-genen zijn al eerder geassocieerd met hand osteoarthrose (hand OA), de 
lichameljke reactie op stress en chronische pijn. Het lijkt er nu dus of dat de SNP rs13227497 de 
lncRNA reguleert en dat deze lncRNA de drie genen KNS1, PI3 en ALDH1A2 vervolgens reguleert in 
één netwerk. Dit moet verder onderzocht worden. 
In Hoofdstuk 4 integreren we de genetische en genomische studies met verouderingsgerelateerde 
musculoskeletale klachten en comorbiditeiten. Musculoskeletale aandoeningen, zoals OA en 
chronische gewrichtspijn, zijn de belangrijkste oorzaken van fysieke achteruitgang. Dit leidt vaak 
tot beperkingen in de mobiliteit, wat vervolgens weer kan leiden tot een verminderde kwaliteit van 
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leven. In Hoofdstuk 4.1 beschrijven we de resultaten van de eerste GWAS studie voor algehele pijn, 
of in het Engels “chonic widespread pain” (CWP). Patiënten met CWP komen veel voor (ongeveer 10% 
van de populatie) en alleen pijnstillers nemen is voor deze mensen eigenlijk geen optie. In de GWAS 
meta-analyse van 1.308 vrouwen met CWP en 5.791 vrouwelijke controles hebben we twee SNPs 
(in één locus) gevonden die significant geassocieerd zijn met de ziekte, plus nog 39 SNPs (in negen 
onafhankelijke gebieden) met een p<1E-6. Na replicatie in nog 1.480 vrouwen met CWP en 7.989 
controles repliceerde alleen de top SNP (rs13361160): het C-allele van deze SNP op chromosoom 
5p15.2 is geassocieerd met 30% groter risico voor het hebben van CWP. De SNP ligt voor het CCT5 
gen en na het FAM173B gen. In muizen met chronische pijn hebben beide genen verhoogde 
genexpressie levels in vergelijking met muizen zonder pijn. Dit is een interessante bevinding en 
kan klinisch zeer interessant zijn om nieuwe aanknopingspunten te vinden om chronische pijn te 
bestrijden. 
In Hoofdstuk 4.2 hebben we een GWAS naar hitte pijn drempels (HPT) gedaan. De HPT is een 
experimentele meting van de pijngevoeligheid: er wordt een blokje op de binnenkant van de niet-
dominante onderarm geplaatst wat kan variëren in temperatuur. De deelnemer wordt gevraagd de 
test te stoppen wanneer de pijn stimulus (de toename in temperatuur van het blokje) onaangenaam 
of pijnlijk begint te voelen. Onze GWAS meta-analyse van 3.795 mensen in de Rotterdam Studie geeft 
slechts één significante SNP: rs192745611. Deze SNP ligt in het vijfde exon van het PAPPA2 gen. Het 
PAPPA2 eiwit lijkt een belangrijke lokale regulator van het insuline-gelijkende groeifactor (IGF) te zijn. 
IGF speelt een belangrijk rol in de pijngevoeligheid van de sensorische zenuwcellen. In het humane 
brein beïnvloedt IGF de aanmaak van nieuwe zenuwcellen, het onderhoud van zenuwcellen en de 
algehele stofwisseling. En, in vitro, zorgen verhoogde IGF levels voor een verhoogde gevoeligheid 
van de zenuwcellen. We vinden grote verschillen in de schattingen voor het percentage van HPT 
variantie wat verklaard kan worden door genetische variaties: in vrouwen schatten we dat 35% van 
de HPT variantie verklaard wordt door SNPs, terwijl dit percentage in mannen slechts 9% is. Ook 
in mensen met chronische pijn ligt het percentage veel lager (slechts 8%) dan in mensen zonder 
chronische pijn (32%). De GWAS analyse is daarom geadjusteerd voor zowel geslacht als het hebben 
van chronische pijn. Omdat de GWAS in een relatief kleine populatie gemeten is, moeten we de 
resultaten eerst repliceren in een onafhankelijk cohort. Dit zal eventueel vals positieve bevindingen 
verwijderen en nu (net) niet significante SNPs significanter maken. Deze bevindingen kunnen meer 
inzicht geven in de onderliggende mechanismen van de pijngevoeligheid. 
In Hoofdstuk 4.3 hebben we gekeken of de genexpressie levels in bloed ook associëren met 
gewrichtseffusie scores in de knie. Gewrichteffusie is gerelateerd aan gewrichtsontsteking en 
recente studies hebben laten zien dat het hebben van gewrichteffusie een sterke predictor is voor 
het ontwikkelen van knie artrose (knie OA). Met deze studie hebben we geprobeerd moleculaire 
biomarkers in het bloed te vinden voor de vroege detectie van knie OA. Met 135 vrouwen van de 
Rotterdam Studie en 98 vrouwen van de GARP studie hebben we 189 genen gevonden waarvan 
de expressielevels nominaal geassocieerd zijn met de gewrichtseffusie scores in de knie. Deze 
genen zijn belangrijk voor de lichamelijke reactie op stress, de regulatie van genexpressie en 
signaaltransductie en de presentatie van antigenen. De kleinste p-waardes zijn gevonden voor 
het C1orf38 gen, ook wel THEMIS2 of ICB-1 genoemd. Dit gen komt tot expressie in verschillende 
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soorten bloedcellen (monocyten, dendritische cellen, NK cellen, T-cellen, B-cellen). Het gen wordt 
geactiveerd door interferon-gamma (IFN-γ), een belangrijke cytokine die verschillende cellulaire 
processen bij een ontsteking reguleert.
In Hoofdstuk 5 worden de resultaten van dit proefschrift bij elkaar gebracht en in een breder 
perspectief besproken. Vervolgens worden suggesties en ideëen voor vervolg onderzoek 
gepresenteerd. 
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PhD period: September 2008 – October 2015
Promotor: Prof.dr. André G. Uitterlinden
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Research Integrity Jul 2015 0.3 ECTS
Biomedical English Writing and Communication Dec 2011 4.0 ECTS
Course EndNote Dec 2008 1 hour
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Biostatistics and Research Methods (NIHES):    
– Modern Statistical Methods (EP03) Dec 2009 4.3 ECTS
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Identification of cis- and trans-acting variants in RNA-seq data – 
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Identification of cis- and trans-acting variants in RNA sequencing 
data: 
a “CHARGE – ENCODE” collaboration – CHARGE meeting
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Jul 2014 Poster
Known and novel RNAs associated with smoking – 
Wetenschapsdagen
Jan 2014 Oral
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Known and novel RNAs associated with smoking – ASHG Nov 2013 Poster
CLEC4A expression levels in blood are associated with Joint 
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associated genes – ASHG
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Meta-analysis of genome-wide association data implicates the 
5p15.2 region to influence chronic widespread pain in women – 
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Transcriptome analyses in the Rotterdam Study – NCHA meeting Mar 2011 Poster
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5p15.2 region to influence chronic widespread pain in women – 
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CHARGE meeting Washington, USA Nov 2014 24 hours
ENCODE consortium meeting Stanford, USA Jul 2014 24 hours
CHARGE meeting Los Angeles, USA Jan 2014 24 hours
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Interviews with participants of the Rotterdam Study 2009-2011 ~250 hours
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Setting up the GWAS QC pipeline of the Rotterdam Study 2008-2009 ~300 hours
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2. Teaching activities
Lecturing
– Epigenetics in the Rotterdam Study (oral at Genomics in  
    Molecular Medicine Course) 
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– Transcriptomics in the Rotterdam Study (oral at Genomics in  
    Molecular Medicine Course)
Aug 2015 8 hours
– RNA sequencing (oral at the NIHES course: An introduction  
    to the analysis of the next-generation sequencing data –  
    GE13)
Apr 2015 8 hours
– From DNA variation to function: gene expression analysis in  
    consortia (oral at Genomics in Molecular Medicine Course) 
Aug 2010 8 hours
32 hours
Supervising practicals
– NIHES Genomics in Molecular Medicine – Computer  
    Practicals
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– MOLMED SNPs and Human Diseases – Computer Practicals Nov 2014 8 hours
– MOLMED SNPs and Human Diseases – Computer Practicals Nov 2013 8 hours
– MOLMED SNPs and Human Diseases – Computer Practicals Nov 2012 8 hours
– NIHES Genomics in Molecular Medicine – Computer  
    Practicals
Aug 2012 8 hours
– MOLMED SNPs and Human Diseases – Computer Practicals Nov 2011 8 hours
– MOLMED SNPs and Human Diseases – Computer Practicals Nov 2010 8 hours
– NIHES Genomics in Molecular Medicine –  
    Computer Practicals
Aug 2010 8 hours
– MOLMED SNPs and Human Diseases – Computer Practicals Nov 2009 8 hours
– MOLMED SNPs and Human Diseases – Computer Practicals Nov 2008 8 hours
– Hugo Course – Computer Practicals Oct 2008 2 hours
82 hours
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Supervising Students
– Joost Verlouw – Bachelor thesis – Avans Hogeschool  
    Breda
Jul 2015 4.5 months
– Annelies Smouter – Bachelor thesis – Hogeschool  
    Leiden
Jun 2013 9 months
– Dennis Schmitz – Bachelor thesis – Avans Hogeschool  
    Breda
Aug 2013 9 months
– Suzanne de Maat – Master thesis – Universiteit Utrecht Jan 2010 3 months
Other
Organization of the Labday for department of Internal Medicine May 2009 10 hours
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onderdeel van het ENCODE data analyse centrum. Marjolein heeft hier gewerkt aan de optimalisatie 
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Rotterdam Studie. Daarnaast heeft Marjolein bestudeerd of trans-eQTL SNPs in “long non-coding 
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Eén ding is zeker: promoveren doe je niet alleen! Daarom wil ik op deze plaats iedereen bedanken 
die de afgelopen jaren, in welke vorm dan ook, een bijdrage heeft geleverd. Ik heb geprobeerd 
niemand te vergeten. Mocht dat toch gebeurd zijn, dan is dat onbewust en zeker niet persoonlijk 
bedoeld. Hierbij dan ook voor diegene: dankjewel! 
Twee belangrijke mensen die ik graag als eerste persoonlijk wil bedanken zijn mijn promotor Prof.dr. 
André G. Uitterlinden en mijn copromotor Dr. Joyce B.J. van Meurs: 
Beste André, al in 2007 kwam ik voor mijn onderzoeksstage bij jouw genetisch lab terecht. Je vroeg 
me hoeveel DNA samples er in een plaat passen en ik had werkelijk geen idee! Gelukkig mocht ik 
toch stage komen lopen en kon ik na mijn stage blijven voor mijn promotieonderzoek. De tijd is 
voorbij gevlogen! Ik ben je erg dankbaar voor alle kansen die je mij gegeven hebt: ik kreeg alle 
ruimte om mijzelf te ontwikkelen, als wetenschapper, maar ook als persoon. Bovendien mocht ik elk 
jaar naar internationale congressen en kreeg ik de kans om drie maanden in Berkeley te werken: een 
fantastische ervaring! Samen met Joyce heb jij mij vertrouwen en kansen gegeven. Hartelijk dank 
voor alles.
Beste Joyce, gedurende mijn promotie waren wij een goed team. Je bent recht voor zijn raap en dat 
waardeer ik enorm. Door jouw kritische vragen en goede suggesties heb ik ontzettend veel geleerd. 
Bovendien ben ik het helemaal met je eens dat onderzoek gewoon goed moet zijn. De snelheid 
waarmee jij reageert op vragen en manuscripten, waar je ook bent, welke dag het ook is, dat vind ik 
echt bewonderenswaardig. Dankjewel voor alles! Als je ooit nog een verzoekje hebt, vraag het me 
gerust :)
Ook wil ik graag de mensen van de leescommissie bedanken: Prof.dr. Joost H. Gribnau, Prof.dr. Lude 
H. Franke, en Prof.dr. Oscar H. Franco. 
Beste Joost, dankjewel voor het plaatsnemen in mijn leescommissie. Ik heb persoonlijk veel 
bewondering voor jouw werk. Ik denk dat het gebruik van iPS-cellen, die we vervolgens weer 
kunnen differentiëren tot weefselspecifieke cellen, erg belangrijk zal worden om de regulatie van 
genexpressie en DNA methylering beter te begrijpen. 
Beste Lude, dankjewel voor alle inzichten die jij mij gegeven hebt in “big data analyse”. Door mijn 
bezoekjes aan jouw groep heb ik veel geleerd over de methodes die jullie ontwikkeld hebben. 
Onze samenwerking was erg vruchtbaar en heeft een aantal mooie papers opgeleverd. Dankjewel 
daarvoor.
Dear Oscar, I am very happy that you joined the reading committee. Many thanks for reading this 
thesis, and especially for your interest in my work during CHARGE meetings and MOLEPI meetings. 
Daarnaast wil ik Prof.dr. Jan H.J. Hoeijmakers, Dr. Ingrid Meulenbelt en Dr. James B. Brown bedanken 
voor het plaatsnemen in de commissie. 
Professor Hoeijmakers, hartelijk dank voor uw bereidheid om zitting te nemen in mijn 
promotiecommissie en te opponeren bij de verdediging van mijn proefschrift.
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Beste Ingrid, bedankt voor de fijne samenwerking. Je was altijd bereid onze bevindingen te repliceren 
en kritisch mee te denken over de impact van onze bevindingen. Dankjewel! 
Dear Ben, thank you so much for giving me the opportunity to visit your lab in Berkeley. I really 
enjoyed my period in the Bay Area! I learned a lot from you and your team, both in research skills and 
in personal skills. It is great that you are willing to join my PhD committee. I loved your enthusiasm 
about my work, and I would like to finish our eQTL manuscript together! 
Lieve Hanneke en Lisette, dankjulliewel dat jullie mijn paranimfen willen zijn. Ik heb ontzettend veel 
plezier met jullie gehad de afgelopen jaren. We kunnen (nog altijd) kletsen over onderzoek, nieuwe 
analyses, problemen met scripts, etc. Maar we kunnen nog veel beter kletsen over andere dingen! Ik 
heb veel van jullie geleerd en ik moest ook erg wennen toen jullie vertrokken van het genetisch lab 
voor een nieuwe uitdaging. 
Hanneke, jij bent alweer in 2012 gepromoveerd en je bent vervolgens bij Pfizer gaan werken. Iedere 
keer ben je nieuwsgierig naar hoe het staat met mijn proefschrift en nu kan ik het echt zeggen: het 
is klaar! Nogmaals dank voor al je hulp en ik vind dat we de frequentie van onze etentjes wel weer 
een beetje kunnen opvoeren! 
Lisette, jij bent nog iets langer gebleven bij het genetisch lab. Na je promotie in 2009 ben je verder 
gegaan als postdoc, maar vorig jaar heb ook jij de stoute schoenen aangetrokken en ben je bij MRC-
Holland gaan werken. Dankjewel voor al je hulp en de vele keren dat je een hotelkamer met mij 
wilde delen. Het was de laatste maandjes erg stil in onze kamer... 
Lieve meiden, dankjulliewel voor alle gezelligheid. Het was een mooie tijd. Ik hoop dat we nog lang 
vriendinnen zullen blijven!
Eline, ook jou wil ik graag persoonlijk bedanken. Je hebt zo ontzettend veel voor mij gedaan voor 
de afronding van mijn promotie. Het was erg fijn dat jij veel administratieve klusjes uit handen nam. 
Bovendien kon ik altijd bij je terecht voor een praatje. Dankjewel daarvoor! 
Natuurlijk wil ik ook graag mijn collega’s van het genetisch lab bedanken: 
Fernando, heel erg bedankt voor je hulp bij mijn statistische problemen en voor het stellen van 
kritische vragen tijdens werkbesprekingen. Ik hoop dat we elkaar blijven zien bij onze loopgroep in 
Nesselande. Ik heb echt respect voor jouw doorzettingsvermogen en ik hoop die marathon zelf ooit 
nog eens te lopen... ik laat het je weten, goed? 
Michael, jij kwam elke dag even om het hoekje kijken of ik tijd had voor een praatje. Altijd gezellig! 
Dankjewel voor je wetenschappelijke input: je hulp met betrekking tot de DNA methylering-
methodes en -analyses was heel fijn! En dankjewel voor je vriendschap. Ik hoop dat we ons “rondje 
bruggen” en de avondjes “Rotterdam Running Crew” zullen blijven doen.
Mila en Pascal, dankjulliewel voor het sequencen van al die samples en het runnen van al die arrays. 
Jullie waren fijne collega’s. Mila, ik heb veel van je geleerd op het lab. Je bent super attent en denkt 
altijd aan iedereen. Dankjewel voor alles! 
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Marijn, super bedankt voor je hulp bij het bouwen van onze website (https://trap.erasmusmc.nl/) 
waarmee collega-onderzoekers de biologische leeftijd van hun samples kunnen voorspellen op 
basis van genexpressie levels in het bloed. Ik ben er (nog altijd) heel erg trots op! Ook bedankt voor 
het fixen van alle computer- en serverproblemen. Dankjewel! 
Marjolein en Ester, bedankt voor alle koffie en thee momentjes. Het was fijn om te kunnen sparren 
met jullie meiden. Soms met een lach en soms met een traan. We zijn nu alle drie bijna klaar: ik ben 
trots op ons! We did it! 
Annemieke, dankjewel voor de gezellige tijd bij het genetisch lab. Lopen we binnenkort nog een 
keer een wedstrijdje samen? 
Cindy, Jeroen, Annelies, Jia-Lian, Djawad en Ling, dankjewel voor jullie input tijdens werkbesprekingen. 
Dank voor de gezellige congressen, lunches en labuitjes. Ik wens jullie heel veel succes en plezier bij 
het afronden van jullie proefschrift. 
Carolina, Pooja, Fatimeh, Katerina, Fjorda, Martha, Karol, and Liz, thanks for your input during my 
workdiscussions. Additionally, thanks for the nice conference meetings and lab days we joined 
together. Carolina and Pooja, good luck with finishing your PhD thesis! You are almost done too! 
Carola, dank voor jouw input bij werkbesprekingen en discussies. Jouw klinische kijk geeft altijd een 
extra dimensie aan ons werk.
Ramazan, Robert, Linda, Stephan, Saskia, Anis, Joost (Verburg), Anke, Sarah, Manoushka, Arnoud en 
Iris: jullie ook bedankt voor de gezellige tijd bij het genetisch lab. 
Mijn studenten: Suzanne, Annelies en Joost (Verlouw). Heel erg bedankt voor jullie bijdrage aan 
dit proefschrift. Ik hoop dat ik jullie iets van mijn enthousiasme voor het onderzoek heb kunnen 
meegeven. Joost, jij bent nu niet langer student bij ons lab. Heel veel succes met het bouwen en 
onderhouden van alle sequencing pipelines. En natuurlijk wil ik ook alle andere studenten van ons 
lab bedanken. 
Verder wil ik iedereen van de vijfde verdieping bedanken voor de gezelligheid tijdens de koffies (met 
....), de borrels, werkbesprekingen, de Wetenschapsdagen in Antwerpen en onze jaarlijkse labdag. 
Ook wil ik graag de deelnemers van de Rotterdam Studie (ERGO) en de andere internationale 
cohort studies bedanken. Natuurlijk wil ik ook de mensen van het ERGO onderzoekscentrum 
graag bedanken voor hun werk, omdat zonder jullie dit proefschrift nooit geschreven had kunnen 
worden. Frank van Rooij, Jeannette Vergeer en Bernadette van Ast, jullie wil ik graag apart noemen 
en bedanken. Frank, voor je hulp bij het verkrijgen van alle benodigde fenotype files. Gelukkig heb 
je sinds de introductie van de ERGO wiki een stuk minder werk aan mij. Jeannette en Bernadette, een 
speciaal dankjewel voor jullie, voor het isoleren van al die RNA samples!
Ook wil ik graag mijn collega’s van de epidemiologie bedanken. Abbas en Janine, Mohsen, Symen, 
Paul, en Daan; dankjulliewel voor de fijne samenwerking. 
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I also owe many thanks to all co-investigators on the projects I have been participating in. In 
particular, all those involved in the CHARGE gene expression working group, especially Dr. Andrew 
Johnson and Prof.dr. Chris O’Donnell. Thank you so much for giving me the opportunity to co-lead 
the gene expression working group, and more specifically our massive age project: getting our 
manuscript accepted in a high impact journal was very challenging. I am very proud to have our 
age manuscript published in Nature Communications, and it gained a lot of international media 
attention. Of course, I am also very proud of the other CHARGE gene expression manuscripts we 
published together! 
Many thanks to Prof.dr. Bruce Psaty and the CHARGE research steering committee for creating a great 
research climate for young researchers to work in. Bruce, your support for the CHARGE fellowship 
gave me a unique experience in Berkeley! 
Many thanks to Dr. Luke Pilling, Dr. Karen Conneely, Dr. Claudia Schurmann, Dr. Katharina Schramm, Dr. 
Brian Chen, Dr. Tanxiao Huan, Dr. Joseph Powell, Dr. Eva Reinmaa, Dr. Johannes Kettunen, Dr. George 
Sutphin, Dr. Sasha Zhernakova, Dr. Tõnu Esko, and their supervisors, for the very nice collaborations 
within CHARGE. The collaborative, friendly, and open nature of these projects has been very exiting: 
it is only through this that we can achieve the best science. Thanks for the collaborations! 
Many thanks to Prof.dr. Peter J. Bickel, who welcomed me at the University of California. Peter, thanks 
for your interest and confidence in my work. I loved your stories about your work and family, and 
I learned a lot from you and Ben about statistical tools. Additionally, I would like to thank Marcus, 
Omid, Mu, Nathan, Taly, Sharmodeep, and Rachel. Thanks for your help during my visit. Thanks for 
the very useful Summer Journal Club meetings, and thanks for the nice lunches in the garden, the 
dinners, the birthday parties, and the barbecues.
Ook de collega’s in Groningen, Leiden en Utrecht wil ik graag bedanken. Harm-Jan, dankjewel voor 
het fixen van alle bugs in de pijplijn. Je zult wel gek geworden zijn van al mijn vragen en problemen 
in de test fase. Maar we hebben uiteindelijk een mooi artikel gepubliceerd samen! Ik wens je heel 
veel succes met je post-doc plek in Boston. Ik hoop dat je ondertussen je draai een beetje kunt 
vinden daar. 
Yolande, dankjewel voor onze samenwerking op het gebied van expressie en artrose. Ik hoop dat jij 
ook snel een nieuwe fijne plek gevonden hebt.
Bas en Peter-Bram, dankjulliewel voor de samenwerking. Ik hoop dat er nog vele mooie artikelen 
mogen volgen uit de BBMRI samenwerking. 
Vered and Marius, thanks for our collaboration. Hopefully, our manuscript regarding quadratic 
regression will be accepted soon. I will keep my fingers crossed!
Hanneke en Annemieke, dankjulliewel voor de fijne samenwerking. Jullie functionele werk in muizen 
was een mooie toevoeging aan ons manuscript over chronische pijn. 
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Lieve vrienden, vriendinnen, familie en schoonfamilie, bedankt voor jullie interesse in mijn werk. En 
dankjulliewel voor de gezellige afspraken en gesprekken over niet-werk gerelateerde dingen! 
Lieve Joost en Michèle, ik ben heel blij dat jullie er altijd voor ons zijn. Gewoon een kop koffie of 
een heerlijke vakantie samen, in goede en in minder goede tijden. Dankjewel voor alles! Een dikke 
knuffel voor jullie allebei! 
Lieve pap en mam, dankjewel dat jullie er altijd voor mij zijn. We hebben aardig wat meegemaakt 
de afgelopen jaren en jullie deur stond (en staat) altijd wagewijd open. Ook nu zijn het weer roerige 
tijden en ik hoop dan ook dat we er altijd voor elkaar kunnen zijn. Jullie hebben me altijd gesteund 
en aangemoedigd en jullie hebben me geleerd mijzelf te zijn. Dankjulliewel voor alles! Ik hou van 
jullie. 
Lieve Thomas, dankjewel dat jij er altijd voor mij bent. Je zorgt heel goed voor mij en je kunt me altijd 
aan het lachen krijgen. Bedankt voor jouw liefde en steun. Ik hou van jou! 
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